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SUMMARY 
A cell cannot sustain without the cell membrane as the proteins embedded in the cell 
membrane are vital for different functions such as RNA, solute and protein transport and 
signal transduction across the membrane. About 60 % of approved drug targets are 
membrane proteins. Some members of the ABC transporter protein family are responsible 
for multidrug resistance to chemotherapeutic drugs. Like other membrane proteins, the 
understanding of ABC transporters function has been hampered by difficulties in membrane 
protein structure determination using x-ray crystallography. Therefore, new strategies to 
obtain crystals of membrane proteins suitable for structure determination are needed. In 
this thesis, in vitro selected designed ankyrin repeat proteins (DARPins) have been used as 
tools for structural and functional studies of four bacterial ABC transporters. In Chapter A of 
this thesis, membrane proteins, particularly ABC transporters and chaperone assisted co-
crystallization are introduced.  
  Chapter B, C and D of this thesis describe the in vitro selection of DARPins using 
ribosome display against detergent solubilized bacterial ABC transporter MsbA and the 
cytosolic nucleotide binding domain of MsbA, respectively. About 2000 DARPins were 
screened to identify a high affinity (KD of 80 nM) binder specific for MsbA, which was named 
DARPin_55. MsbA could be crystallized alone in its inward-facing state and its structure was 
partially solved at 7 Å using molecular replacement. Co-crystallization trials of MsbA with 
DARPin_55 did not result in crystals. Interestingly, DARPin_55 increased the ATPase activity 
of MsbA by a factor of two. Methanethiosulfonate mediated cross-links between two single 
cysteines on the DARPin and MsbA saturated at a stoichiometry of 1 DARPin binding to 
homodimeric MsbA. This provided the first experimental evidence suggesting asymmetry in 
homodimeric MsbA.  The binding epitope of DARPin_55 could be determined using 
extensive electron paramagnetic resonance (EPR) and cysteine cross-linking measurements 
and was mapped to the transmembrane region of MsbA. For the first time, experimental 
evidence for asymmetry in the transmembrane domain of a homodimeric ABC transporter 
was provided.  
  It was tremendously challenging to identify a specific, monomeric and high affinity 
DARPin that binds to detergent solubilized MsbA. Most of the ELISA positive DARPins were 
either unspecific or found to form soluble aggregates as analyzed by size exclusion 
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chromatography. It was reasoned that this may be due to the accumulation of hydrophobic 
binders during the ribosome display selection cycles against membrane proteins. To avoid 
these problems, the cytosolic domain of MsbA (nucleotide binding domain or NBD) was also 
used for DARPin binder selection (Chapter D). About 1500 binders were screened to find a 
DARPin specific for the NBD, which was named DNBD_14. Interestingly, DNBD_14 did not 
bind to the full length protein, implying that the epitope is likely to be located in the region 
where the transmembrane domain interacts with the nucleotide binding domain in full 
length MsbA. 
Chapter E of this thesis describes the in vitro selection of DARPins using ribosome 
display against detergent solubilized bacterial ABC transporter LmrCD. The identification of 
LmrCD specific binders was done by ELISA experiments (in vitro) and by the functional 
screening in L. lactis cells (in vivo). Three LmrCD specific DARPin activators were found in the 
in vivo screening. These binders stimulated the basal ATPase activity of reconstituted LmrCD 
in proteoliposomes and increased the daunomycin resistance in L. lactis cells. The cytosolic 
part of the transmembrane domain of LmrD chain was identified as the epitope for all 
DARPin activators.  
Chapter F (in the appendix) summarizes initial efforts in identifying specific DARPins 
against two different ABC transporters, namely LmrA and YDDA. Selection and screening of 
DARPins against LmrA was performed using a N2C DARPin library. LmrA specific DARPin 
binders were used for co-crystallization trials, which unfortunately did not result in crystals.  
DARPin selections against YDDA were performed using a N3C DARPin library. The enriched 
library of DARPins was screened by ELISA to identify 9 YDDA specific binders. A thorough 
analysis of the YDDA-DARPin complex by SEC revealed that the DARPins failed to elute in 
complex with YDDA. Although, DARPin selections against LmrA & YDDA were only partially 
successful, the gained experience was important to establish a work flow for the selection 
and screening of DARPins against membrane proteins. In Chapter B, C, D and E, this 
methodology helped to find monomeric and specific DARPin binders for MsbA, the NBD of 
MsbA and LmrCD, respectively.  
The work presented in this thesis illustrates the potential of in vitro selected binders 
to recognize novel conformational states of membrane transporters and thereby facilitating 
their structural and functional characterization. 
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ZUSAMMENFASSUNG 
Eine Zelle kann ohne Zellmembran nicht überleben. Proteine in der Zellwand übernehmen 
lebensnotwendige Funktionen wie z.B. den Transport von RNA, gelösten Substanzen und 
Proteinen sowie der Weitergabe von Signalen über die Membran. Ungefähr 60% der 
Zielmoleküle von Medikamenten sind Membranproteine. Einige Vertreter aus der 
Proteinfamilie der ABC Transporter sind verantwortlich für die Resistenz gegen 
chemotherapeutische Medikamente. Schwierigkeiten bei der Bestimmung von 
Proteinstrukturen von ABC Transportern mittels Röntgenkristallisation sind der Grund für ein 
immer noch mangelhaftes Verständnis der Funktion dieser wichtigen Proteinfamilie. Darum 
sind neue Strategien gefragt, um Membranproteinkristalle zu züchten, welche sich zur 
Strukturbestimmung eignen. In dieser Dissertation wurden DARPins benutzt, um die Struktur 
und Funktion von vier bakteriellen ABC Transportern zu untersuchen. In Kapitel A werden 
Membranproteine, im speziellen ABC Transporter, und die Methode der sogenannten 
„chaperone-assisted crystallography“  beschrieben.  
Die Kapitel B, C und D beschreiben die in vitro Selektion von  DARPins gegen den in 
Detergenz gereinigten ABC Transporter MsbA sowie die zytosolische Nukleotid 
indungsdomäne von MsbA mittels Ribosome Display. Ungefähr 2000 DARPins wurden auf 
Bindung gegen MsbA getestet. Dabei wurde ein MsbA-spezifischer Binder mit einer 
geschätzten Affinität von KD = 80 nM identifiziert, der DARPin_55 genannt wurde. Versuche 
MsbA zusammen mit DARPin_55 zu kristallisieren waren nicht von Erfolg gekrönt. In der 
Abwesenheit von DARPin_55 konnte MsbA in einem gegen innen geöffneten Zustand 
kristallisiert werden. Eine partielle Struktur konnte bei einer Auflösung von 7 Å gelöst 
werden. Interessanterweise erhöhte DARPin_55 die ATPase Aktivität von MsbA um das 
Zweifache. Mittels Methanethiolsulfonat wurden Vernetzungen und damit räumliche Nähe 
zwischen gewissen Cystein-Paaren auf dem DARPin und MsbA nachgewiesen. Diese 
Vernetzungsversuche zeigten, dass die Bindungsstoichiometrie von DARPin_55 und 
homodimerem MsbA 1:1 beträgt, was darauf hinwies, dass DARPin_55 einen 
asymmetrischen Zustand von MsbA erkennt. Die Bindungsstelle von DARPin_55 konnte 
mittels electron paramagnetic resonance (EPR) Messungen und einer Vielzahl von 
Vernetzungen zwischen Cysteinen genauer bestimmt werden und wurde auf dem 
transmembranen Bereich von MsbA lokalisiert. Damit wurde der ersten experimentellen 
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Hinweis für das Bestehen von Asymmetrie im transmembranen Bereich eines homodimeren 
ABC Tranporters erbracht.  
Es war eine grosse Herausforderung, einen spezifischen, monomeren DARPin zu 
identifizieren, der mit hoher Affinität an in Detergenz gereinigtes MsbA bindet. Die meisten 
ELISA-positiven DARPins waren entweder unspezifisch oder bildeten lösliche Aggregate, was 
mittels Gelfiltrations-Chromatografie (size exclusion chromatography oder SEC) 
nachgewiesen werden konnte. Es wurde daraus geschlossen, dass dies wegen der 
Anreicherung von hydrophoben Bindern während der Selektion mittels Ribosome Display 
gegen das untersuchte Membranproteine geschah. Um solche Probleme zu vermeiden 
wurde die DARPin Selektion auch gegen den cytosolischen Teil von MsbA (genannt 
nucleotide binding domain oder NBD) durchgeführt (Kapitel D). Ungefähr 1500 Binder 
wurden analysiert. Dabei wurde ein für das NBD spezifischen DARPin gefunden, der 
DNBD_14 genannt wurde. Interessanterweise bindet DNBD_14 nicht an MsbA in seiner 
vollen Länge. Dies weist darauf hin, dass sich die Bindungsstelle von DNBD_14 
wahrscheinlich in einer Region befindet, in welcher der Transmembranteil von MsbA mit 
dem NBD interagiert. 
Kapitel E der Thesis beschreibt die in vitro Selektion von DARPins gegen Detergenz 
gereinigten, bakteriellen ABC Transporter LmrCD mittels Ribosome Display. Die Identifikation 
von LmrCD spezifischen Bindern wurde mit ELISA Experimenten (in vitro) und funktionalem 
Screening in L. lactis Zellen (in vivo) durchgeführt. In vivo Screening führte zur Identifikation 
von drei verschiedenen, aktivierenden DARPins. Die Binder stimulierten die basale ATPase 
Aktivität von rekonstituiertem LmrCD in Proteoliposomen und erhöhten die Daunomycin 
Resistenz in L. lactis Zellen. Der zytosolische Teil der Transmembran Domäne der LmrD Kette 
wurde als Bindungsepitop aller drei aktivierenden DARPins identifiziert.  
Kapitel F (im Appendix) fasst erste Bemühungen zusammen, einen spezifischen 
DARPin gegen zwei verschiedene ABC Transporter zu identifizieren, nämlich LmrA und YDDA. 
Für die DARPin Selektion gegen LmrA wurde eine sogenannte N2C DARPin Bibliothek 
verwendet. LmrA-spezifische DARPin Binder wurden für Ko-Kristallisationsversuche 
verwendet, welche unglücklicherweise keine Kristalle hervorbrachten. DARPin Selektionen 
gegen YDDA wurden mit einer N3C DARPin Bibliothek durchgeführt. Dabei wurden 9 YDDA-
spezifische Binder identifiziert. Eine gründliche Analyse der YDDA-DARPin Komplexe durch 
SEC zeigte, dass die DARPins nicht zusammen mit YDDA eluierten. Obwohl die DARPin 
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Selektionen gegen LmrA und YDDA nur teilweise erfolgreich waren, war die gewonnene 
Erfahrung wichtig, um einen Arbeitsablauf für die Selektion und Identifikation von DARPins 
gegen Membranproteine zu etablieren. Diese Methode half monomere und spezifische 
DARPins gegen MsbA und NBD_MsbA zu finden (wie in den Kapiteln B, C und D 
beschrieben). 
Die in dieser Dissertation präsentierte Arbeit zeigt das Potential von in vitro 
selektionierten Bindern auf, um neue Konformationen von Membrantransportern zu 
erkennen und dadurch ihre strukturelle und funktionelle Charakterisierung zu ermöglichen. 
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CHAPTER A 
A.1 Introduction  
A cell is the basic unit of life and the plasma membrane defines its territory and controls 
what substances have to go in and out of the cell. The major components of plasma 
membranes are lipids, proteins and carbohydrates, held together by noncovalent 
interactions. The "Fluid Mosaic Model", described by Singer and Nicolson, explains the 
membrane as a fluid phospholipid bilayer, wherein proteins and lipids can freely diffuse 
within the plane of the membrane1. 
 The basic structure of the plasma membrane is provided by the lipid bilayer, which is 
impermeable for ions and other solutes. The other component of the bilayer are membrane 
proteins, that perform various functions such as ion, RNA and protein transport across the 
membrane, signal transduction and attachment to neighboring cell2. In 1992, the structure 
of a bilayer of pure DOPC lipids was determined3. This study suggested that the hydrophobic 
core is 30 Å thick and interface region is 15 Å thick on either side4 (Figure_A1). 
 
Membrane proteins can be classified as integral proteins, peripheral proteins, and lipid-
bound proteins, based on their interactions with the lipid layer. The transmembrane region 
of the membrane proteins are either α-helices or β-sheets (Figure_A2). The inner membrane 
of bacteria is typically spanned by α-helices, while the outer membrane is abundant in 
proteins consisting of β-sheets, in form of closed barrels (therefore called β-barrels)5. 
Members of β-barrel protein are composed of a varied number of β-strands, such as OmpA 
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(8 β-strands), porins (16 β-strands) and FepA (22 β-strands). Some of them are pore forming 
proteins and allow selected hydrophilic solutes to cross the lipid bilayer of the outer 
membrane6.  The α-helical transmembrane proteins vary from channels (K+ or Cl- channels 
etc)7,8, receptors (bacteriorhodopsin, β-adrenergic receptor etc)9,10 to transporters (AcrB, 
Sav1866 and MsbA etc)11-13, and are associated with different functions. The focus of this 
thesis is on transport proteins, in particular ABC transporters. 
 
A.2 Classification of transport proteins 
The lipid bilayer is the skin of a cell, which serves as a barrier to the passage of polar 
molecules.  Cells have evolved ways to accomplish the transport of water soluble molecules 
in order to import nutrients, export toxins or waste products and maintain ion gradients. 
This suggests that transport is an essential function of every living cell and therefore, 
classification of transporters is required. 
The international Union of Biochemistry and Molecular Biology has approved a 
classification system for membrane transport proteins including ion channels. This 
classification system is termed as “transporter classification database” (TCDB). TCDB is a 
freely accessible web resource (www.tcdb.org) and is based on structural, functional and 
evolutionary information about transport systems from different living organism14. The TCDB 
is an organized repository of published information from over 10000 references (Table 1).  
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Transporter proteins in cell membrane may be divided into channels and carriers. Channels 
function as selective pores that regulate the flow of ions across the membrane and open in 
response to a chemical or electrical signal, temperature, or mechanical force, depending on 
the type of channel. All channel proteins mediate transportation across the cell membrane 
by passive transport or facilitated diffusion.  Carrier proteins are also called permeases or 
transporters. These proteins bind to the substrate to be transported specifically and undergo 
a series of conformational changes in order to transfer the substrate across the cell 
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membrane. These carrier proteins mediate the transfer across the membrane by passive or 
active transport. Secondary active transporters use the energy from ion driven concentration 
gradient to drive the translocation of substrate across the membrane. Primary active 
transporter such as ATP-binding cassette (ABC) transporters couple ATP binding and 
hydrolysis to the transport of a variety of substrates against their electrochemical gradient15 
(Figure_A3).    
 
A.2.1 ABC transporters 
A.2.1.1 Introduction 
ABC transporters are one of the largest superfamily of membrane proteins and are found in 
all kingdoms of life. They are primary active transporters, which act as exporters, importers, 
receptors and channels. ABC exporters are found in both eukaryotes and prokaryotes while 
importers are identified exclusively in prokaryotes16. These transmembrane proteins 
mediate a plethora of physiological phenomena, including transport of metabolic products, 
nutrients, proteins, peptides, lipids, polysaccharides, ions and drugs17,18.  Genetic disorders 
in ABC transporters can lead to several human malfunctions including cystic fibrosis, 
neurological disease, retinal degeneration, cholesterol and bile transport defects, anemia, 
and drug resistance. Many ABC genes play a role in the maintenance of the lipid bilayer and 
in the transport of fatty acids and sterols within the body17. Based on phylogenetic analysis, 
human ABC transporters are divided into seven subfamilies (subfamily ABCA to subfamily 
ABCG). This particular study focuses on bacterial homologs of the ABCB subfamily. The ABCB 
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subfamily is unique in that it contains both full and half transporters and some of the 
members are characterized to be involved in multidrug resistance (MDR)19. At the molecular 
level, ABC transporters consist of four domains, two transmembrane domains (TMDs) and 
two nucleotide-binding domains (NBDs). The TMDs are composed of multiple α-helices, 
which form the pathway to transport the substrate and provide specificity. The NBDs also 
known as ATP-binding cassettes, power the transporter by binding and hydrolyzing ATP that 
is coupled to conformational changes in the TMDs to mediate unidirectional transport across 
the membrane18.  
A.2.1.1.1 Nucleotide binding domains 
Structure determination of ABC transporter proteins initially started with the crystallization 
of hydrophilic ATP-binding subunits in isolation from the full transporters. The first structure 
of an NBD in complex with ATP was determined for histidine permease HisP at 1.5 Å 
resolution. This structure provided the details of interaction between the conserved NBD 
motifs and ATP but did not reveal the dimer interface of the domain20. Later, the crystal 
structures of a symmetrical NBD dimer formed by the E171Q mutant of the ABC transporter 
MJ0796 in complex with two ATP molecules, the NBD of the maltose transporter (MalK) with 
and without ATP and the NBD of the haemolysin transporter (HlyB) revealed a head-to-tail 
arrangement of the NBD-NBD dimer interface sandwiching two molecules of nucleotide at 
the interface21-23. The structure of the NBD monomer can be divided into two subdomains: a 
larger RecA-like core-subdomain and a helical subdomain24. The RecA-like core-subdomain 
comprises of 6 conserved motifs, which are the Walker A motif (yellow), the Walker B motif 
(green), the Q loop (purple), the A loop (red), the D loop (orange) and the H loop (dark blue). 
The helical subdomain contains ABC signature motif (cyan) (Figure_A4A). A nucleotide 
binding site (NBS) is comprised of the D loop and ABC signature motif (LSGGQ) of one NBD 
and the Walker A and B motifs and the H loop as well as the Q loop from the second NBD 
(Figure_A4B).  This head-to-tail arrangement of the NBD dimer interface was first predicted 
by Jones and George25 and later has also been verified in full length transporter 
structures12,13. In the inward facing state of ABC transporter, the TMDs are replenished with 
substrates and the NBDs are partially or fully disengaged.  The binding of 2 ATP molecules 
leads to formation of the closed NBD dimer and TMDs adopt an outward facing state. The 
transition from the inward facing to the outward facing state has been associated with a 
switch from high to low affinity for the substrate26. The hydrolysis of ATP in the NBDs revert 
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the transporter back to the inward facing state.  Switching between the inward and the 
outward facing state therefore facilitates vectorial transport of substrate across the 
membrane. This transport mechanism has been termed as ATP-switch model26. 
 
A.2.1.1.2 Transmembrane domains 
The membrane spanning domains of ABC transporters are structurally heterogeneous and 
three distinct folds are currently recognized based on structural studies of full length ABC 
transporters27. These folds are named type I ABC importer (or small ABC importers), type II 
ABC importer (or large ABC importers) and ABC exporter folds27,28 (Figure_A5).   
The type I ABC importer fold was originally observed in the transmembrane subunit 
of molybdate/tungstate transporter ModBC from Archaeoglobus fulgidus 29 and was later 
found in the transmembrane subunit of MalFGK2
30 and Met transporter MetI31. The type I 
fold is composed of minimally 5 TM helices in each transmembrane domain subunit. A total  
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of 10, 12 and 14 transmembrane helices are found in the methionine, molybdate and 
maltose transporters, respectively16. The conformational changes generated by ATP binding 
and hydrolysis are transmitted from the NBD to the TMD  by ‘’coupling helices’’32. Coupling 
helices are located at the tips of the cytoplasmic loops of TM-helices and interact with the α-
helical subdomain of NBDs. In the type I importers, coupling helices are formed between 
TM3 and TM4. The type II ABC importer fold is found in BtuCD and in Hi1471, and contains 
10 TM helices in each subunit (20 helices in a full transporter). In this fold, coupling helices 
are formed between TM6 and TM7. The ABC exporter fold was first observed in Sav186632, 
MsbA12 and subsequently in TM287/28833. In Sav1866, MsbA and TM287/288 each TMD is 
composed of 6 TM helices (12 in a full transporter).  In the outward facing conformation, the 
TM-spanning region is organized into two wings and each wing is composed of TM3, TM4, 
TM5, and TM6 of one subunit and TM1, TM2 of the other due to domain swapping. The 
unique feature of ABC exporters is that the transmembrane domains extend into the 
cytoplasm by 25 Å.  These extended parts of the TMDs are called intracellular loops (ICLs).  
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The transmission interface between the TMDs and NBDs of ABC exporters is established by 
intracellular loops ICL1 (loop between TM2 and TM3) and ICL2 (loop between TM4 and 
TM5).  These ICLs contain short helices oriented roughly parallel to the membrane plane. 
The coupling helix 1 (ICL-1) contacts the NBDs of both subunits, while coupling helix 2 (ICL-2) 
interacts with that of the opposite subunit exclusively32 (domain swapping) (Figure_A6). 
A.3 Membrane protein crystallization 
Membrane proteins are difficult to handle due to their amphipathic surface. The hydrophilic 
surface is exposed to the aqueous environment on both sides of the membrane while the 
hydrophobic surface is embedded within the lipid bilayer. Non-ionic detergents are used to 
extract membrane proteins from the lipid bilayers. The detergent mimics the lipid bilayer by 
covering the hydrophobic surface of the protein generating a protein-detergent micelle. 
Structure determination of proteins at the atomic level is important for providing insight into 
the mechanisms of protein function. Crystallization is currently the optimal method for 
obtaining three‐dimensional structural models at atomic resolution for large proteins and 
membrane proteins.  
Membrane proteins are notoriously difficult to crystallize. Even if crystals are 
obtained their diffraction is often found to be limited, which poses a major barrier to solve a 
structure.  A variety of techniques exist to produce suitable three dimensional crystals; these 
are based on detergent (in surfo)7,32, lipid systems (in cubo)34,35 or on the use of lipid 
bicelles34. The basis of the in surfo method is the incorporation of protein into detergent 
micelles.  The in surfo method has been the most successful and widely used method for 
membrane protein crystallization.   
Conformational heterogeneity, surface chemistry and polydisperse character of 
membrane proteins are common obstacles in determining the crystal structure of these 
proteins. A successful alternative approach to overcome these problems is to use auxiliary 
binding protein, commonly termed as ‘’crystallization chaperones’’. Crystallization 
chaperones bind to a specific conformation of a target protein, thereby minimizing the 
conformational heterogeneity and increasing the hydrophilic surface area for crystal lattice 
formation36. These chaperones are divided into two categories; antibody based and non-
antibody based scaffolds.  
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A.3.1 Complexing with antibody based scaffolds 
The crystal structure of a full length monoclonal antibody IgG2a (PDB 1IGT)36 is shown in 
Figure_A7. It is a heterotetramer of 2 heavy chains (green) and 2 light chains (red). The 
antigen binding site (blue) is formed by 3 loops from each domain, which are highly diverse 
in sequence and length (3 from light chains (cyan) and 3 from heavy chains (dark blue)). The 
fragment antigen-binding (Fab fragment) is part of an antibody that binds to an antigen and 
it is composed of one constant and one variable domain from each heavy and light chain of 
the antibody. The antigen-binding unit can be further reduced to the Fv consisting of the 
variable light and heavy chains (VL and VH). A single chain variable fragment (scFv) is 
generated by fusing the VL and VH through a polypeptide linker
37-41. In 1993, Hamers-
Casterman et al discovered a novel antibody format devoid of light chains in the camelid 
species, termed as heavy chain antibodies42 or nanobodies (VHHs). The simplest antigen-
binding unit, VHHs is similar in size to the heavy chain variable region domain of Fv 
fragments from conventional antibodies. The first use of antibody based chaperones can be 
traced back to co-crystallization of N9 neuraminidase in complex with a Fab fragments 
originating from monoclonal antibodies43. Since then, antibody based chaperones have been 
successfully used in structure determination of several soluble44 and membrane proteins45,46 
that are difficult to crystallize. Antibody based scaffolds, Fabs45 and Fvs47 in particular, are 
the dominant chaperones used for the co-crystallization of membrane proteins. In addition 
to the well-established Fab or Fv fragments, single chain antibody domain such as scFvs or 
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nanobodies are also used to crystallize challenging proteins such as MazE48 and β2-
adrenergic receptor49.  
A.3.2 Complexing with alternative scaffolds 
Non-antibody scaffold based binders such as affibodies, monobodies, and repeat proteins 
have been developed by protein engineering techniques.  These alternative scaffolds retain 
antibody like properties such as specificity and affinity.  They have been developed to 
improve some of the undesirable properties of antibody based scaffolds. Many of the novel 
scaffolds are free of disulfide bonds and exhibit high expression yields in bacteria. This thesis 
focuses on in vitro selected designed ankyrin repeat protein (DARPin) binders. Ankyrin 
repeat proteins occur in all phyla and mediate important protein–protein interactions in cell 
compartments50. Binz et al have used the ankyrin repeat fold to design a consensus based 
library51.  Their modular structure is built from stacked, 33-amino acid repeats, each 
consisting of a β-turn, followed by a pair of antiparallel α helices and a loop that connect to 
the next repeat52. Varying numbers of repeats are stabilized by adding the N and C-terminal 
capping-repeats, which seal the hydrophobic core from the solvent. Target specific DARPins 
are selected using ribosome display51 or phage display53, and the enriched selected library is 
further screened by ELISA54. A DARPin molecule is often abbreviated as NXC, where X 
indicates number of internal repeats (Figure_A8). 
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Target specific DARPins have been used successfully for the crystallization of several 
soluble proteins55-57. The first structure of a membrane protein in complex with a DARPin 
was reported for the multidrug transporter AcrB, which was crystallized in an asymmetric 
conformation58 (Figure_A9). This work demonstrated the effectiveness of DARPins as a tool 
for structural and functional studies of challenging proteins. 
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Background: ABC exporters are suggested to hydrolyze ATP sequentially implying the existence of asymmetries.
Results: An in vitro selected binder (DARPin) was identified that binds to homodimeric MsbA at a stoichiometric ratio of 1:1.
Conclusion: The DARPin recognizes asymmetries in MsbA.
Significance: Selected binding proteins are useful tools to recognize membrane transporters in novel conformational states.
ABC transporters harness the energy from ATP binding and
hydrolysis to translocate substrates across themembrane. Bind-
ing of two ATP molecules at the nucleotide binding domains
(NBDs) leads to the formation of an outward-facing state. The
conformational changes required to reset the transporter to
the inward-facing state are initiated by sequential hydrolysis of
the bound nucleotides. In a homodimeric ABC exporter such as
MsbA responsible for lipid A transport in Escherichia coli,
sequential ATP hydrolysis implies the existence of an asymmet-
ric conformation. Here we report the in vitro selection of a
designed ankyrin repeat protein (DARPin) specifically binding
to detergent-solubilized MsbA. Only one DARPin binds to the
homodimeric transporter in the absence as well as in the pres-
ence of nucleotides, suggesting that it recognizes asymmetries
in MsbA. DARPin binding increases the rate of ATP hydrolysis
by a factor of two independent of the substrate-inducedATPase
stimulation. Electron paramagnetic resonance (EPR) measure-
ments are found to be in good agreement with the available
crystal structures and reveal that DARPin binding does not
affect the large nucleotide-driven conformational changes of
MsbA. The binding epitope was mapped by cross-linking and
EPR to the membrane-spanning part of the transmembrane
domain (TMD). Using cross-linked DARPin-MsbA com-
plexes, 8-azido-ATP was found to preferentially photolabel one
chain of the homodimer, suggesting that the asymmetries cap-
tured by DARPin binding at the TMDs are propagated to the
NBDs. This work demonstrates that in vitro selected binders are
useful tools to study the mechanism of membrane proteins.
ATP-binding cassette (ABC)4 transporters are primary
active transporters, which act as exporters, importers, recep-
tors, and channels. These transmembrane proteins mediate a
plethora of physiological phenomena, including transport of
metabolic products, nutrients, proteins, peptides, lipids, poly-
saccharides, ions, and drugs (1). In humans, malfunction of
ABC transporters leads to several genetic disorders including
cystic fibrosis, neurological diseases, retinal degeneration, cho-
lesterol, and bile transport defects, anemia, and insufficient
drug response.
MsbA is a homodimeric ABC exporter involved in the trans-
port of lipidA and lipopolysaccharides to the outer leaflet of the
inner membrane of several Gram-negative bacteria (2), and the
msbA gene is essential in Escherichia coli (3). MsbA is homolo-
gous to the multidrug transporter LmrA of Gram-positive Lac-
tococcus lactis (4) and mammalian multidrug resistance trans-
porters such as P-glycoprotein (5) and shows overlapping
substrate specificity with them (6, 7). At a molecular level, ABC
transporters consist of four domains, two transmembrane
domains (TMDs) and two nucleotide-binding domains
(NBDs). In ABC exporters, the TMDs are composed of at least
six transmembrane helices, which form the substrate transport
pathway and provide specificity. The NBDs are also known as
ATP-binding cassettes and drive the transport cycle by binding
and hydrolyzing ATP. The motional energy of the NBDs are
coupled to conformational changes in the TMDs which alter-
nate between an inward- and an outward-facing state and
thereby form a pathway to mediate unidirectional transport
across the membrane (8).
Current molecular understanding of ABC exporters is based
on crystal structures of Sav1866 (8) solved at 3 Å in its outward-
facing state, P-glycoprotein solved at 3.8 Å in its inward-facing
state (5), and the structures of three homologues of MsbA
solved in three different conformations at resolutions ranging
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from 3.7 Å to 5.5 Å (9). Based on these crystal structures, large
conformational changes are expected to occur in ABC export-
ers upon nucleotide binding and hydrolysis, which could be
confirmed by cross-linking experiments and EPR measure-
ments (10–14).
Themechanistic details of how the binding and hydrolysis of
ATP at the NBDs is coupled to the transport process at the
TMDs are still a matter of controversy. In many heterodimeric
ABC transporters, one of the two ATPase sites deviates from
the consensus sequence and is therefore called the degenerate
site (15). Such heterodimeric ABC exporters mainly hydrolyze
ATP at the consensus site and thus operate in an asymmetric
fashion. In homodimeric ABC exporters such as BmrA as well
as in P-glycoprotein which is a fused heterodimer but exhibits
two consensus ATPase sites, biochemical experiments demon-
strated that only one ATP molecule is trapped by vanadate in
the post-hydrolytic state per ABC transporter dimer (16, 17). It
was concluded thatABCexporters hydrolyze the twoATPmol-
ecules sequentially instead of simultaneously, possibly involv-
ing a mechanism of alternating catalytic sites (18). This mech-
anism implies that the NBD homodimer must switch to an
asymmetric conformation before ATP is hydrolyzed at one of
the two catalytic sites. In support of this notion, asymmetric
homodimers have been observed in crystal structures of the
ATP-bound NBDs of the ABC transporter HlyB (19). On the
other hand, current crystal structures of outward-facing MsbA
and Sav1866 feature two bound AMP-PNP at the NBDs (thus
representing a pre-hydrolytic state) and display only minor
structural differences between the two chains, that are related
by 2-fold non-crystallographic symmetry (9, 20). Molecular
dynamics simulation using the symmetric Sav1866 and MsbA
structures as starting points revealed that the NBDs readily
switch to an asymmetric state in which only one molecule of
ATP enters the hydrolysis reaction at a time (21, 22). Further
work addressing the question of asymmetry inABC exporters is
clearly needed to resolve the apparent discrepancies between
asymmetries found based on biochemical experiments and the
symmetric crystal structures of the homodimers Sav1866 and
MsbA.
Designed Ankyrin Repeat Proteins (DARPins) represent a
well-established randomized scaffold used as an alternative to
antibody fragments (Fabs and scFvs) and have been selected
against a variety of target proteins (23–25). A growing number
of DARPin co-crystal structures demonstrate the successful
application of such designed binding proteins as crystallization
aids (24). Besides possible improvements of crystal diffraction,
DARPins have the potential to trap the targeted protein in alter-
nate conformations. DARPins selected against the multidrug
transporter AcrB for example trap this protein in an asymmet-
ric state with two DARPins bound to the homotrimer (25, 26).
In the absence of DARPins, AcrB was initially crystallized in its
symmetric and later in its asymmetric state (27, 28).
Here, we describe the selection of DARPins against deter-
gent-purified MsbA using ribosome display. We identified a
DARPin which binds to the homodimeric transporter in a 1:1
stoichiometric ratio. TheDARPin binding epitope wasmapped
to the TMDs and was found to be located away from the 2-fold
symmetry axis ofMsbA, suggesting that theDARPin recognizes
asymmetries inMsbA.DEERmeasurements revealed that addi-
tion of the DARPin toMsbA does not influence the large ATP-
induced conformational changes during transporter cycling.
Nevertheless, DARPin binding enhances the basal ATPase
activity of the transporter without impairing the substrate-in-
duced stimulation suggesting that the catalytic cycle is acceler-
ated when asymmetric MsbA conformations are populated.
EXPERIMENTAL PROCEDURES
Purification, Biotinylation, and Spin Labeling of MsbA and
DARPin—A detailed description of the cloning, expression,
and purification ofMsbA is given in the supplemental Exper-
imental Procedures. MsbAwas expressed in E. coliC43 (DE3)
cells from a pBAD vector and purified using -UDM as deter-
gent. DARPin expression and purification has been described
previously (29). Enzymatic biotinylation was facilitated by fus-
ing an Avi-tag sequence to the of MsbA. Single cysteine
mutants at positions A25C, R103C, N191C, S206C, and S246C
of MsbA were introduced by site-directed mutagenesis taking
Cys-lessmsbA (C88S/C315S) as template. Likewise, single cys-
teine mutants were also introduced into the N- and C-terminal
caps of DARPin_55 (which is Cys-less by design) at the posi-
tions S12C, K16C, E29C, D151C, and D160C. For methane-
thiosulfonate cross-linking and spin labeling, single cysteine
mutants ofMsbA andDARPin were purified by supplementing
5 mM dithiothreitol (DTT), which was removed (PD-10 col-
umn, GE Healthcare) prior to labeling with 10 times molar
excess of MTSSL ((1-oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-
methyl) methanethiosulfonate; Toronto Research Chemicals).
Excess spin label was removed by size exclusion chromatogra-
phy. For the EPR measurements, DARPin-MsbA complexes
were made by spin labeling the freshly purified proteins indi-
vidually, followed by gel-filtration of the protein complex.
Selection and Screening of DARPin Specific to MsbA—The
N3CDARPin library (23) was used for binder selection by ribo-
some display as described (25, 30). Four rounds of selections
were carried out following the solution panning strategy (29).
0.05% of -UDM were used to maintain MsbA in active form.
Single clones of the enriched pool of DARPins from the 4th
selection round were expressed from the vector pQE30myc5
(29)in E. coliXL-1 Blue yielding DARPins carrying an N-termi-
nal RGS-His6 tag (MRGSHHHHHH) and a C-terminal Myc5
tag (5 times amino acid sequence MEQKLISEEDLNE). Single
DARPin clones were analyzed for binding to bMsbAAviC by
crude cell extract ELISAs as described previously (29).
SEC of Isolated DARPins and the MsbA-DARPin Comp-
lexes—ELISA-positive MsbA-specific DARPins were sub-
cloned into pQE30 (Qiagen) devoid of the C-terminal Myc5 tag
for further biochemical analysis. Amolar excess (2 to 3 times) of
freshly gel-filtrated monomeric DARPins were mixed with
MsbA and incubated in 20 mM Tris/HCl (pH 7.5), 150 mM
NaCl, and 0.05% -UDM for at least 30min at 4 °C for complex
formation. The protein complex was separated on a Superdex
200 10/300GL column (GEHealthcare) (supplemental Fig. S4).
The fractions corresponding to the MsbA-DARPin complex
were analyzed by on-chip protein analysis according to the
manufacturer’s protocol (Protein 80 Kit, Agilent Technologies)
(supplemental Fig. S8).
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Cysteine Cross-linking of MsbA and DARPin_55 Mutants—
For cross-linking studies, two thiol-specific homobifunctional
cross-linkers namely M5M (1,5-pentanediyl bismethanethiosul-
fonate, Toronto ResearchChemicals) andM11M (3,6,9-trioxaun-
decane-1,11-diyl-bismethanethiosulfonate, Toronto Research
Chemicals) with spacer arms of 9.1 Å and 16.9 Å were used (32).
TheMsbA andDARPin_55mutant proteins weremixed at ratios
of 1:3 and incubatedwith 0.5mMof cross-linker for 15min at 4 °C
(ifnot statedotherwise).Thereactionswere stoppedbyadditionof
SDS sample buffer and separated by non-reducing SDS-PAGE.
The ability of DARPin_55_29C to cross-link to MsbA_191C was
also tested using inside-out membrane vesicles (ISOVs) con-
taining overexpressed MsbA_191C (with detergent purified
MsbA_191C, this cross-link is readily formed). To this end,
MsbA_191C containing ISOVs (6 mg in 3 ml) were mixed with
DARPin_55_29C (35 mg in 7 ml) and M11M (1 mM) was added.
After incubation for30min,N-ethylmaleimide (NEM,10mM)was
added to react with the remaining free cysteines for another 30
min. Subsequently, MsbA was purified according to the standard
protocol and subjected to non-reducing SDS-PAGE (supplemen-
tal Fig. S8).
ATPase Assay—The ATPase activity of purified protein was
measured from the release of Pi from ATP in a colorimetric
malachite green assay as described (33). Briefly, purified protein
(200 nM) in 50 mM K-HEPES buffer pH 7.4 containing 0.05%
-UMD, 2.5 mM MgCl2 and 2 mM ATP was incubated at 30 °C
in a total reaction volume of 50 l for 10–15 min. MsbA was
inactivated by heating at 80 °C for 2 min and free Pi was meas-
ured using malachite green solution. The A600 of the samples
was measured in a Microplate reader Infinite M100 (TECAN)
and compared with the A600 of standards containing 0.5–4
nmol Pi. Readings were corrected for Pi contamination origi-
nating from the ATP and buffer. DARPin_55-stimulated
ATPase activity ofMsbAwas performed by adding DARPin_55
at concentrations as indicated to MsbA (200 nM) 15 min prior
to the assay start. All cysteine mutants used in this study
showed ATPase activity comparable to the wild-type. Spin
labeling did not affect the activity ofMsbA (supplemental Table
S1).
Reconstitution of MsbA into Liposomes—Detergent-purified
MsbA was reconstituted into lipid membrane vesicles made of
polar E. coli lipids and egg phosphatidylcholinemixed at a ratio
of 3:1 (34). For EPR and DARPin binding experiments, the
reconstitution buffer was 20 mM Tris/HCl pH 7.4, 150 mM
NaCl, for ATPase activity measurements it was 50 mM
K-HEPES pH 7.0. MgCl2 was added only where indicated
shortly before performing ATPase activity or EPR experiments
to avoid aggregation of the liposomes. The amount of reconsti-
tuted MsbA was determined by the Bio-Rad DC Protein Assay
according to manufacturer’s protocol and compared BSA pro-
tein concentration standards. Binding of DARPin_55 to the
reconstituted MsbA was tested by incubating the DARPin_55
with reconstitutedMsbA (3:1 ratios) or empty liposomes for 15
min at 4 °C. UnboundDARPin_55 was removed by three buffer
washes after centrifugation at 20,000 g for 20min at 4 °C. The
pelleted liposomes were dissolved in SDS buffer and were sep-
arated by SDS-PAGE (15% acrylamide gel) followed by SYPRO
ruby staining (supplemental Fig. S6B).
Distance Measurements by Pulse EPR Experiments—Dipolar
time evolution data were acquired using the four-pulse DEER
(Double Electron Electron Resonance) experiment (35). DEER
traces were measured in a home-made high power Q band
spectrometer equipped with a home-made oversized resonator
(36). All pulse lengths were set to 12 ns and deuterium modu-
lation artifacts were averaged (8 times d1 time increment of 16
ns). The pump frequency was placed at the maximum intensity
of the nitroxide spectrum, and the observer frequency 80 MHz
lower. All samples were prepared independently from different
batches and the DEER traces were found to be reproducible.
Samples contained 10% (v/v) d8-glycerol and were shock-fro-
zen in liquid nitrogen before measurement. Data analysis was
performed with the software DeerAnalysis 2010 (37). The sim-
ulation of the possible spin label rotamers attached at selected
positions in MsbA was performed using the Matlab program
package MMM based on a rotamer library approach (38).
8-N3-[-32P]ATP Photolabeling—MsbA191C (1.5 M) and
DARPin_55_29C (6 M) were cross-linked with M11M (1.5
mM) in 20 mM Tris, pH 7.5, 150 mM NaCl, 0.05% -UDM con-
taining 3 mM MgCl2. 8-N3-[-32P]ATP (1 M, 0.6 Ci/mmol)
was added to 10 l protein sample (quadruplicates), and the
reactionmixtureswere incubated at 25 °C for 5min followed by
UV irradiation (100millijoules, UV cross-linker, Hoefer) on ice.
Labeled cross-linked MsbA-DARPin complex was analyzed by
SDS-PAGE and photolabeling was quantified using a phosphor
imager (Molecular Dynamics, Storm 840). To analyze the
amount of cross-linking, four aliquots were supplemented with
cold 8-N3-ATP followed by UV radiation, SDS-PAGE and
staining with SYPRO Ruby (Invitrogen). The fluorescent signal
was read with the LAS-3000 imaging system, and the bands
were quantified using the Aida software (Raytest).
RESULTS
In Vitro Selection and Identification of DARPins Specific for
MsbA—DARPin selection against biotinylated avi-tagged
MsbA (bMsbAAviC) was performed using ribosome display
with a DARPin library containing three randomized modules
(23, 31, 39) (supplemental Fig. S1). From 2000 DARPin clones
analyzed for binding to bMsbAAviC by an initial ELISA (supple-
mental Fig. S2), 42DARPinswere further analyzed using a spec-
ificity ELISA in which besides bMsbAAviC the ABC transporter
LmrCD and the secondary-active multidrug transporter AcrB
(both prepared as biotinylated Avi-tagged proteins) were used
(supplemental Fig. S3). This assay revealed 37 MsbA-specific
DARPins that were further analyzed by size-exclusion chroma-
tography. 27 of these DARPins displayed various degrees of
oligomerization (soluble aggregates) and 6 of them showed
monomer/dimer equilibriumandwere therefore excluded. The
remaining 4MsbA-specificDARPinsweremonomeric but only
one DARPin (named DARPin_55) formed a stable complex
withMsbA that could be isolated by size exclusion chromatog-
raphy (supplemental Fig. S4). The affinity of DARPin_55 for
MsbA was estimated by competition ELISA (23), in which the
binding of bMsbAAviC to immobilized DARPin_55myc5 was
competed by pre-incubation with increasing amounts of free
DARPin_55. The dissociation constant KD derived from these
experiments was 80 nM (supplemental Fig. S5). Hence, from
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2000 potential DARPin binders analyzed, we could identify one
specific high-affinity binder (Fig. 1A).
The ATPase Activity of MsbA Is Stimulated upon Complex
Formation with DARPin_55—The effect of DARPin binding to
MsbA was studied with respect to the ATPase activity of the
transporter. The basal ATPase activity of detergent-purified
MsbA (200 nM) was stimulated up to 2.1-fold upon complex
formation with DARPin_55 (serial dilution from 50 nM to 1.6
M) in a dose-dependent manner reaching its maximum at a
concentration of 400 nM DARPin_55 (Fig. 1C). Addition of the
control DARPin E3_5 (39, 40) did not alter the ATPase activity
of MsbA and DARPin_55 alone did not hydrolyze ATP. By
determining the Michaelis-Menten kinetics of ATP hydrolysis
it was found that DARPin_55 binding increases the maximal
velocity Vmax (increase from 162  9 to 255  8 nmol
Pi/min/mgMsbA)while the apparentKm of theATPase activity
remains unchanged (102 22 and 117 14MATP forMsbA
and the MsbA/DARPin_55 complex, respectively) (Fig. 1D).
Lipid A and daunomycin are known substrates of MsbA and
were found to stimulate the ATPase activity of the detergent-
purified transporter about 2-fold in the absence (41) and 3–4
fold in complex with DARPin_55. This implies that drug-in-
FIGURE 1. Characterization of DARPin_55: Specificity, epitope mapping and modulation of ATPase activity of MsbA. A, ELISA to determine binding
specificity of DARPin_55. DARPin_55 specifically binds to its target protein bMsbAAviC but not to the control proteins bLmrCDAviC and bAcrBAviC. DAR-
Pin_110819 specifically recognizing bAcrBAviC was used as a control. B, ELISA assay to delineate DARPin_55 binding to subdomains ofMsbA. DARPin_55 binds
to the transmembranedomain (bTMDAviC) but not to thenucleotidebindingdomain (bNBDAviC) ofMsbA. bAcrBAviC is used as anegative control.C,modulation
of basal ATPase activity of detergent-solubilized MsbA in complex with DARPin_55. DARPin_55 was added to MsbA (200 nM) in a 2-fold serial dilution series
ranging from 50 nM to 1.6M leading to a stimulation of the ATPase activity of MsbA by up to 2.1-fold. Addition of the unselected DARPin E3_5 (1M) toMsbA
doesnot increase itsATPase activity. DARPin_55 (1M) alonedoesnothydrolyzeATP.D, ATPase activity ofMsbAwasdetermined in thepresenceofDARPin_55
(1M) or E3_5 (1M) as well as in absence of DARPins at varying ATP concentrations. Addition of DARPin_55 results in a highermaximal rate of ATP hydrolysis
(Vmax), while the apparent affinity for ATP (Km) is not affected. E and F, stimulations of the ATPase activity of MsbA by substrates and DARPin_55 are additive.
Lipid A was added to detergent-purified MsbA at concentrations of 0, 0.05, 0.1, and 0.2 mg/ml E, daunomycin was added at concentrations of 0, 50, 100, and
200 M F and ATPase was measured in the absence and presence of DARPin_55 (1 M). Error bars represent standard deviations.
Asymmetry inMsbA Recognized by a DARPin
20398 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 24•JUNE 8, 2012
duced and DARPin_55-mediated stimulations of the basal
ATPase activity of MsbA are additive (Fig. 1, E and F). There-
fore, DARPin binding does not appear to interfere withMsbA’s
capability to bind its cargo substrates. MsbA and the
MsbA_E506Q (42) mutant (whose ATPase activity is abol-
ished) were reconstituted in proteoliposomes (34). The addi-
tion of lipidA and daunomycin stimulate theATPase activity of
reconstituted MsbA about 2-fold as described previously (sup-
plemental Fig. S6) (41). In contrast to detergent-purifiedMsbA
the basal ATPase activity of reconstituted MsbA was not stim-
ulated by the addition ofDARPin_55, becauseDARPin_55 does
not bind to membrane-embedded MsbA as discussed below
(supplemental Fig. S7).
Binding of DARPinDoesNot ImpairMsbAAbility toUndergo
Conformational Changes—To study the possible structural
effects induced by DARPin binding to the transporter, single
cysteine mutants ofMsbAwere labeled withMTSSL and inter-
spin distances between the two labeled sites were measured by
DEER in the apo- and AMP- PNP- stsates. The DEER analysis
on two representative spin-labeled sites (position 191 in the
TMDs and position 539 in theNBDs) is presented in Fig. 2. The
191–191 distance in the apo-state centered at 5.8 nmwas found
to be in line with the apo crystal structure (9), showing a C-C
distance of 4.7 nm. The distance decreased to 4.1 nm upon
addition of AMP-PNP and MgCl2 (Fig. 2A), which fully agrees
with the interspin distance simulated with the programMMM
FIGURE2. Intra-MsbAdistancemeasurementsbyDEERrevealnomajor conformational changesof the transporteruponbindingofwild-typeDARPin.
A, left, normalized DEER form factors F(t) and fits obtained with DeerAnalysis2010 on detergent-purified MsbA_191R1 alone and in complex with wild-type
DARPin_55. Traces were detected in the apo-state and in the AMP-PNP-state (5 mM AMP-PNP and 5 mM MgCl2) in the absence and in the presence of
DARPin_55, as indicated. Right, distance distributions obtained with Tikhonov regularization parameters 100 or 1000. The intra-MsbA distances simulated
based on the AMP-PNP x-ray structure (PDB 3B60) are superimposed (red dotted). B, DEER analysis on MsbA_539R1 alone and in complex with DARPin_55
analogous to A.
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(38) based on the AMP-PNP structure ofMsbA. Upon complex
formation with DARPin_55, MsbA showed the same distance
distributions, indicating that the detergent-solubilized MsbA
retained the ability to accomplish the conformational changes
induced by nucleotide binding (Fig. 2A).
The AMP-PNP-state exhibited a sharp 1.8 nm distance
between the two 539 labels located in the NBDs, both in the
absence and presence of DARPin_55 (Fig. 2B). The obtained
distance is again in perfect agreement with the crystallographic
data, strongly indicating that DARPin binding does not lead to
major structural changes in MsbA. The apo-state of the 539
mutant of MsbA showed a peak at about 6 nm in line with the
inverted V-shaped apo crystal structure, which is characterized
by a C-C distance of 6.4 nm. A second broad peak between 2
and 4 nmwas present whichmight represent intermediate con-
formations adopted during NBD closure or disengagement.
However, these intermediate states were only observed in this
particular mutant and they were strongly suppressed after
reconstitution into liposomes (supplemental Fig. S6). Interest-
ingly, adding DARPin_55 to the apo-state of the 539 mutant of
MsbA diminished the short distances but did not affect the 6
nm peak suggesting a stabilization of the open-apo structure by
DARPin_55 in analogy to the reconstitution into liposomes
(Fig. 2B, supplemental Fig. S6). Taking into consideration all
testedmutants, the inverted V-shaped crystal structure and the
outward-facing AMP-PNP bound structure (9) appear to
describe the conformational changes of detergent-solubilized
MsbA appropriately.
DARPin_55 Binds to the Transmembrane Domain of Deter-
gent-purifiedMsbA—Todelineate the binding epitope of DAR-
Pin_55 on full-length MsbA we used purified sub-domains of
MsbA, namely the TMD and the NBD. For this purpose, the
domains were purified as Avi-tagged biotinylated proteins
(bTMDAviC and bNBDAviC) and binding to DARPin_55 was
assessed by the same ELISA setup as used to identify MsbA-
specific DARPins described above (Fig. 1B, supplemental Fig.
S2). This ELISA experiment revealed that DARPin_55 binds to
the transmembrane domain (bTMDAviC) but not to the nucle-
otide binding domain (bNBDAviC) of MsbA. Binding of DAR-
Pin_55 to bTMDAviC resulted in a comparatively smaller ELISA
signal than binding to full length bMsbAAviC. This could be due
to partially unstructured regions on theTMDs in the absence of
the NBDs. Binding of DARPin_55 was further tested using
membrane vesicles containing overexpressedMsbA andMsbA
reconstituted in proteoliposomes (supplemental Fig. S7). In
contrast to detergent-purified MsbA, DARPin_55 did not bind
to the membrane-embedded transporter indicating that the
binding epitope on MsbA cannot be accessed by DARPin_55
because it is (at least partially) masked by the lipid bilayer.
Cysteine Cross-linking of DARPin and MsbA Mutants—To
further specify the binding epitope of DARPin_55 on MsbA,
single cysteines were introduced into MsbA and DARPin_55
and proximities between these cysteines were detected using
the thiol-specific homobifunctional cross-linkers M5M and
M11M. A total of nine single cysteine mutants were made at
different positions in the cytoplasmic part of the TMDofMsbA
and inDARPin_55 (four inMsbAat positions 103, 191, 206, and
246 and five inDARPin_55 at positions 12, 16, 29, 151, and 160).
Using ELISA, each mutated DARPin was confirmed to bind to
every single cysteine MsbA mutant (data not shown). All pos-
sible combinations ofMsbA andDARPin_55 cysteinesmutants
were then cross-linked as described in the experimental proce-
dures. The single cysteine mutants of MsbA alone did not form
any cross-linked products in the presence of M11M and M5M
(Fig. 3A) nor could any of the DARPin mutants be cross-linked
to Cys-less MsbA (supplemental Fig. S8). Cysteines introduced
at the N terminus of DARPin_55 (at positions 12, 16, and 29)
were efficiently cross-linked to MsbA_191C and to a lesser
extent toMsbA_206C andMsbA_246Cwith both cross-linkers
(supplemental Fig. S8). MsbA_103C formed only faint cross-
linking products with all DARPin mutants tested. Likewise, the
cysteines at the C terminus of DARPin_55 (at positions 151 and
160) were only poorly cross-linked with the four MsbA single
cysteine mutants with either cross-linker. These faint cross-
linking products seemed promiscuous and were therefore con-
sidered as background. In summary, the N terminus of DAR-
Pin_55 is in close proximity to the MsbA_191C position
whereas the orientation of the C-terminal part of DARPin_55
could not be resolved by only this analysis.
OneMolecule of DARPin_55 Binds to the MsbA Homodimer—
The maximal degree of DARPin cross-linking to MsbA never
seemed to exceed 50% of the MsbA chains (supplemental Fig.
S8). To further investigate this phenomenon, cross-linking
between DARPin_55_29C and MsbA_191C was carried out in
the absence of nucleotides as well as in the presence of AMP-
PNP or ATP-vanadate using increasing amounts of DARPin
(Fig. 3). Interestingly, cross-linking was saturated at a stoichi-
ometry of approximately one DARPin binding to homodimeric
MsbA in its apo-state (Fig. 3A). The exact stoichiometry was
quantified by SYPRO Ruby staining to 0.73  0.01 DARPins
cross-linked to MsbA (Fig. 4A). The presence of AMP-PNP or
ATP-vanadate appears to diminish the cross-linking reaction
(Fig. 3, B and C), which might be caused by a longer distance
between the thiol groups in this state (see EPR data below)
and/or a decreased binding affinity of the DARPin for the
nucleotide-bound state(s) of MsbA. Despite multiple attempts,
we were not able to perform surface plasmon resonance (SPR)
measurements which would have allowed for the determina-
tion of binding constants of DARPin_55 recognizing different
conformational states of MsbA. The ATPase activity of the
DARPin_55_29C/MsbA_191C complex is stimulated by a fac-
tor of two compared with MsbA_191C alone and remains
unchanged upon cross-linking using M11M (Fig. 3D). This
indicates that the DARPin_55 remains bound to MsbA during
its entire catalytic cycle. Binding stoichiometries were further
studied by gel filtration experiments. The MsbA/DARPin_55
complex was separated from excess DARPin_55 by size-exclu-
sion chromatography (supplemental Fig. S4) followed by a
quantitative analysis of DARPin_55 and MsbA using the pro-
tein chip technology (Agilent Technologies) (supplemental Fig.
S9). In agreement with the cross-linking results, the ratio
between DARPin_55 and MsbA dimer was quantified to 0.8.
The binding stoichiometries in the gel filtration assay as well as
in the cross-linking experiment were slightly less than one
DARPin bound per MsbA dimer. For the gel filtration assay,
this is likely due to partial dissociation of DARPin_55 from
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MsbA during the size-exclusion run whereas in the cross-link-
ing experiment, some of the thiol moieties of the cysteines
might have undergone oxidation during the purification and as
a consequence would not react with the methanethiosulfonate
cross-linker. At this point, two scenarios can explain the bind-
ing stoichiometry of one DARPin bound per homodimeric
MsbA: (i) Binding of the first DARPin molecule to MsbA steri-
cally prevents binding of the second or (ii) the DARPin recog-
nizes asymmetries in MsbA.
EPR Distances between DARPin_55 and MsbA—To rule out
possible steric clashes between the two DARPins in the com-
plex, the binding epitope of DARPin_55 onMsbA was mapped
by EPR. Various combinations of five spin-labeled single cys-
teine mutants spanning the MsbA structure (positions 25, 65,
103, 191, 482) and two spin-labeledDARPin_55 (positions 29 or
160) were measured to extract interspin distances by DEER.
Because of the 1:1 stoichiometric ratio between DARPin_55
andMsbA, binding of one spin-labeledDARPin to the homodi-
meric spin-labeled transporter gives rise to a three-spin com-
plex. This was confirmed by measuring the spin concentration
in the MsbA-DARPin complexes using continuous wave EPR
(data not shown). To disentangle the intra-MsbA from the
FIGURE 3.Methanethiosulfonate-mediated cross-linking of one DARPin to homodimeric MsbA. A–C, MsbA_191C (1 M) was incubated with increasing
amounts of DARPin_55_29C (from500 nM to 16M) in the absence of nucleotidesA, in the presence ofMgCl2 (3.5mM) andAMP-PNP (3mM) B, or ATP-vanadate
(2.5mM, each).C, protein complexeswere cross-linked using the homobifunctionalM11Mcross-linker (2mM) for 15min at 4 °C and separated by non-reducing
SDS-PAGE. D, ATPase activities of cross-linked MsbA191C-DARPin_55_29C complexes are equal to those of non-treated MsbA-DARPin complexes and are
consistently increased by a factor of two compared with MsbA alone.
FIGURE 4. Preferential nucleotide binding to one chain of asymmetrically stabilizedMsbA as determined by 8-N3-[-
32P]ATP photolabeling. A and B,
DARPin_55_29C was cross-linked to MsbA_191C using M11M, followed by addition of 8-N3-[-
32P]ATP (1 M) and UV-cross-linking (performed as quadrupli-
cates). The samples were separated by non-reducing SDS-PAGE and analyzed by SYPRO Ruby staining A and autoradiography B. C, band intensities corre-
sponding to cross-linked DARPin-MsbA complex and free MsbAmonomer obtained in A and Bwere quantified.
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MsbA-DARPin distances, we measured theMsbA alone and in
the presence of the DARPin. To reduce the known effects of
three-spin artifacts in the distance distributions (44), the intra-
MsbA and theMsbA-DARPin distances should be as distinct as
possible.
Among all combinations tested, only two (MsbA_191R1-
DARPin_55_29R1 and MsbA_65R1-DARPin_55_160R1, with
R1 denoting the MTSSL spin-labeled side chain) resulted in
extractable MsbA-DARPin distances (Fig. 5) (all DEER dis-
tances are presented in Fig. 6). The intra-MsbA_191R1 dis-
tances in the apo- and AMP-PNP- states are shown in Fig.
5A. Addition of DARPin_55_29R1 resulted in the appear-
ance of a short distance peak at 1.5–2 nm confirming the
close proximity of the N-terminal region (N-cap) of
DARPin_55 to position 191 in the TMDs already observed by
cross-linking (supplemental Fig. S8). Interestingly, the dis-
tance between these two positions becomes slightly longer
(2 nm) in the presence of AMP-PNP. In agreement with
the DEER results obtained with unlabeled DARPin_55 (Fig.
2A), the intra-MsbA_191R1 distance remains unchanged
upon addition of DARPin_55_29R1 in the apo-state and in
the presence of AMP-PNP (Fig. 5A). The longer distance
observed between the two nitroxide labels in MsbA and
DARPin_55 might explain the reduced degree of M11M
mediated cross-linking observed upon addition of nucleo-
tides (Fig. 3, B and C).
FIGURE 5.Determination of the binding epitope of DARPin_55 byDEER. A, left, normalized DEER form factors F(t) and fits obtainedwith DeerAnalysis2010
ondetergent-purifiedMsbA_191R1 alone and in complexwithDARPin_55 spin labeled at position 29 (N-cap). Traceswere detected in the apo-state and in the
AMP-PNP-state (5 mM AMP-PNP and 5 mM MgCl2) in the absence and in the presence of DARPin_55_29R, as indicated. Right, distance distributions obtained
with Tikhonov regularization parameters 100 or 1000. Assigned MsbA-DARPin distances are marked in the distance distribution. B, DEER analysis on
MsbA_65R1 alone and in complex with DARPin_55 spin labeled at position 160 (C-cap) analogous to A. The vicinity of the intra-MsbA and DARPin-MsbA
distances in the apo-state prevented a clear assignment of the DEER constraint.
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Whereas the position of the N-cap of DARPin_55 with
respect to the TMD could be readily mapped by cross-linking
and EPR, the orientation of the DARPin’s C-cap was challeng-
ing to find, also because no cross-link could be established
between the 151 and 160 positions ofDARPin_55 and any of the
MsbAmutants used (supplemental Fig. S8). After screening by
DEER a number of complexes with DARPin_55 labeled at the
C-cap (position 160), we found a clear distance constraint
between the C-cap and the extracellular region of the trans-
porter (position 65). In aggrement with the structural changes
expected from the x-ray data, addition of AMP-PNP to isolated
MsbA resulted in an increase of the 65–65 distance from 4 to 6
nm (Fig. 4B). When DARPin_55_160R1 was analyzed in com-
plex with MsbA_65R1, we found a distinct MsbA-DARPin_55
distance centered at 3.9 nm in the AMP-PNP-state, while the
overlap with the intra-MsbA distance prevented a clear MsbA-
DARPin_55 distance assignment in the apo-state. In contrast,
we could exclude distances 5 nm between the C-cap of DAR-
Pin_55 and other spin labels in the NBDs (position 482) and in
the cytoplasmic-facing region of the TMDs (positions 25, 103,
191) (Fig. 6). Based on these observations we could rule out that
the C-cap is oriented toward the NBDs, thus the transmem-
brane domain of MsbA seems to be covered at least partially by
DARPin_55. Importantly, the DARPin binding epitope was
found to be far away from the 2-fold symmetry axis of MsbA,
thus ruling out the possibility of steric clashes between two
DARPins as the cause for the stoichiometric ratio observed.
The ATPase Sites of Asymmetrically Stabilized MsbA Dis-
play Different Nucleotide Binding Properties—Cross-linking
DARPin_55_29C to asymmetric MsbA_191C provides the
unprecedented advantage that the conformationally unequal
chains of homodimeric MsbA can be separated by SDS-PAGE.
Thus questions as whether the two ATPase sites of asymmetric
MsbA display differences with respect to nucleotide binding
can be for the first time addressed. The cross-linked DARPin-
MsbA complex was incubated with 8-N3-[-32P]ATP followed
by UV cross-linking of the nucleotide to the two chains of
MsbA. Subsequently, the proteins were separated by SDS-
PAGE and the amount of cross-linking was determined by
autoradiography (Fig. 4). The ratio between the bands of DAR-
Pin_55 cross-linked toMsbA andMsbAalonewas quantified to
be 0.73  0.01 by SYPRO Ruby staining. Interestingly, the
MsbA chain cross-linked to DARPin_55 showed a stronger
photolabeling with 8-N3-[-32P]ATP than the MsbA chain
alone (ratio between MsbA-DARPin_55 to MsbA of 1.39 
0.07). This indicates that the MsbA monomer to which the
DARPin was cross-linked to was photolabeled 1.9 times stron-
ger than the free MsbA chain.
DISCUSSION
Asymmetries in the NBDs of ABC exporters arising from
trapping of nucleotides by vanadate have been discussed since
the mid-nineties when Urbatsch and Senior first described the
catalytic cycle of P-glycoprotein and laterwere also found in the
homodimeric transporter BmrA (16, 17). Using an in vitro
selected DARPin binder, we provide here novel evidence sup-
porting considerable asymmetries to be found in a well-studied
ABC exporter.
Our biochemical analysis shows that DARPin_55 binds to
the TMDs of MsbA in a stoichiometry of one DARPin per
homodimeric transporter. The binding epitope was mapped
to the TMDs of MsbA and therefore, the possibility that bind-
ing of the first DARPin sterically hinders binding of a second
DARPin to the symmetry-related epitope on MsbA could be
excluded. In further support of this notion, DARPin binding
does not affect the closure of theNBDs and the transition to the
FIGURE 6. The MsbA-DARPin complex based on cross-linking and DEER data. A, overview of the cross-linking data (supplemental Fig. S8) using the x-ray
structure of MsbA (PDB 3B60) and a homology model of DARPin_55 as templates. The black straight lines indicate thiol pairs showing strong cross-links, the
black dotted lines denote pairs showing weak cross-links. B, overview of interspin distances between MsbA and DARPin_55. The possible spin label rotamers
attached at selected positions in MsbA were simulated using the Matlab program package MMM and are indicated as green clouds. The black straight lines
highlight the pairs for which DEER constraints were obtained. All DEER data including the restraints are presented in the table.
Asymmetry inMsbA Recognized by a DARPin
JUNE 8, 2012•VOLUME 287•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 20403
outward-facing state ofMsbAupon addition ofAMP-PNP.The
DARPin therefore recognizes asymmetries in MsbA.
Asymmetric homodimers are not unusual. The epidermal
growth factor receptor fromDrosophila has been recently crys-
tallized in an asymmetric state in complex with two growth
factor ligands binding in a low- and a high-affinity mode (45).
Caspase-9 is activated by dimerization and was crystallized as
asymmetric homodimer exhibiting one active and one inactive
catalytic site (46). However, despite serious efforts we did not
succeed to solve the co-crystal structure of the MsbA-DAR-
Pin_55 complex and therefore the molecular details of the
asymmetries in MsbA remain elusive.
Epitope mapping revealed that the DARPin binding site
includes membrane-spanning portions of the TMD (Fig. 6).
There are two observations which further support this unex-
pected finding. First, DARPin_55 only binds to MsbA in its
detergent-purified but not in its membrane-bound form (sup-
plemental Fig. S7). In a detergent-purified MsbA sample, free
detergent monomers, protein-free detergent micelles and
detergent bound to the membrane protein are in equilibrium
(47). There is constant rapid exchange of detergents molecules
between these pools. Lipid bilayers in contrast are more rigid
(48). It is therefore likely that DARPin_55 partly displaces the
detergent micelle, but not the relatively stiffer lipid membrane
to bind to its epitope. Second, in agreement with the position-
ing of DARPin_55 with respect to themembrane boundary, the
randomized positions in the-turns of the second and the third
DARPin repeat exclusively harbor hydrophobic amino acids
(supplemental Fig. S10). These residues could mediate hydro-
phobic contacts with the transmembrane helices of MsbA,
whereas in the first repeat, there are two glutamates which
could interact with the cytoplasmic portion of the TMD.
Importantly, DARPin_55 only recognizes MsbA, but not its
homologue LmrCD or the multidrug transporter AcrB. There-
fore, unspecific hydrophobic interactions of DARPin_55 with
membrane proteins in general can be excluded. Interestingly,
the presence of DARPin_55 increased the ATPase activity of
the -UDM-solubilized transporter by influencing the Vmax
term, independent of the substrate-induced stimulations. This
finding is reminiscent of a recent biochemical characterization
of the P-glycoprotein-specific antibodyMRC16 the addition of
which was found to increase the ATPase activity of the trans-
porter in the absence as well as in the presence of the substrate
nicardipine (49).
It has often been argued that in vitro selected binding pro-
teins may distort the target protein thereby trapping it in an
unnatural and non-physiological state. However, numerous
examples of crystal structures solved alone and in complexwith
a binding partner in very similar conformations speak against
this argument (as reviewed in Refs. 24, 50, 51). One prominent
example reminiscent to the study presented here is the
homotrimeric multidrug transporter AcrB, that has been crys-
tallized alone and in complex with DARPins in an asymmetric
conformation in which each conformer represents a consecu-
tive step of the transport cycle (25, 27, 28). Only two DARPins
were found to bind to the trimer, and at the third expected
DARPin binding site, a steric clash between a conformationally
altered subdomain of AcrB with the back side of the DARPin
prevented binding (25, 26). The DARPins did not induce the
asymmetric state, but rather recognized the intrinsic asymme-
try of the targeted protein. It is therefore plausible that the
asymmetric conformational states of MsbA to which DAR-
Pin_55 binds to belong to the intrinsic ensemble of possible
conformations of the transporter.
DEER and cross-linking experiments show that DARPin_55
binds to homodimeric MsbA in the apo-state as well as in the
presence of AMP-PNP and ATP-vanadate and therefore the
recognized asymmetries in MsbA do not appear to be state-
specific. In support of this notion, cross-linked MsbA-DARPin
complexes retain their increased ATPase activity suggesting
that the DARPin remains bound during the entire catalytic
cycle. Importantly, DARPin binding does not trap MsbA in an
asymmetric state, which would lead to an inhibition of the
ATPase activity, but rather enables the transporter to inter-
convert between conformations necessary for function at a
higher rate. Our findings stand in partial contrast to a recent
study on P-glycoprotein antibodies MRK16 and UIC2, which
were shown to bind to the transporter in the apo-state as well as
in the presence of AMP-PNP (pre-hydrolytic state), but not if
the transporter is trapped with ADP-vanadate (post-hydrolytic
state) (49). In addition to earlier studies dealing with the asym-
metric nature of the catalytic cycle at the NBDs (16, 17), our
results indicate that distinct asymmetries also inhere to the
TMDs ofMsbAwhere the DARPin_55 epitope is located. Lipid
A, the natural substrate of MsbA, is rather big (molecular
weight of around 1.8 kDa) and asymmetric. Therefore, it is
plausible to assume that only one molecule of lipid A can be
accommodated by the substrate binding cavity of MsbA which
might require asymmetries in the TMDs. We found that the
ATPase activity of detergent-purified MsbA was stimulated by
lipid A and daunomycin. Our observations with lipid A agree
with a previous study (41), although the stimulation observed
by us is not as pronounced as reported, whereas in the same
study stimulation of theATPase by daunomycinwas not appar-
ent. These differencesmight arise from the different detergents
used for purification of MsbA (-UDM in our case and -DM
in the mentioned study (41)). Interestingly, the stimulation of
MsbA’s ATPase activity by lipid A or daunomycin and DAR-
Pin_55 are additive (Fig. 1,D and E). DARPin binding therefore
does not seem to interfere with substrate interactions at the
binding cavity. 8-N3-[-32P]ATP was shown to preferentially
photolabel one of the chains of asymmetric homodimeric
MsbA, hence supporting the notion that the asymmetries rec-
ognized by the DARPin at the TMDs are conformationally
linked to the nucleotide binding sites at the NBDs and vice
versa. Since photocross-linking using 8-N3-[-32P]ATP is a
non-equilibrium bindingmethod, further biochemical analyses
are difficult. Nevertheless, in symmetricMsbA both nucleotide
binding sites are identical and expected to be labeled by equal
amounts of 8-N3-[-32P]ATP. This is not the case and there-
fore, the two nucleotide binding sites are different from each
other. As previously proposed based on biochemical experi-
ments and molecular dynamics simulations, the asymmetric
switching at the NBDs might be a prerequisite for ATP hydrol-
ysis (16, 17, 19, 21). Our data suggest that DARPin binding to
MsbA populates asymmetric states of the transporter from an
Asymmetry inMsbA Recognized by a DARPin
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ensemble of structurally similar conformations which exhibits
increased basal ATPase activities and is fully compatible with
its function to bind lipid A and drugs.
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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
 
Generation of genetic constructs 
The E.coli msbA gene was cloned into the pBAD24 (1) for the protein production in E. coli. The 
5’ end of msbA gene was extended with sequences encoding a His-10 sequence, a C3 protease site (L-
E-V-L-F-Q-G-P) and a linker (D-E-A-E-K-L-F-N-Q).  The 3’ end of msbA gene was amplified using a 
reverse primer priming on the msbA gene. The PCR amplified product flanked by NcoI and XbaI 
restriction sites was ligated into the E. coli expression vector pBAD24 (1) yielding the expression 
vector pBADMsbA (expressed protein termed MsbAHis). The Avi-tag (G-L-N-D-I-F-E-A-Q-K-I-E-W-
H-E) coding sequence was added to the 3’ end of msbA, which facilitated site specific biotinylation of 
the target protein as will be described in another manuscript (Seeger and van Veen, submitted). The 
wild type E.coli msbA gene was mutated to cys-less msbA (C88S/C315S) and single cysteine mutants 
at the positions A25C, R103C, N191C, S206C and S246C of msbA were introduced by site directed 
mutagenesis. Likewise, single cysteine mutants were also introduced into the N- and C- terminal caps 
of DARPin_55 (which is cys-less by design) at the positions S12C, K16C, E29C, D151C and D160C. 
ATPase-inactive MsbA mutant was generated by mutating the conserved glutamate of the Walker B 
motif to glutamine (referred to as MsbA_E506Q mutant). The transmembrane domain (amino acid 
number 1 to 348) and nucleotide binding domain (starting from amino acid number 337 to 582) were 
cloned to contain an N-terminal His10-tag and a C-terminal Avi-tag sequence (the expressed protein 
termed as TMDAviC and NBDAviC respectively) into pBAD24 (1). All constructs were confirmed by 
DNA sequencing (Microsynth). 
 
Protein expression, purification and spin labeling 
MsbA expression was performed in E.coli C43(DE3) (2) cells, grown in 2YT media. Protein 
production was induced at OD600 of 0.8 with 0.02% L-arabinose (Sigma) for 12-14 hours at 25°C. 
Harvested cell pellets were resuspended in 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 25 μg/ml 
DNaseI and protease inhibitor cocktail (Sigma) and cells were lysed using EmulsiFlex-C3 (Avestin). 
Unbroken cells and cell debris were removed by centrifugation at 8000 rpm (SS34 rotor) for 10 min at 
4°C and membrane vesicles were then harvested by centrifugation at 45,000 rpm (Ti70 rotor) for 60 
min at 4°C. MsbA was solubilized from membrane vesicles using 1% β-DDM in 50 mM Tris/HCl (pH 
7.4), 150 mM NaCl (TBS) at 4°C for 90 minutes. The insolubilized membrane fraction was removed 
by centrifugation at 45,000 rpm (Ti70 rotor) for 60 min at 4°C and cleared lysate was loaded onto a 
Ni
2+
-NTA gravity flow column containing 1.5 ml resin (Qiagen). The resin was washed with 35 mM 
imidazole pH 7.5, TBS and 0.05 % β-UDM (50 ml) and MsbA was eluted from the column in the 
same buffer containing 250 mM imidazole pH 7.5 (7 ml). Avi-tagged MsbA was enzymatically 
biotinylated in vitro using purified BirA yielding bMsbAAviC (3). Every MsbA preparation used in this 
work was separated from aggregated material by gel filtration (Superdex 200, 10/300, GE Healthcare) 
in 20 mM Tris/HCl (pH 7.5), 150 mM NaCl and 0.05% β-UDM and the fractions of the homogenous 
main peak corresponding to dimeric MsbA were pooled. Purified MsbA was supplemented with 10% 
glycerol and was snap-frozen in liquid nitrogen and stored at -80°C. Freezing of MsbA did not 
decrease its ATPase activity even after prolonged storage and did not lead to aggregation of the 
protein (not shown). Single cysteine mutants of MsbA for methanthiosulfonate cross-linking and spin 
labeling were purified by supplementing 5 mM dithiothreitol (DTT) to the Ni
2+
-NTA washing and 
elution buffers. In order to spin label MsbA, DTT was removed on a PD-10 column (GE Healthcare) 
in TBS containing 0.05% β-UDM buffer according to the manufacturer’s protocol. Single cysteine 
MsbA was spin labeled at 4°C overnight using a 10 times molar excess of MTSSL ( (1-Oxyl-2,2,5,5-
tetramethyl-∆3-pyrroline-3-methyl) methanethiosulfonate; Toronto Research Chemicals). Excess spin 
label was removed by size exclusion chromatography. DARPin expression and purification has been 
described previously (4). In case of the single cysteine mutants of DARPin_55, 5 mM DTT was added 
during the Ni
+2
-NTA purification. DTT was removed by the size-exclusion chromatography (Superdex 
200, 10/300, GE Healthcare) in 20 mM Tris/HCl pH 7.5, 150 mM NaCl. Monomeric DARPin_55 was 
snap-frozen in the presence of 10% of glycerol in liquid nitrogen and stored at -80 °C. For the EPR 
measurements, DARPin-MsbA complexes were made by spin labeling the proteins individually, 
followed by gel-filtration of the protein complex. 
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SUPPLEMETARY TABLE 
 
Supplementary Table S1 
MsbA mutant 
ATPase activity  
nmol/min/mg protein 
MsbA* 136.7 ± 8.3 
MsbA_cysless 130.8 ± 9.2 
MsbA_V65C 230.1 ± 16.9 
MsbA_V65C_R1 234 ± 22.2 
MsbA_R103C 121.1 ± 0.7 
MsbA_R103C_R1 115.7 ± 5.9 
MsbA_N191C 111.3 ± 17.8 
MsbA_N191C_R1 126.86 ± 20.6 
MsbA_S482C 28.1 ±  6.5 
MsbA_S482C_R1 29.0 ±  0.7 
MsbA_L539C 133.9 ± 11.4 
MsbA_L539C_R1 136.54 ± 9.1 
 
*Wild-type;  
R1, methanothiosulfonate spin label 
 
 
 
 
 
SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1.   Schematic representation of the binder selection cycle using ribosome display 
 
An mRNA library is in vitro translated and a ternary complex composed of mRNA, nascent 
polypeptide and ribosome (linkage of genotype to phenotype) is used for the binding selection against 
the immobilized target protein. Unbound ternary complexes are removed by washing whereas the 
mRNA encoding for bound DARPins is eluted by dissociating the ribosomal complex using EDTA. 
The released mRNA is reverse transcribed to DNA and is either used for another round of selection or 
is analyzed by expressing single clones of the enriched library followed by ELISA (picture adopted 
from Huber et al. (29)) 
 
 
Figure S2.   Schematic drawing of the ELISA set up 
First, an anti-myc antibody is immobilized on an ELISA plate coated with Protein A. DARPins are 
then captured by the anti-myc antibody via their C-terminal Myc5-tag. Biotinylated target protein 
(LmrCD, AcrB or MsbA in our study) are then allowed to bind to the DARPin of interest and target 
protein binding is detected using a streptavidin-alkaline phosphatase. Its activity is detected 
colourimetrically at OD405 using p-nitrophenyl phosphate as a substrate.  
 
Figure S3.   Exclusion of unspecific DARPin binders 
42 DARPin clones were selected from the initial ELISA hits and were further analyzed in this 
specificity ELISA. Besides bMsbAAviC, ABC transporter bLmrCDAviC and secondary-active multidrug 
transporter bAcrBAviC were used to identify unspecific binders. Out of 42 primary hits, 37 hits were 
exclusively binding to bMsbAAviC, while 5 clones were promiscuously binding to other target proteins 
in the ELISA. 
 
Figure S4.   Size-exclusion chromatography profile of the MsbA-DARPin_55 complex 
MsbA and DARPin_55 were mixed at a molar ratio of 1:3 and incubated at 4 °C for 15 minutes. The 
MsbA-DARPin_55 complex and excess DARPin_55 were separated by size-exclusion 
chromatography (Superdex 200 10/300 GL column, GE Healthcare). The fractions containing the 
MsbA-DARPin_55 complex were quantified by on-chip protein analysis according to the 
manufacturer’s protocol (Protein 80 Kit, Agilent Technologies; Fig. S8). The ratio between DARPin55 
and MsbA was determined to 0.8 suggesting that one DARPin binds to homodimeric MsbA.  
 
Figure S5.   Estimation of DARPin_55 binding affinity to MsbA by a competition ELISA  
MsbA (50 nM) was pre-incubated with varying concentrations of free DARPin_55 (10 nM to 1000 
nM) and the mixtures were allowed to bind to immobilized DARPin_55myc5. At a free DARPin_55 
concentration of 80 nM, half-maximal ELISA signal was observed, suggesting that the binding affinity 
of DARPin_55 is around 80 nM (as described by Binz et al (23)). Addition of the unselected DARPin 
E3_5 (1 µM) did not compete with MsbA binding to immobilized DARPin_55 myc5. Error bars 
represent standard deviations. 
Figure S6.   Biochemical characterization of MsbA reconstituted into proteoliposomes 
A and B The ATPase activity of reconstituted was measured in the absence and the presence of 
DARPin_55 using a concentration range of the MsbA substrates lipid A A and daunomycin B. Error 
bars represent standard deviations. C  and D DEER analysis of detergent-solubilized and reconstituted 
MsbA. MsbA spin-labeled at position 539 was used.  Left, normalized DEER form factors F(t) and fits 
obtained with DeerAnalysis2010. Right, distance distributions obtained with Tikhonov regularization 
parameters 100 or 1000. C Interspin distances in the apo-state in β-UDM (black), β-DDM (green) and 
reconstituted in proteoliposomes (blue) are shown. This particular mutation was found to destabilize 
the apo-state conformation in β-UDM leading to the appearance of a main peak at about 6 nm and of 
additional short distances. Both β-DDM and liposomes stabilize the inward-facing conformation. D 
Analogous DEER analysis as in C but recorded in the presence of AMP-PNP and MgCl2.  
 
Figure S7.   DARPin_55 does not bind to membrane-embedded MsbA 
A Comparison of cross-linking of DARPin_55_29C to MsbA_191C in inside-out membrane vesicles 
(lane 2), reconstituted in proteoliposomes (lane 3) and in its detergent-solubilized form (lane 4). Cross-
linking was not observed for membrane-embedded MsbA_191C. B DARPin_55 (3.5 µM) was 
allowed to bind to reconstituted wild-type MsbA (1 µM) in proteoliposomes and empty liposomes at 
4°C for 30 minutes. Unbound DARPin_55 was removed by three washes and the protein was analyzed 
by SDS-PAGE followed by Ruby staining. DARPin_55 does not bind to reconstituted MsbA 
confirming the results described in A. 
 
Figure S8.   SDS-PAGE analysis of M11M and M5M-mediated cross-links between single 
cysteine mutants of MsbA and DARPin_55 
Cross-links were performed as described in the materials and methods. The analysis concludes that the 
N-terminus of DARPin_55 (positions 12, 16 and 29) is in close proximity to positions 191, 206 and 
246 of MsbA while the C-terminus of DARPin_55 (positions 151 and 160) is far apart from any of the 
cysteines introduced into MsbA (see also Fig. 6).  
 
Figure S9.   Stoichiometry analysis of a DARPin_55-MsbA complex 
A Calibration of protein concentration determination by on-chip protein analysis (Agilent 
Technologies). DARPin_55 at concentrations of 4 μM, 2 μM and 1 μM was analyzed on a protein 
chip, and the areas of the resulting peaks were plotted against the known protein concentration 
(determined at A280). The error bars of duplicate measurements were very small and the data could be 
fitted by linear regression. Note that the curve does not intercept at the origin, which likely reflects the 
detection threshold of this method. For the quantification of the MsbA-DARPin_55 complex, the 
protein concentrations were chosen to be in the linear range of detection. B Raw data of on-chip 
analysis of the MsbA-DARPin_55 complex eluted after gel-filtration. Peaks 9 and 10 correspond to 
DARPin_55 and MsbA respectively and the peak area is quantified taking the internal standard peak 
11 as reference using the manufacturer’s software. Using calibrations curves as determined in A, the 
stoichiometry between DARPin_55 and MsbA was determined. 
 
Figure S10.   Surface properties of DARPin_55 
A A homology model of DARPin_55 was generated based on the coordinates of DARPin E3_5 
(PDB entry 1MJ0) using SWISS-MODEL (51). The protein surface is colored according to its 
hydrophobicity (intensity of red color indicates increasing hydrophobicity) using the Eisenberg 
hydrophobicity scale (52). The DARPin scaffold is shown as cartoon and randomized residues are 
shown as sticks. B The sequence of DARPin_55 is depicted and randomized positions of the DARPin 
library are indicated in the Template_N3C sequence.  
 
Figure S1 Figure S2
 
 
 
 
 
 
 
 
 
 
0.0000
0.5000
1.0000
1.5000
2.0000
2.5000
bMsbAAviC
bLmrCDAviC
bAcrBAviC
O
D
40
5
Figure S3
0100
200
300
400
- DARPin_55 + DARPin_55
   
 A
TP
as
e 
ac
tiv
ity
 n
m
ol
 P
i/m
in
/m
g 
pr
ot
ei
n
Lipid A
0 0.2
Lipid A
0 0.2 mg/ml
0
100
200
300
400
0        2 0 200mM
Daunomycin Daunomycin
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
AT
P
as
e 
ac
tiv
ity
 n
m
ol
 P
i/m
in
/m
g 
pr
ot
ei
n
- DARPin_55 + DARPin_55
A B
Figure S6
Figure S4 Figure S5
C
0 1 2 3
0.2
0.4
0.6
0.8
1
F(
t) 
/ F
(0
)
2 3 4 5 6 7 8
0 0.2 0.4 0.6 0.8
0.6
0.7
0.8
0.9
1
F(
t) 
/ F
(0
)
2 3 4 5 6 7 8
D
t / ms
t / mst / ms
t / ms
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
5 7 9 11 13 15 17 19
DARPin_55
MsbA-DARPin_55 complex
MsbA
M
ar
ke
r 
M
sb
A
C
om
pl
ex
D
A
R
P
in
_5
5
65
45
25
15
6.5
kDa
Volume (ml)
A
28
0
B
Figure S7
A
130
100
70
55
40
35
25
15
kDa
Marker Empty liposomeMsbA liposome
MsbA
kDa
170
130
100
70
55
40
35
25
15
10
1          2            3             4
Free MsbA 
cross-linked
DARPin_55 dimer
DARPin_55 
monomer
cross-linked
DARPin_55 - MsbA 
DARPin55_29C cross-linking with MsbA mutants (M11M and M5M cross-linkers)
DARPin55_16C cross-linking with MsbA mutants (M11M and M5M cross-linkers)
DARPin55_12C cross-linking with MsbA mutants (M11M and M5M cross-linkers)
1        2        3         4         5                                    6        7         8          9        10   
kDa
130
100
55
40
35
25
15
10
70
kDa
170
130
100
55
40
35
25
15
70
DARPin55 cross-linked 
MsbA monomer
Free MsbA monomer
DARPin dimer
DARPin monomer
1      2      3                  4        5                 6        7       8         9       10
DARPin55_160C cross-linking with MsbA mutants (M11M and M5M cross-linkers)
DARPin55_151C cross-linking with MsbA mutants (M11M and M5M cross-linkers)
1          2      3       4         5                6        7        8       9       10
kDa
170
130
100
55
40
35
25
15
70
1       2       3      4      5             6       7         8                9        10
Figure S8
1.   DARPin_29C_MsbA_103C_M11M
2.   DARPin_29C_MsbA_191C_M11M
3.   DARPin_29C_MsbA_206C_M11M
4.   DARPin_29C_MsbA_246C_M11M
5.   DARPin_29C_MsbA_cysless_M11M
6.   DARPin_29C_MsbA_103C_M5M
7.   DARPin_29C_MsbA_191C_M5M
8.   DARPin_29C_MsbA_206C_M5M
9.   DARPin_29C_MsbA_246C_M5M
10. DARPin_29C_MsbA_cysless_M5M
1.   DARPin_12C_MsbA_103C_M11M
2.   DARPin_12C_MsbA_191C_M11M
3.   DARPin_12C_MsbA_206C_M11M
4.   DARPin_12C_MsbA_cysless_M11M
5.   DARPin_12C_MsbA_246C_M11M
6.   DARPin_12C_MsbA_103C_M5M
7.   DARPin_12C_MsbA_191C_M5M
8.   DARPin_12C_MsbA_206C_M5M
9.   DARPin_12C_MsbA_246C_M5M
10. DARPin_12C_MsbA_cysless_M5M
1.   DARPin_151C_MsbA_103C_M11M
2.   DARPin_151C_MsbA_191C_M11M
3.   DARPin_151C_MsbA_206C_M11M
4.   DARPin_151C_MsbA_246C_M11M
5.   DARPin_151C_MsbA_cysless_M11M
6.   DARPin_151C_MsbA_103C_M5M
7.   DARPin_151C_MsbA_191C_M5M
8.   DARPin_151C_MsbA_206C_M5M
9.   DARPin_151C_MsbA_246C_M5M
10. DARPin_151C_MsbA_cysless_M5M
1.   DARPin_160C_MsbA_103C_M11M
2.   DARPin_160C_MsbA_191C_M11M
3.   DARPin_160C_MsbA_206C_M11M
4.   DARPin_160C_MsbA_246C_M11M
5.   DARPin_160C_MsbA_cysless_M11M
6.   DARPin_160C_MsbA_103C_M5M
7.   DARPin_160C_MsbA_191C_M5M
8.   DARPin_160C_MsbA_206C_M5M
9.   DARPin_160C_MsbA_246C_M5M
10. DARPin_160C_MsbA_cysless_M5M
1.   DARPin_16C_MsbA_103C_M11M
2.   DARPin_16C_MsbA_191C_M11M
3.   DARPin_16C_MsbA_206C_M11M
4.   DARPin_16C_MsbA_246C_M11M
5.   DARPin_16C_MsbA_cysless_M11M
6.   DARPin_16C_MsbA_103C_M5M
7.   DARPin_16C_MsbA_191C_M5M
8.   DARPin_16C_MsbA_206C_M5M
9.   DARPin_16C_MsbA_246C_M5M
10. DARPin_16C_MsbA_cysless_M5M
kDa
170
130
100
55
40
35
25
15
70
1        2      3      4       5                 6      7      8         9      10
kDa
170
130
100
55
40
35
25
15
10
70
y = 31.554x - 11.575
R² = 0.9985
0
20
40
60
80
100
120
140
0 1 2 3 4 5
P
ea
k 
ar
ea
 (a
.u
.)
DARPin_55 conc (µM)
MsbA
DARPin_55
MsbA
DARPin_55
Figure S9
A
B
   N cap             Repeat 1         Repeat 2       Repeat 3                   C cap
N-cap Repeat 1
Template_N3C     MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAXDXXGXTPLHLSAXXGHL 
DARPin_55        MRGSHHHHHHGSDLGKELLEAARADQDDEVRILMANGADVNANDIEGETPLRLAAMLGHL  
 
      
Template_N3C     EIVEVLLKXGADVNAXDXXGXTPLHLAAXXGHLEIIEVLVKXGADVNAXDXXGXSPLHLA 
DARPin_55        EIVEVLLKNGADVNAKDWVGFTPLHLAATFGHLEIVEVLLKHGADVNAQDFLGSTPLHLA
 
 
 
 
Template_N3C     AXXGHLEIVEVLLKXGADVSAQDEFGKTAFDISIDNGNEDLAEILQKLN
 
DARPin_55        AKRGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN
 
Repeat 2
Repeat 3 C-cap
Figure S10
A
B
b-turn 1
b-turn 2 b-turn 3
41 
 
CHAPTER C 
Structural and functional studies of homodimeric ABC 
transporter MsbA using an in vitro selected DARPin 
binder 
C.1 Introduction 
The envelope of Gram-negative bacteria is composed of two distinct lipid membranes, an 
inner membrane, consisting of glycerophospholipids, and an outer membrane, which is an 
asymmetric bilayer. The outer leaflet of the outer membrane consists of lipopolysaccharides 
(LPS). A molecule of LPS consists of two parts - a covalently bound lipid component, termed 
lipid A, and a hydrophilic hetero-polysaccharide (Figure _C1). The lipid A moiety is unique to 
Gram-negative bacteria. It is a potent activator of the innate immune system in animals via 
the TLR-4 receptor1,2.  First insights into MsbA function came from studies performed on an 
E.coli htrB-deficient mutant. HtrB is a lauroyl transferase involved in lipid A biosynthesis. 
Lack of HtrB results in the accumulation of LPS in the inner membrane of E.coli and is toxic at 
elevated temperatures. The overexpression of MsbA in the htrB mutant was found to 
restore the translocation of LPS to the outer membrane at 42°C. Further evidence came from 
an E.coli mutant called WD2, which carries a A270T substitution in MsbA1. WD2 is a 
temperature-sensitive mutant, in which the function of MsbA (A270T) is inhibited if cells are 
shifted from 30°C to 44°C. Using 32P and 14C- acetate labeling, it was shown that the export 
of newly made LPS and phospholipids to the outer membrane is hampered. These 
experiments demonstrated that MsbA is an essential component of the lipid A transport 
system in E.coli1.  
The first molecular structure of MsbA3 (E.coli homologues of eukaryotic MDR ABC 
transporter) was reported by Chang and colleagues in 2001. However, the crystal structure 
of Sav18664 (53 % sequence similarity with MsbA) reported by the Locher group in 2006 
indicated that the MsbA structures were incorrect in both, the hand and the topology. This 
lead to the retraction of all structures of MsbA published by the Chang group3,5,6. Chang and 
colleagues reported that the initial error in the structure determinations was the accidental 
inversion of the sign of the anomalous difference in a data-conversion step that converted  
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experimental intensity (I) values to structure factor moduli (F). Specifically, I(h, k, l) 
and I(-h, -k, -l) were converted to |F(-h, -k, -l)| and |F(h, k, l)|, respectively7,8. The corrected 
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structures of three homologues of MsbA9 in three different conformations at resolutions 
ranging from 3.7 Å to 5.5 Å were published later (Figure_C2). These structures describe two 
inward-facing states obtained in the absence of nucleotides and one outward-facing state 
obtained in the presence of the nucleotide analog AMP-PNP. One nucleotide-free state is 
called open-apo state, in which NBDs are far apart. The second nucleotide-free state is 
named closed apo-state displaying the NBDs in partial molecular contact. In the nucleotide 
bound state, the MsbA structure is virtually identical to the Sav1866 structure, in which the 
NBDs dimerize and sandwich the two nucleotides at the binding interface. 
Despite the availability of MsbA structures, many mechanistic details remain unclear 
due to the low-resolution data (between 3.7 Å and 5.5 Å). By using the Designed Ankyrin 
Repeat Proteins (DARPins) technology, we hoped to trap ABC-transporters in novel 
conformational states. The DARPins represent a well-established randomized scaffold used 
as an alternative to antibody fragments (Fab and scFv) and have been selected against a 
variety of target proteins10-15. DARPins have the potential to trap the targeted protein in 
alternative conformations and have been previously shown to mediate crystal 
contacts12,15,16. A DARPin selected against the multidrug transporter AcrB for example, traps 
this protein in an asymmetric state with two DARPins bound to the homotrimer. The third 
subunit is in a different conformation in which the DARPin binding site is altered15,16. In the 
absence of the DARPins, AcrB was initially crystallized in a symmetric17 and later in an 
asymmetric state18,19. In analogy to the work on AcrB, MsbA-specific DARPins can be used as 
crystallization chaperones that might lead to well diffracting crystals. This chapter describes 
the selection of DARPins against MsbA and summarizes our attempts to crystallize MsbA 
with the help of DARPins. 
C.2 Results 
C.2.1 Target protein (MsbA) biotinylation 
Adequate biotinylation of the target protein is a prerequisite for ribosome display (RD) 
selections and ELISA screening. In RD selection using solution panning, the fraction of 
unbiotinylated target protein contributes to the loss of specific binders due to a lower 
degree of immobilization than estimated; while in our ELISA format, it competes with the 
biotinylated protein undesirably (Chapter B-Figure_S2 and section C.4.4.2). To overcome 
such methodological problems, we used the Avi-tag technology. The Avi tag is a fusion tag of 
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15 amino acids comprising a lysine residue that becomes specifically biotinylated by the 
biotin ligase enzyme (BirA). In the presence of biotin and ATP, BirA catalyzes amide linkage 
between the biotin and the lysine. The Avi tag is fused by genetic engineering to the target 
protein20 either at the N or C terminus. The recombinant Avi-tagged protein is purified in the 
same manner as the target protein, and in vitro enzymatic biotinylation is carried out using 
purified BirA21 (Figure_C3).  Here in this thesis, we used in vitro enzymatic biotinylation 
facilitated by the Avi-tag methodology to achieve maximally biotinylated target protein for 
ribosome display selection procedure and binders screening by ELISA.  
 
C.2.2 Selection and screening of MsbA specific DARPins 
A ribosome display selection procedure is illustrated in Chapter B-Figure_S1. Briefly, 
biotinylated MsbA (bMsbAAviC) was mixed with in vitro translated DARPin library and 
followed by capturing of the bMsbAAviC-DARPin complexes with streptavidin-coated 
paramagnetic beads. The enriched DARPin pool of the fourth round of ribosome display was 
subcloned into the expression vector pQE30myc5. Single clones (about 2000) of the fourth 
round were further analyzed by crude extract ELISA. In this ELISA set up, the selected 
DARPins were immobilized on the plate via myc-tag and the binding of membrane protein 
was detected (Chapter B-Figure_S2). The detergent solubilized membrane protein was 
added to the ELISA experiment at the latest possible stage in order to reduce the washing 
and incubation to a minimum. From the initial ELISA hits (not shown), about 42 of the 
DARPin clones (2.1 % of all examined) showed binding to bMsbAAviC. To test whether the  
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binding is specific for MsbA, other biotinylated membrane proteins like bLmrCDAviC 
and bAcrBAviC were also included in the ELISA assay. About 37 of the DARPin clones (1.85% of 
all examined) were exclusively binding to bMsbAAviC, while 5 clones were unspecifically 
binding to other target proteins in the ELISA (Figure_C4A). The 37 MsbA-specific DARPins 
were analyzed by SEC. About 27 clones displayed various degrees of oligomerization (soluble 
aggregates) and 6 clones displayed monomer/dimer equilibria and were therefore excluded 
(Figure_C4B). The remaining 4 MsbA-specific DARPins were monomeric but only one DARPin 
(0.05% of all examined) eluted in complex with purified MsbA in SEC (Figure_C5). The affinity 
of DARPin_55 for MsbA was determined by competition ELISA10, where the binding of 
bMsbAAviC to immobilized DARPin_55myc5 was competed by pre-incubation with increasing 
amounts of free DARPin_55. The dissociation constant KD estimated from these experiments 
was 80 nM. Hence, from 2000 potential DARPin binders analyzed, we could identify one 
specific and high affinity binder termed DARPin_55. 
Binding of DARPin_55 was also analyzed with closely related homologues of E.coli  
MsbA, namely Vibrio cholera (MsbA-VC), and Salmonella typhimurium (MsbA-ST). 
DARPin_55 was found to bind to all three homologues. A competition ELISA was performed 
to test specific binding of DARPin_55, where E.coli MsbA was used as a competitor.  
DARPin_55 binding to bMsbA-STAviC and bMsbA-VCAviC was competed by non-biotinylated 
MsbA-EC (Figure_C4C). The binding signal was decreased to the background level upon 
addition of excess competitor MsbA-EC, confirming specific binding of DARPin_55. The ELISA 
signal is reduced for bMsbA-STAviC and bMsbA-VCAviC, which suggests lower binding affinity of 
DARPin_55 for these close homologues. 
C.2.3 Crystallization of MsbA alone and the MsbA-DARPin_55 
complex 
The structures of MsbA from three closely related bacterial homologues, namely Escherichia 
coli (MsbA-EC), Vibrio cholera (MsbA-VC), and Salmonella typhimurium (MsbA-ST) were 
determined in three different conformations at resolution ranging from 3.7 Å to 5.5 Å. 
Nucleotide bound and open apo structures of MsbA were determined at 3.7 Å and 5.3 Å 
using MsbA-ST and MsbA-EC, respectively9 (Figure_C2). We used MsbA-EC with and without 
DARPin_55 in the apo and the nucleotide bound state to set up crystallization plates. 
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C.2.3.1 Crystallization  
The MsbA-DARPin_55 complex was concentrated to 15-16 mg/ml and used for crystallization 
while MsbA alone at 13-14 mg/ml served as a control (Figure_C5).  Despite extensive efforts, 
the MsbA-DARPin_55 complex did not crystallize while MsbA alone crystallized in different 
conditions (Figure_C6). The initial conditions identified were further refined. The crystals 
appeared in 50 mM Tris-Cl pH 8.4, 15% PEG 400 and 1 M Ammonium formate at 20 °C and 
diffracted to 11 Å. To further improve the crystal quality, an additive screen including salts, 
small organic molecule, sugars, amino acids, dyes, cryo-preservatives, was performed. The 
condition was further refined using different PEG solutions (PEG 300, PEG 350 MME, PEG 
4000, PEG 6000) and different buffers (HEPES and Glycine).  Lipid A (the natural substrate of 
MsbA) as well as ATP or ADP with and without EDTA or MgCl2 were also used to optimize the 
crystallization conditions. The optimized condition, which included jeffamine M600 50 % 
(v/v) as an additive to the original condition improved the diffraction quality of the crystals 
from 11 to 7 Å resolution (Figure_C6, A, B, C, D, E, F). 
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C.2.3.2 Crystallographic analysis  
Data were collected on a Pilatus 6M detector at the Swiss Light Source (beamline X06SA), 
Villigen, and Switzerland.  The MsbA crystals diffracted to a resolution of around 7 Å using 
the synchrotron light source. A complete data set of 180° was obtained with an oscillation  
range of 0.5°. The data were processed using the program XDS22. The space group was 
determined to be P21. The probable number of homodimers in the asymmetric unit is 4, 5 or 
6, with solvent contents of 73.80, 67.25 or 60.70, respectively (Table 1). The Matthew’s 
coefficient was calculated as Vm = 4.69, 3.76 or 3.13 Å
3/Dalton for 4, 5 or 6 molecule in the 
asymmetric unit, respectively (calculations were based on the molecular weight of dimeric 
MsbA as 135 kDa). The reported MsbA structure in the apo state (PDB ID 3B60) was 
determined in space group P1 with solvent content of 75.4 % and 4 molecules in the 
asymmetric unit. In general, membrane protein crystals contain solvent contents of around 
70 %. We therefore considered 4 molecules in the asymmetric unit with the solvent content 
of 73.8 % for the molecular replacement (Table 1). 
To determine the MsbA structure from the native data set, we tried molecular 
replacement using MsbA coordinates9 (PDB ID: 3B5W) as a search model. We attempted 
molecular replacement in PHASER23 using one monomeric chain of MsbA with and without 
TM4 and TM5 (the trans-membranes involved in domain swapping, which is deviating most 
between different MsbA structures (Figure_A6)) as search model. Phaser found only 3 MsbA 
monomers as molecular replacement solution. The log-likelihood-gain (LLG) and translation 
function (TFZ) were 42 and 13.5, respectively, when TM4 & TM5 were included in the MsbA 
search model. However, LLG was increased to 91 with a TFZ value of 13.5, if the truncated 
monomeric chain of MsbA devoid of TM4 & TM5 was used to calculate phases. The 
maximum likelihood asserts the best model probability based on the data provided23. A 
positive value of LLG and TFZ value greater than 10 indicate that the partial molecular 
replacement solution is likely to be correct. Therefore, we used the partial structure solution 
with the higher value for LLG for further analysis. The partial structure solution includes one 
MsbA dimer and one MsbA monomer, which is much less than the expected 8 MsbA 
monomers in the asymmetric unit. The 3 detected truncated monomer MsbA contain a 
relatively low fraction of the total scattering mass, which makes the detection of the 
remaining MsbA molecules very difficult due to the large signal to background at poor 
resolution (>7 Å). The partial structure solution was then optimized by rigid body refinement 
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using PHENIX. The Rfree and Rwork values obtained were very high.  This is primarily due to 
the fact that only a partial structure could be used for phasing and structure factor 
calculation. The structure could not be further refined using Refmac5 (CCP4i) or PHENIX. A 
comparison of the structure determination of the present study and the published structure9 
has been included in Table 2. Crystals that diffract to higher resolution are needed to 
determine the full structure of MsbA in this crystal form. 
C.3 Discussion 
Despite the advances in macromolecular crystallography, structural studies of interesting 
macromolecules and membrane proteins are frequently hampered at several steps including 
high throughput screening of expression and purification, robotics crystallization (vapor 
diffusion, lipid cubic phase) and synchrotron radiation. Conformational heterogeneity, 
flexible structure and surface chemistry are reasons why a particular protein is difficult to 
crystallize. Such hurdles have been successfully overcome by co-crystallization of these 
proteins together with natural ligands9,24 or by genetic engineering25,26. Chaperone assisted 
crystallography is a promising approach, which dates back to the co-crystallization of hen 
egg-white lysozyme and the Fab of a monoclonal anti-lysozyme antibody27. The concept 
behind chaperone assisted crystallography is to increase the probability of obtaining well-
ordered crystals by minimizing the conformational heterogeneity of the target protein or by 
increasing the hydrophilic surface for potential crystal contacts. Antibody based chaperones 
have successfully been used to crystallize membrane proteins28,29. Non-antibody based 
scaffolds such as Designed Ankyrin Repeat Proteins (DARPins) have been developed by 
protein engineering with improved properties (Cysteine less scaffold, higher expression in 
bacteria)10,30,31. The continuously increasing numbers of co-crystal structures in complex 
with DARPins have validated the importance of this scaffold in macromolecular 
crystallography32.  
In the present study, MsbA has been successfully expressed and purified with a deca-
his-tag at the N-terminus. Detergent (β-UDM) solubilized MsbA shows basal ATPase activity, 
indicating that the purified protein is suitable for functional characterization and 
crystallographic studies. MsbA can be expressed and purified in reasonable quantities, which 
makes it an attractive target for crystallization studies. MsbA was considered as a promising 
target to apply the chaperone assisted crystallography approach, because it provides crystals 
that diffract only to low resolution (5.3 Å and 5.5 Å)9. The resulting MsbA structures in two 
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different apo-states are currently of very poor quality. With MsbA-specific DARPins, it was 
hoped that: (i) the MsbA-DARPin complexes would give rise to better diffracting crystals, and 
(ii) DARPins potentially could trap the intrinsically flexible transporter in a different 
conformational state.  
Here, the use of in vitro selection method is demonstrated to identify a specific 
binder for MsbA, named DARPin_55. DARPin_55 showed a homogenous monomeric gel-
filtration profile, which is a critical requirement to separate the ‘’target protein-DARPin’’ 
complex from excess DARPin by gel-filtration chromatography. The stoichiometry of MsbA 
and DARPin_55 was determined as 1 DARPin binding to homodimeric MsbA (Chapter B). 
Also, the possibility of using DARPin_55 in complex with other homologues of MsbA, namely 
MsbA-VC, and MsbA-ST for co-crystallization studies was investigated. DARPin_55 binds to 
MsbA-ST with a similar affinity as MsbA-EC, while binding affinity to MsbA-VC is about 60 % 
of the affinity to MsbA-EC, judged from ELISA signals (Figure_C4C). The epitope for 
DARPin_55 is located in the membrane spanning part of the transmembrane domain (TMDs) 
of MsbA (Chapter B). The TMD sequence identity between MsbA-EC and MsbA-ST and 
MsbA-VC is 97 and 64 %, respectively. It is therefore not surprising that DARPin_55 binds to 
MsbA-ST equally well as to MsbA-EC. Although the sequences of MsbA-EC and MsbA-VC are 
quite different, DARPin_55 specifically binds to MsbA-VC reasonably well (Figure_C4C) (as 
seen by ELISA), which would suggest that the binding epitope is rather conserved. This 
provided the opportunity to co-crystallize DARPin_55 in complex with MsbA_EC and 
MsbA_ST. However, the co-crystallization of DARPin_55 with either homologue did not lead 
to any crystal. Interestingly, several crystallization conditions for MsbA-EC and MsbA-ST 
alone were found. This indicates that in this particular case, addition of DARPin_55 was 
rather inhibiting than promoting crystal growth. Therefore, the chaperone assisted 
crystallography approach is not a generic method for obtaining better crystals, but remains 
one of many methods that can be used. The identification of only one MsbA-specific DARPin 
restricted our efforts to improve the current MsbA structures. In a previous study on AcrB, it 
was found that only a subset of DARPins could successfully be used as crystallization 
chaperones, whereas many DARPins were recalcitrant to co-crystallize in complex with 
AcrB33.  
One of the MsbA-EC crystallization conditions was refined and datasets to 7 Å were 
collected. A partial structure could be solved by molecular replacement. The partial structure 
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solution shows the inverted V shaped structure as reported previously9. Compared to the 
previous structure the distance between the NBDs are about 5 Å shorter. The distance 
differences between the two NBDs of MsbA can be attributed to the different detergent 
used in the purification and crystallization or to the intrinsic flexibility of the apo-state of 
MsbA. 
Binders of other scaffolds such as Fabs, nanobodies etc. can be selected against 
MsbA. The identification of a number of binders of various scaffolds would increase the 
likelihood to find better diffracting co-crystals. The MsbA-DARPin_55 complex did not 
crystallize using the vapor diffusion method. In the future, lipid cubic phase could be an 
alternative to crystallize the MsbA-DARPin_55 complex.  
C.4 Experimental procedure 
C.4.1 Generation of genetic constructs 
All the constructs of E.coli MsbA used in this study are described in Chapter B. Salmonella 
typhimurium and Vibrio cholerae msbA genes were amplified using forward primers 
(MsbA_ST_PstI_F and MsbA_VC_PstI_F) and reverse primers (MsbA_ST_XbaI_R and 
MsbA_VC_XbaI_R). The PCR amplified product flanked by PstI and XbaI restriction sites was  
ligated into the E. coli expression vector pBAD2434 . These expression vectors were named as 
pBADMsbA_ST and pBADMsbA_VC (expressed protein were termed MsbA_STHis and 
MsbA_VCHis respectively).  
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The generation of C-terminally Avi-tagged MsbA constructs of 3 different 
homologues is described here. A DNA fragment encoding the Avi-tag sequence flanked by 
the restriction sites NheI and BamHI was formed by annealing the two oligonucleotides 
avitag_for and avitag_rev, and was ligated into the E.coli cloning vector pGEM using the NcoI 
and XbaI restriction sites. This vector was named as pGEM_Avi. The E.coli msbA gene was 
cloned into pGEM_Avi vector between the NcoI and NheI restriction site, amplified with the 
primers msbA_DecaHisN_for and msba_AviC_rev from the clone pNZMsbA35. Then the 3’ 
Avi-tagged E.coli msbA gene was sub-cloned into pBAD24 using the restriction sites NcoI and 
XbaI resulting in pBADMsbA_EC_AviC (the expressed protein was termed as MsbA_EC_AviC).  
The pBADAviC vector backbone flanking PstI/KpnI restriction site was generated from the 
pBADMsbA_EC_AviC using the primers pBAD_10his_PstI_F and pBAD_N10his3C_KpnI. The 
Salmonella typhimurium and Vibrio cholerae msbA genes were amplified using forward 
primers (MsbA_ST_PstI_F, MsbA_VC_PstI_F) and reverse primers (MsbA_ST_XbaI_R, 
MsbA_VC_KpnI_R). The amplified product flanked by PstI and KpnI restriction sites was 
ligated into the E. coli expression vector pBADAviC (expressed proteins were termed as 
MsbA_ST_AviC and MsbA_VC_AviC, respectively) (Figure_C8). 
C.4.2 Protein expression and purification  
C.4.2.1 Expression and purification of MsbA 
MsbA expression and purification has been described in Chapter B (see 
supplementary experimental procedure). For crystallization studies, the N-terminal deca-his-
tag of MsbA was cleaved by overnight incubation of the IMAC purified protein with 3C 
protease at a 1:2 molar ratio. For MsbA-DARPin_55 complex formation, first concentrated 
DARPin_55 was gel filtrated in TBS150-UDM buffer and monomeric fractions were mixed with 
freshly IMAC purified MsbA at a 3:1 ratio and further incubated for 15 minutes at 4 °C. The 
MsbA-DARPin_55 complex was separated by SEC from the excess DARPin_55. MsbA alone 
and the MsbA-DARPin_55 complex were concentrated on a 100 kDa cutoff (Millipore) filter 
to 13-14 and 15-16 mg/ml for crystallization experiments. 
C.4.2.2 Expression and purification of DARPins 
DARPin expression was performed in E. coli XL1-Blue in 2YT medium. Protein expression was 
induced with 0.5 mM IPTG at OD600 of 0.7 to 0.9 for 3–4 h at 37 °C. Harvested cell pellets 
were resuspended in 20 mM Tris/HCl (pH 7.4) buffers containing 150 mM NaCl, 25 μg/ml 
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DNaseI and protease inhibitor cocktail (Sigma). Cells were lysed using an EmulsiFlex-C3 
(Avestin) cell disrupter. Unbroken cells and cell debris were removed by centrifugation at 
20,000 rpm (SS34 rotor) for 30 minutes at 4 °C and the cleared lysate was applied to an IMAC 
column (Ni+2–NTA, Qiagen). The resin was washed with 20 mM imidazole pH 7.5, TBS and 
10% glycerol (30 ml) and DARPins were eluted from the column using 250 mM imidazole pH 
7.5 and 10% glycerol (10 ml) in the same buffer. IMAC purified DARPins were analyzed by 
SEC using a Superdex 200, 10/300 (GE Healthcare) column. 
C.4.3 Procedure of enzymatic biotinylation using BirA 
The purified protein (for example MsbAAviC 5 µM) was enzymatically in vitro biotinylated by 
incubation with ATP (10 mM), Biotin (5 µM), magnesium acetate (10 mM), 10 % glycerol, 
TBS150-UDM buffer and BirA ligase (3 µl from 8 mg/ml stock) with a total volume of 2.5 ml at 
4°C overnight. We termed biotinylated Avi-tagged MsbAAviC as bMsbAAviC.  
C.4.4 Selection and screening of DARPin binders against MsbA 
C.4.4.1 Selection of DARPin binders (Ribosome display) 
The N3C DARPin library was used for DARPin selection against MsbA using ribosome 
display10. Ribosome display is a cell-free system for in vitro binder selection. The principle of 
binder selection strategy is the coupling of genotype (RNA, DNA) and phenotype (protein). In 
ribosome display, this coupling is achieved during in vitro translation by the ternary complex, 
consisting of mRNA (genotype), the ribosome and the nascent polypeptide (phenotype)36. 
Ribosome display has several advantages over other selection methods, as follows:            
  i). the diversity of the working library is not limited by transformation steps involved in 
contrast to Phage display,  
ii). in contrast to immunization of animals, such as mice and llama, in vitro selection 
conditions can be monitored (for example, a suitable detergent or ligand can be included to 
avoid protein precipitation while in in vivo selection process conformational integrity of the 
protein cannot be controlled after injection into the animal).  
A detailed process of DARPin binders selection by ribosome display has been 
described by Zahnd et al31. Briefly, a DNA library encoding open reading frames lacking stop 
codons is transcribed in vitro. The mRNA is in vitro translated; the encoded protein is not 
released and folds correctly on the ribosome. The mRNA-ribosome-protein complexes are 
used for affinity selection on an immobilized target protein. After washing, the bound 
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ribosomal complexes are dissociated using EDTA. The mRNA is purified and used for reverse 
transcription followed by PCR amplification. The PCR product can be used directly for the 
next ribosome display selection cycle36 (Chapter B-Figure_S1). The selection of DARPin 
binders against MsbA was done using ribosome display following the standard protocol31 
with some modifications. Briefly, in all 4 selection rounds, 0.05 % of β-UDM detergent was 
used to maintain the MsbA in soluble state during the selection procedure. For membrane 
proteins solution panning has been shown to have advantages over surface panning30. In 
solution panning, biotinylated MsbA is immobilized on the surface of magnetic beads by 
virtue of the streptavidin-biotin interactions.  Therefore, all 4 selection rounds were done 
using solution panning instead of surface panning. Streptavidin coated magnetic beads 
(Roche 11641778001 or Dynabeads MyoneTMStreptavidinT1 or Invitrogen 800.955.6288) 
were blocked in TBS-BSA (100 µl per 10 µl initial suspension) overnight at 4 °C or 2 hours at 
room temperature (RT) and washed once with WBT-BSA_0.05% β-UDM prior to use. A pre-
panning step was included to remove the DARPins which unspecifically stick to the beads. In 
the pre-panning step, in vitro translated DARPin library (the translation mix, containing the 
ternary mRNA–ribosome–DARPin complexes) was incubated with streptavidin coated beads 
for 1 hour at 4°C. Unbound ternary complexes were mixed with bMsbAAviC (120 nM for first 
and second round, 60 nM for third and fourth round) for 1 hour (first and second round) or 
45 minutes (third and fourth round). The panning solution was transferred to the fresh 
streptavidin magnetic beads and incubated for 15 minutes at 4°C. The immobilized 
bMsbAAviC binding to the streptavidin beads was washed 4 times with WBT-BSA-0.05% β-
UDM. The washing time was increased from round to round (15 minutes total washing time 
in the first round to 120 minutes total washing time in the fourth round). After washing, the 
mRNA was eluted with 200 µl elution buffer, which disintegrates the ternary complex. Four 
rounds of ribosome display were performed. The number of PCR cycles after reverse 
transcription were reduced from round to round from 45 (first round) to 30 (fourth round). 
To avoid the capture of unspecific binders, we used hydrophilic (Roche 11641778001) and 
hydrophobic (Dynabeads® MyOne™ Streptavidin T1) streptavidin beads alternatively in the 
RD rounds.   
C.4.4.2 Screening of specific DARPin binders (Crude cell extract ELISA)  
The DARPin pool of the 4th selection round was cloned into pQE30myc5 containing an N-
terminal M-R-G-S-(H)6 tag and C-terminal Myc5-tag (5 times amino acid sequence M-E-Q-K-L-
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I-S-E-E-D-L-N-E) (the expressed protein is termed DARPinmyc5). Preparation of crude cell 
lysate and ELISA screening of the specific binders were done as described earlier30. Briefly, 
96-well ELISA plates (Nunc MaxiSorp) were coated with Protein A (Sigma, 100 μl, 5 μg/ml in 
PBS) overnight at 4 °C and blocked with TBS-BSA (300 μl) for 2 hours at room temperature. 
Then, anti-myc antibody (Sigma, clone 9E10, 1:2000 diluted) was immobilized via a specific 
interaction between the coated Protein A and its constant Fc region for 3-4 hours at 4°C. 
After washing with TBS, the plate was incubated with the diluted DARPinmyc5 containing 
crude cell extracts for 1 hour, followed by another washing step and the incubation with 50 
nM biotinylated target protein (100 μl). The wells were washed 3 times with TBS-BSA-0.05% 
β-UDM and incubated with Streptavidin-alkaline phosphatase conjugate for 30 minutes 
(Roche, 1:1000 diluted) at room temperature.  Final extensive washes (TBS-BSA-0.05% β-
UDM) for 4 times were made before the ELISA signal was developed using the p-nitrophenyl 
phosphate (pNPP) substrate and the OD405 was measured. Competition ELISA with purified 
DARPin proteins was performed to demonstrate the specificity of the selected DARPins for 
MsbA. For competition experiments, 500 nM of MsbA (competitor) were pre-incubated with 
50 nM of bMsbAAviC before adding to the immobilized DARPinmyc5.  
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CHAPTER D 
DARPin selection against the Nucleotide binding 
domain of homodimeric ABC transporter MsbA for 
structural and functional studies 
D.1 Introduction  
ABC (ATP-binding cassette) transporters are primary active transporters that translocate 
allocrites across the lipid bilayer. The term ‘allocrite’ was coined by Blight and Holland  to 
describe the ‘transport substrate’, the compound that is translocated, but not changed 
chemically1. A prototypical ABC transporter consists of four domains, namely two cytosolic 
nucleotide binding domains (NBDs) and two transmembrane domains (TMDs). The amino 
acid sequence is highly conserved in the NBDs throughout the ABC transporter superfamily. 
The NBDs energize the transport cycle by binding and hydrolyzing ATP (Figure_D1). The 
TMDs are quite disparate in amino acid sequence and structural fold2 (thereby, they are 
classified as Type I, II ABC importers and ABC exporters) and form a translocation pathway 
across the lipid membrane which determines the substrate specificity.  
Multidrug resistance (MDR) in eukaryotes (example in cancer cells) has been 
implicated due to the overexpression of multidrug transporters. To understand the 
molecular mechanism of transport of chemically distinct molecules across the lipid 
membrane3, structural information of these proteins is required. The expression and 
purification of full length ABC transporter proteins has always been more difficult than of 
isolated nucleotide binding domains. The first high-resolution structure of a bacterial ABC 
transporter’s domain was determined for the isolated NBD of histidine permease4. 
Thereafter, about 50 crystal structures of  NBDs ranging from bacteria to humans have been 
determined5. The structural fold of the NBD is conserved throughout the most distantly 
related members of ABC transporter superfamily. The structure of the NBD monomer can be 
divided into two subdomains: a larger RecA-like core-subdomain and a helical subdomain6 
(Figure_D2). The core-subdomain consists of 6 conserved motifs. 
1). Walker A motif (yellow, consensus sequence GXXGXGKS[S/T], where X denotes any amino 
acid) (Figure_D2A). In a closed NBD dimer, the Walker A motif of the cis-NBD monomer and 
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Signature motif (light blue, LSGGQ) of the trans-NBD monomer sandwich the γ-phosphate of 
the bound ATP molecule that leads to the formation of a composite nucleotide binding site.  
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2). Walker B motif (green, consensus sequence hhhhDE, where h is a hydrophobic amino 
acid). A conserved glutamate (hhhhDE) in the Walker B motif is important for the proper 
positioning of the γ-phosphate of the ATP and proposed to play a central role in the ATP 
hydrolysis by acting as a general base.7 
3). The A loop (red) forms π-π interactions with the adenine ring of the bound ATP. 
4). In the Q loop (purple), a conserved glutamine interacts with the γ-phosphate of ATP via a 
water molecule. 
 5). Residues of the D-loop (orange) in the cis-NBD make contact with residues of the trans-
NBD and thereby play a role in the communication between the two catalytic sites. 
6). In the H-loop (dark blue), a conserved histidine interacts with the Walker B glutamate and 
thereby plays a role in ATP hydrolysis. 
 The helical subdomain is unique to ABC transporters and is not seen in other ATPases.  It 
contains the ABC signature motif (light blue, consensus sequence LSGGQ) which interacts 
with the γ-phosphate of ATP in the closed NBD dimer. The presence of this motif is 
diagnostic for members of ABC superfamily6,8,9.  
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DARPin selection against the full length ABC transporters resulted either into the binders 
those binding to the TMDs of the full length protein (MsbA-Chapter B, C and LmrCD-Chapter 
E) or the hydrophobic “sticky” binders forming various degrees of oligomers and were 
unsuitable for further studies (MsbA-Chapter B, C and YDDA-Chapter F). We tried to 
circumvent these problems by using the cytoplasmic nucleotide binding domain of MsbA as 
a target protein. These NBD specific binders increase the probability of co-crystallization of 
the MsbA-DARPin complex because cytosolic domains are not surrounded by the detergent 
micelles and therefore DARPin bound to the NBDs can increase the hydrophilic surface area 
for crystal lattice formation. At the functional level, any allosteric effect on the functionality 
of MsbA after DARPin binding will be analyzed by established ATPase assay. In this chapter, 
we used ribosome display to select specific binders against the isolated NBD of MsbA. We 
aimed to find specific and monomeric binders for the functional and structural 
characterization of MsbA.  
D.2 Results 
D.2.1 Selection and screening of DARPins against the NBD of MsbA 
Selection against the NBD of MsbA was performed by Dr. Thilo Schroeder using the RD.  The 
RD procedure is summarized in Chapter C.4.4.1. Briefly, the N3C DARPin DNA-library10 was 
used and four rounds of  RD selections were carried out following the surface panning 
strategy as described10. The enriched pool of binders from the fourth round of RD was sub-
cloned into the expression vector pQE30. About 1500 clones were analyzed for binding to 
NBD-MsbA by crude extract ELISA. 19 binders (DNBD_1-19) were found in the initial ELISA 
screen and were further analyzed by ELISA using chemically biotinylated maltose binding 
protein (bMBP) as a control besides biotinylated nucleotide binding domain (bNBDAviC). 10 of 
these clones were found exclusively binding to bNBDAviC (Figure_D3) and about half of the 
clones (9 of 19 clones) did bind to both bNBDAviC-MsbA and bMBP and were therefore false 
positives (not shown). 
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D.2.2 Analysis of the NBD-DARPin complex formation  
The plasmids of NBD-specific DARPin clones were sequenced to analyze the diversity of the 
selected binders. The multiple sequence alignment confirmed that all 10 specific binders 
were unique (Figure_D4). 6 out of 10 binders could be overexpressed and purified by IMAC 
and were further analyzed for homogeneity by size-exclusion chromatography (Figure_D5A). 
One DARPin named DNBD_14 (DARPin for the NBD) displayed a monomer/dimer equilibrium 
and eluted in complex with the NBD as analyzed by SEC (Figure_D5A, C). The other 5 
DARPins displayed various degree of oligomerization (soluble aggregates) and were 
therefore excluded. Further, DNBD_14 binding to full length MsbA was analyzed by ELISA.  It 
was found that DNBD_14 does not bind to full length MsbA (Figure_D6). DARPin_55 served 
as a control; the epitope for DARPin_55 has been shown to be located at the trans-
membrane domain of MsbA (Chapter B), which could be confirmed in this ELISA.  This result 
suggested that DNBD_14 binds to a region of the isolated NBD which interacts with the 
transmembrane domain in full length MsbA. Alternatively, the conformation of the isolated 
NBD might be different from the NBD conformation in the context of the full-length MsbA. In 
any case the epitope is accessible in  
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the isolated NBD but not in full length MsbA (Figure_D6). Neither DNBD_14 nor DARPin_55 
binds to the maltose binding protein, which indicates that the selected DARPins, DNBD_14 
and DARPin_55 are specific for their respective target protein. 
D.2.3 ATPase activity of the purified NBD of MsbA 
The ATPase activity of purified full length MsbA and isolated NBD of MsbA were measured 
by detecting the release of Pi from ATP in a colorimetric malachite green assay as described 
in Chapter B. To measure the background ATPase activities, the ATPase deficient mutant 
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E506Q11 of MsbA was used as a control. Full length MsbA was used as a positive control for 
ATPase activity. The ATPase activities of the NBD and NBD_E506Q were measured at varying 
concentration increasing from 1.8 µM to 15 µM. The isolated NBD does not hydrolyze ATP as 
indicated by virtually identical ATPase activities of NBD and NBD_E506Q (Figure_D7A). 
DNBD_14 did not modulate the ATPase activity of full length MsbA, which corroborates the 
ELISA finding that DNBD_14 does not bind to full length MsbA (Figure_D7B). 
 
D.2.4 Crystallization experiments with the NBD of MsbA alone and 
in complex with DARPin DNBD_14 
NBD of MsbA and DNBD_14 were purified by IMAC separately. IMAC purified DNBD_14 was 
further purified by SEC and fractions containing monomeric DNBD_14 were mixed with 
purified NBD of MsbA. The NBD-DNBD_14 complex was separated from the excess DARPin 
DNBD_14 by SEC (Figure_D5C). The NBD and the NBD-DNBD_14 complex were concentrated 
to 15 mg/ml to perform crystallization experiments. Various screens from the NCCR 
structural Biology platform were used, testing a wide range of PEG, buffers, salt  
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concentrations etc.  None of the crystallization experiments with the NBD alone and with the 
NBD-DNBD_14 complex indicated signs for crystal formation. 
D.3 Discussion 
The selection of specific and monomeric binders of any scaffold (Fab, nanobody, DARPin etc) 
for membrane proteins is a challenging task. We have observed that using full-length ABC 
transporters as target proteins for in vitro selection of DARPins either yielded binders, which 
were binding to the transmembrane domain (MsbA-Chapter B, LmrCD-Chapter E) or yielded 
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binders that aggregate. DARPins bound to the TMD cannot be used for crystallization 
because they cannot reach beyond the detergent micelle layer and therefore do not increase 
the hydrophilic area needed to increase the chances for the formation of specific 
intermolecular interactions that help in the formation of a well ordered crystal lattice. In the 
present study we tried to avoid these problems by selecting DARPins against the cytosolic 
NBD of MsbA.  
The isolated NBD of MsbA was purified in a monomeric and ATPase inactive form. 
Selected DARPin binders were selected against the NBD of MsbA and tested for their target 
specificity by ELISA. About 10 NBD specific DARPins were found after screening 1500 clones. 
A monomeric/dimeric NBD-specific DARPin was found and named DNBD_14. The DNBD_14 
did not modulate the ATPase activity of full length MsbA. The DNBD_14’s epitope was 
analyzed by ELISA. DNBD_14 binds to the isolated NBD but does not bind to full length 
MsbA. The inability of DNBD_14 to bind to full length MsbA suggests that the epitope on the 
NBD is masked by interactions with the TMD in the full length protein. This made it 
impossible to use DNBD_14 as a chaperone for co-crystallization with full length MsbA.  
Moreover, the NBD-DNBD_14 complex did also not crystallize. To reach the goal to 
obtain MsbA-binder complex crystals, the following experiments can be envisaged: (i) 
besides DARPins, binders of other scaffolds such as Fab, scFv and nanobody can be selected 
against the NBD of MsbA, (ii) the enriched libraries of any scaffold selected against the NBD 
could be screened for binding full length MsbA, which would provide binders that bind to 
the cytosolic part of the full length protein, and (iii) the modulation of ATPase activity of full 
length protein in complex with DARPins could be analyzed in 96 well-plates, which would be 
useful to delineate functionally interesting clones.  
D.4 Experimental procedure 
D.4.1 Cloning, expression and purification of the NBD of MsbA 
The nucleotide binding domain coding gene sequence was amplified from E.coli msbA gene 
using forward primer NBD_MsbA_PstI and reverse primer reverse_MsbA_ XbaI. The PCR 
amplified product flanked by PstI and XbaI restriction sites was ligated into the E. coli 
expression vector pBAD2412 yielding the expression vector pBADNBDHis10  (expressed protein 
termed NBDHis10). For the Avi tagged NBD construct, the NBD coding sequence was cloned 
into the E. coli expression vector pBAD_AviC yielding the expression vector pBADNBDAviC  
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(expressed protein termed NBDAviC). The NBD over-expression was performed in E.coli BL-
21(DE3) cells, grown in 2YT media. The protein expression was induced at OD600 of 0.7 – 0.8 
with 0.02% L-arabinose (Sigma) for 12-14 hours at 25°C. Harvested cell pellets were 
resuspended in 20 mM Tris/HCl (pH 7.4) buffer containing 150 mM NaCl, 25 μg/ml DNaseI 
and protease inhibitor cocktail (Sigma). Cells were lysed using an EmulsiFlex-C3 (Avestin) cell 
disrupter. Unbroken cells and cell debris were removed by centrifugation at 20000 rpm 
(SS34 rotor) for 30 min at 4°C and the cleared lysate was loaded onto a Ni2+-NTA gravity flow 
column containing 1.5 ml resin (Qiagen). The resin was washed with 55 mM imidazole pH 
7.5, 20 mM Tris/HCl (pH 7.4), 150 mM NaCl and the NBD was eluted from the column using 
250 mM imidazole pH 7.5 (7 ml) in the same buffer.  
The Avi-tagged NBD was expressed and purified as described above. In vitro 
enzymatic biotinylation was done as described in Chapter C.4.3 and the biotinylated NBD 
was termed bNBDAviC. Every NBD preparation used in this work was separated from 
aggregated material by gel filtration in 20 mM Tris/HCl (pH 7.5), 150 mM NaCl using a 
Superdex 200 10/300 (GE Healthcare) column. Fractions of the main peak corresponding to 
monomeric NBD were pooled. Purified and biotinylated bNBDAviC was supplemented with 
10% glycerol, snap-frozen in liquid nitrogen and stored at -80°C.  
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D.4.2 Selection, screening and purification of DARPins 
The selection of DARPins against the NBD was performed by Dr. Thilo Schroeder. The 
DARPins pool after the 4th selection round was amplified with the primers EWT5 and MTS46. 
The PCR amplified product was digested using BamHI/HindIII and ligated into the pQE30-
based (Qiagen) vector containing an N-terminal RGS-6his tag. For epitope mapping, selected 
DARPins (DNBD_14 and DARPin_55) were amplified with the primers EWT5 and WTC4. The 
PCR amplified product was digested using BamHI/HindIII and ligated into the pQE30-myc1 
vector (constructed by Sibylle Engeler) containing an N-terminal RGS-6his tag and a C-
terminal myc1 tag. All plasmids used in the study were sequenced at Microsynth. DARPin 
expression and purification are described in Chapter C.4.2.2. 
D.4.3 Preparation of the NBD of MsbA and the NBD-DNBD_14 
complex for crystallization and ATPase assay  
NBD was purified by IMAC and concentrated by using the 20 kDa cutoff filter (Amicon) and 
further purified by SEC. IMAC purified DNBD_14 was gel-filtrated and fractions containing 
monomeric protein were mixed with the IMAC purified NBD at a 3:1 ratio. The NBD-
DNBD_14 complex was separated from the excess DNBD_14 by SEC (Figure_D4C). The NBD 
alone and the NBD-DNBD_14 complex were concentrated to 14- 16 mg/ml and 15-18 mg/ml 
concentration, respectively by using a 20 kDa cutoff filter (Amicon) for crystallization 
experiments. 
To measure the basal ATPase activity of NBD, an ATPase inactive mutant 
NBD_E506Q11 was purified in a similar way as the NBD (described above). The NBD_E506Q 
was used as a background control in ATPase assays. NBD and NBD_E-Q were used at 
different concentrations from 15 µM to 1.8 µM (serially diluted). MsbA was used as a 
positive control. The effect of DNBD_14 on the basal ATPase activity of MsbA (200 nM) was 
measured at different concentrations of DNBD_14 (0.1 and 1.0 µM) (Figure_D7). The ATPase 
assay was performed as described in Chapter B.   
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Abstract
ABC transporters use the energy from binding and hydrolysis of ATP to import or extrude substrates across the membrane.
Using ribosome display, we raised designed ankyrin repeat proteins (DARPins) against detergent solubilized LmrCD, a
heterodimeric multidrug ABC exporter from Lactococcus lactis. Several target-specific DARPin binders were identified that
bind to at least three distinct, partially overlapping epitopes on LmrD in detergent solution as well as in native membranes.
Remarkably, functional screening of the LmrCD-specific DARPin pools in L. lactis revealed three homologous DARPins which,
when generated in LmrCD-expressing cells, strongly activated LmrCD-mediated drug transport. As LmrCD expression in the
cell membrane was unaltered upon the co-expression of activator DARPins, the activation is suggested to occur at the level
of LmrCD activity. Consistent with this, purified activator DARPins were found to stimulate the ATPase activity of LmrCD
in vitro when reconstituted in proteoliposomes. This study suggests that membrane transporters are tunable in vivo by in
vitro selected binding proteins. Our approach could be of biopharmaceutical importance and might facilitate studies on
molecular mechanisms of ABC transporters.
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Introduction
In the past decade, unprecedented progress has been made in the
elucidation of ten complete ABC transporter structures solved by X-
ray crystallography, which guide current functional studies on these
transport proteins [1–5]. However, the mechanisms of transport of
both, ABC importers and exporters are still controversial [6]. One
reason for the uncertainties is due to the fact that crystal structures
represent snapshots of the proteins in specific conformations. In
order to describe the transport cycle in detail, several structures of
the same transporter captured in different conformational states
need to be solved. This often requires the trapping of the transport
protein in a specific conformational state which, for crystallized
primary-active transporters, was achieved by using non-hydrolyz-
able nucleotide analogs such as AMP-PNP [7,8] or various
nucleotide trapping agents such as vanadate, aluminium fluoride
and beryllium fluoride [9,10], or by generating mutant proteins that
are unable to hydrolyze ATP [11]. However, as these different
techniques interrupt the catalytic cycle of ATP hydrolysis at similar
stages, the repertoire of conformations that can be stabilized is
limited.
To overcome this limitation, we used designed ankyrin repeat
proteins (DARPins) which represent a novel binding scaffold [12].
DARPins typically consist of two or three internal ankyrin repeat
units encoding the randomized surface flanked by an N-terminal
and a C-terminal capping repeat [13,14]. DARPins are devoid of
disulfide bonds, easy to produce in E. coli and extraordinarily
robust [15]. High-affinity binders have been raised against a
growing number protein targets [16,17]. Amongst these is an AcrB
specific DARPin that was co-crystallized with AcrB to obtain the
highest resolution structure at 2.5 A˚ of this membrane protein to
date [18,19].
Traditionally, monoclonal antibodies (mAbs) specific for inte-
gral membrane proteins have been generated using the hybridoma
technology [20]. This procedure relies on the natural generation of
binders against the targeted protein in mice [21–26]. However, the
process of binder selection after the injection of the protein sample
into the animal is beyond experimental control. In vitro selections
using either phage display or ribosome display in contrast allow
binder selection under defined conditions [27,28]. Nevertheless,
the small number of less than ten published studies on the
complete in vitro selection of binders (Fab fragments and DARPins)
against detergent-purified membrane proteins embodies the
difficulties in using membrane proteins for this purpose [18,29–
36].
ABC transporters play a pivotal role in the active transport of
molecules in organisms of all kingdoms of life. The mammalian
multidrug transporter ABCB1 (also termed P-glycoprotein or
MDR1) has probably attracted most attention of all ABC
transporters, since it can play an important role in the extrusion
of noxious substances out of the cell, and has been linked to drug
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resistance in tumor cells [37,38]. Prokaryotic homologues of
ABCB1 such as LmrA from Lactococcus lactis and MsbA from
Escherichia coli, and analogues such as LmrCD from L. lactis were
studied in detail and are involved in the transport of drugs, lipids
and small ions [39–45]. ABC transporters use the energy of ATP
binding and hydrolysis catalyzed by the nucleotide binding
domains (NBDs) to translocate substrates through the membrane
domain (MDs). For this purpose, the NBDs need to dimerize in a
sandwich-like fashion forming two composite catalytic sites [46].
The amino acids involved in ATP binding and hydrolysis are
encoded by a number of highly conserved sequence motifs
including Walker A, Walker B, ABC Signature and H-loop (for
review, see [2]).
In LmrCD, one of the two composite catalytic sites at the NBDs
deviates from the consensus sequence and is postulated to mediate
ATP binding, but not ATP hydrolysis [47]. The deviation from
the canonical sequence concerns the catalytically important
Walker B glutamate and H-loop histidine that are changed to
aspartate and glutamine, respectively. The same substitutions are
found in the non-canonical sites of the antigen peptide transporter
TAP1/2 and the yeast multidrug transporter Pdr5 [48,49]. Here,
we demonstrate the successful in vitro selection of binders against
detergent-solubilized LmrCD using ribosome display. Moreover,
we use the lactococcal cells for a novel in vivo functional screen
applicable for multidrug transporters, and we characterize the
functional consequences of DARPin binding to LmrCD.
Results
Selection of DARPins Against Detergent Solubilized
LmrCD
We cloned the lmrCD genes with a His10-tag N-terminally to
LmrC, and were able to purify functionally active LmrCD to
homogeneity from lactococcal membrane vesicles. The proteins
could be isolated as heterodimeric species from size exclusion
chromatography (SEC) columns (Figure S1A and B). Interestingly,
the heterodimeric complex of LmrCD was stable when the
purified protein was analyzed by nano-electrospray mass spec-
trometry [50]. In order to immobilize LmrCD during the DARPin
selection procedure, an Avi-tag was introduced C-terminally to
LmrD, which allowed for site-specific enzymatic biotinylation of a
lysine residue comprised within the Avi-tag sequence (biotinylated
LmrCD is denoted bLmrCDAviC) [51]. The DARPin selection was
performed using the ribosome display method with DARPins
including three internal randomized repeats (N3C DARPins)
(Figure 1A) [12,18,28]. A total of 4 sequential selection rounds
were performed in which catalytically active bLmrCDAviC and
orthovanadate-trapped bLmrCDAviC were used as two indepen-
dent protein formulations. In the presence of 1 mM ATP, LmrCD
could be trapped by orthovanadate with a concentration giving
half-maximal inhibition of ATP hydrolysis (IC50) of 120 mM which
is in agreement with a recent study on the heterodimeric ABC
transporter BmrCD [52] (data not shown). The orthovanadate
concentration (1 mM) used during the DARPin selections
comfortably exceeded this IC50. It should be noted that around
0.6 mM of ATP originating from the in vitro translation buffer and
around 40 mM magnesium acetate were present during the
incubation of the DARPins with the target protein. This means
that in case of the non-trapped bLmrCDAviC formulation, the
DARPins were selected against transporters slowly hydrolyzing
ATP and presumably adopting various conformational states.
Figure 1. Ribosome display and ELISA set-up. (A) Sketch
delineating one DARPin selection round using ribosome display
(adopted from [31]). The DARPin library in form of mRNA is in vitro
translated and stable ribosomal complexes linking the phenotype
(folded DARPins) with the genotype (translated mRNA) are generated.
The ribosomal complexes are allowed to bind to immobilized
bLmrCDAviC. After a washing step of variable length (depending on
selection stringency), bound ribosomal complexes are destabilized and
LmrCD-Specific in vitro Selected DARPins
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Identification of LmrCD-specific DARPin Binders by ELISA
We analyzed 190 clones from the DARPin pools, enriched over
four selection rounds against untreated or vanadate-trapped
bLmrCDAviC, by an established ELISA protocol (95 DARPins
for each protein formulation) (Figure 1B, Figure 2) [31]. From the
initial ELISA (not shown) we chose the clones giving rise to the 30
most intense ELISA signals against bLmrCDAviC (15.8% of
examined clones) for a second comparative ELISA (Figure 3A).
Besides LmrCD, the ABC transporter MsbA and the secondary-
active multidrug transporter AcrB were used in the assay
(prepared as proteins biotinylated at the C-terminal Avi-tag).
From the 30 ELISA-positive DARPins, 8 were exclusively binding
to bLmrCDAviC but not to bMsbAAviC or bAcrBAviC (4.2% of all
examined clones), whereas the other 22 DARPins were promis-
cuously binding to all membrane proteins used in the specificity
ELISA (Figure 3A). The quality of the control proteins bMsbAAviC
and bAcrBAviC was confirmed by using target-specific DARPins in
the ELISA assay (AcrB-specific DARPin 110819 is described [18];
the selection of the MsbA-specific DARPin_55 will be published
elsewhere). The genes encoding the eight LmrCD-specific
DARPins were sub-cloned, expressed without the C-terminal
Myc5-tag and analyzed by size exclusion chromatography. Four of
these DARPins displayed a substantial degree of aggregation
(soluble aggregates) and were therefore excluded. The other four
LmrCD-specific DARPins (a-LmrCD#1-4) ran as monomeric or
dimeric species on SEC taking the elution profile of the
monomeric control DARPin E3_5 as a reference (Table 1, Figure
S1C). Three out of these four DARPins exhibited tight binding to
purified LmrCD, and eluted in complex with their target from the
size exclusion column. Thus, the initially chosen 190 DARPin
clones could be narrowed down to 3 specific high-affinity binders,
corresponding to a hit rate of 1.6%. A fifth high-affinity DARPin
(a-LmrCD#5) was found in another ELISA screen identical to the
one above (not shown).
Identification of Activators of LmrCD by Functional
Screening in L. Lactis
LmrCD-mediated daunomycin resistance in L. lactis [53] was
used for screening of DARPins that affect LmrCD activity.
Individual DARPins of the pool obtained after four selection
rounds (Figure 2; note: these are not the DARPin binders
identified by ELISA from the previous section) were expressed at
high levels in the cytoplasm of L. lactis using the nisin-inducible
lactococcal vector pNZ8048 (estimated to 2–5% of total soluble
protein, not shown) [54]. We first attempted to find DARPins
whose expression lead to a decrease of LmrCD-dependent
daunomycin resistance (inhibitors). Around 20 apparent inhibitors
were found by screening 400 DARPin clones expressed in L. lactis.
A closer inspection of these initial hits however, revealed that they
were false positives; lactococcal cells expressing these DARPins
grew considerably slower than cells expressing the control
DARPin E3_5*. When these DARPin inhibitors were expressed
in the L. lactis strain lacking the chromosomal lmrCD genes (L. lactis
NZ9000 DlmrA DlmrCD [55]), the apparent inhibition was also
observed. Hence, the increased drug susceptibility of L. lactis
expressing these DARPins was independent of LmrCD. Surpris-
ingly, we also found DARPins the expression of which increased
daunomycin resistance in L. lactis, suggesting enhancement of
LmrCD activity. Three strong activators (DARPin_Act1-3) were
found in a screen including 1128 clones (Figure 2). In cell growth
experiments, the daunomycin resistance of L. lactis NZ9000
expressing the activator DARPins was compared to the control
DARPin E3_5* in the wildtype and the DlmrCD background
(Figure 4A and B). In wildtype cells, the IC50 for daunomycin was
increased by a factor of 3.3, 2.6 and 1.7 upon the production of
DARPin_Act1, DARPin_Act2, and DARPin_Act3, respectively.
Importantly, the expression of the activator DARPins in the
L. lactis NZ9000 DlmrA DlmrCD background did not affect the
daunomycin resistance of the cells, indicating an LmrCD-specific
functional stimulation. The knock-out of lmrCD in L. lactis results in
an 8.3-fold decrease of the IC50 for daunomycin (Figure 4A and
B). Therefore, the DARPin-induced stimulation of LmrCD-
mediated drug transport by a factor up to 3.2 is substantial. The
DARPins a-LmrCD#1-5 that were identified in the ELISA screen
to bind to LmrCD (see previous section) were also assayed
regarding the potential modulation of the LmrCD-mediated drug
resistance in L. lactis. Although DARPins a-LmrCD#1-5, the
DARPin activators and DARPin E3_5* were overproduced
equally well in L. lactis, expression of DARPins a-LmrCD#1-5
did not alter the drug resistance of lactococcal cells towards
daunomycin (not shown).
Further Characterization of the LmrCD-activating
DARPins
The chromosomal knock-out of the lmrCD gene on L. lactis has
been shown to result in an increased susceptibility of the
lactococcal cells towards Hoechst 33342 (3.6 fold difference
between wiltype L. lactis and the DlmrCD mutant) [53]. We
therefore tested whether the DARPin_Act1 to Act3 are also
capable of increasing the LmrCD-mediated transport of Hoechst
33342. However, in contrast to the observations on daunomycin
resistance in L. lactis (Figure 4) the expression of the DARPin
activators did not increase the resistance towards Hoechst 33342
(not shown).
The observed LmrCD-associated daunomycin resistance in
L. lactis could be due to enhanced drug efflux by LmrCD.
However, as the entry of fluorescent daunomycin from the
aqueous buffer into cells followed by its intercalation in DNA
results in a minor quenching of total fluorescence, detection of
daunomycin transport by fluorescence spectroscopy is hampered
by a poor signal-to-noise ratio in the fluorescence data. In an
alternative assay, we studied the LmrCD-mediated transport of
non-fluorescent, hydrophobic 29,79-bis-(2-carboxyethyl)-5(6)-car-
boxyfluorescein acetoxymethyl ester (BCECF-AM), which is
extruded from the plasma membrane by bacterial and mammalian
multidrug ABC transporters before it can be hydrolyzed in the
cytoplasm into fluorescent BCECF by non-specific esterases [56–
58]. In this assay, a slower increase in the fluorescence signal is
associated with enhanced extrusion of BCECF-AM from the cell.
As BCECF is a pH-sensitive fluorophore, valinomycin and
nigericin were added to the cells prior to the transport
measurement to dissipate the electrochemical proton gradient
across the plasma membrane, so that the intracellular pH was
made equal to the constant pH of the extracellular buffer. In
agreement with the observations for daunomycin, increased
BCECF-AM efflux was observed upon expression of DARPi-
mRNA encoding for potential target-specific DARPins is liberated. The
eluted mRNA is amplified by reverse transcription and PCR to double
stranded DNA, which is in vitro transcribed into mRNA for another
round of selection or used for binder analysis. (B) Schematic drawing of
the ELISA set up. Protein A is coated onto the ELISA well and is
decorated with an anti-myc antibody that immobilizes the DARPins via
the C-terminal Myc5-tag. Upon binding of purified, biotinylated target
protein (e.g. LmrCD, AcrB or MsbA in our study) to DARPin, the target
protein is detected using a streptavidin-alkaline phosphatase the
activity of which was detected colourimetrically at OD405 using p-
nitrophenyl phosphate as a substrate.
doi:10.1371/journal.pone.0037845.g001
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n_Act2 in wildtype L. lactis, whereas DARPin_Act2 expression in
the lmrCD knockout-strain did not affect transport (Figure 4C).
Sequencing revealed that DARPin_Act1 lacked the N-terminal
cap repeat and therefore exhibited severe aggregation (but not
precipitation) in purified form as demonstrated in SEC experi-
Figure 2. Workflow of DARPin selection and screening. DARPins were selected by ribosome display against LmrCD with and without vanadate
trapping (purple rectangle). After four sequential selection rounds of increasing stringency, the pools of potential binders were analyzed either by
ELISA and SEC (blue rectangle) or in a functional screen in L. lactis (red rectangle).
doi:10.1371/journal.pone.0037845.g002
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Figure 3. Identification and characterization of DARPin binders by ELISA (A) Specificity ELISA using bLmrCDAviC, bMsbAAviC and bAcrBAviC
as target proteins. Seven DARPins (a-LmrCD#1-5, DARPin_Act2 and DARPin_Act3) were found to be highly specific for bLmrCDAviC. Many initial
DARPin binder-hits promiscuously bound to bLmrCDAviC, bMsbAAviC and bAcrBAviC as exemplified with the ‘‘unsp. DARPin’’ and were therefore not
useful for further analysis. DARPins specific for bMsbAAviC (DARPin_55) and bAcrBAviC (110819) were used as a positive control. (B) ELISA analyzing
LmrCD-Specific in vitro Selected DARPins
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ments (Table 1, Figure S1D). This impeded further biochemical
and biophysical characterization of DARPin_Act1. Although
DARPin_Act2 was of the expected N3C format, it was prone to
form soluble aggregates (hexamers), presumably due to a high
number of hydrophobic residues found in its randomized
positions. DARPin_Act3 predominantly existed as a monomer
and the aggregated species could successfully be removed by SEC.
Expression of LmrCD-activating DARPins does not
Increase the LmrCD Production Level
The observed gain of cellular drug resistance and enhanced
rates of substrate efflux in DARPin producing cells could be
explained if DARPin expression would upregulate the expression
level of LmrCD. In order to compare the amounts of expressed
LmrCD protein in the plasma membrane from DARPin-
producing and control cells, we introduced a V5-tag downstream
to the lmrD copy on the chromosome by homologous recombi-
nation. Cells producing the V5-tagged version of LmrD (LmrDV5)
were as resistant to daunomycin as the wildtype cells. A specific
band for LmrDV5 could be detected by Western blotting with an
anti-V5 antibody (Figure 5A). L. lactis NZ9000 lmrDV5 expressing
the activator DARPins and the control DARPin E3_5* were
grown in the absence of drug and in the presence of the
daunomycin concentration (see Materials and Methods). The
amount of LmrDV5 was then analyzed by Western blotting
whereas the total protein was quantified using SYPRO ruby
staining. The LmrDV5 production level was consistently increased
by a factor of around 1.5 upon the exposure to daunomycin
irrespective of the DARPin expressed (Figure 5B). However, the
activator DARPins did not lead to a significant increase in
LmrDV5 production compared to the control cells, indicating that
the DARPin activators directly stimulate the drug efflux activity of
existing transporters.
LmrCD-specific DARPins Bind to LmrD in a 1:1
Stoichiometry Covering at least Three Partially
Overlapping Epitopes
To gain further insights into the binding epitopes of the
LmrCD-specific DARPins, LmrC and LmrD were expressed
separately including GFP fused to the C-termini. The proteins
were purified by Ni2+-NTA chromatography, followed by
chemical biotinylation and size exclusion chromatography (Figure
S1E). Further, the isolated NBDs of LmrC and LmrD were
purified from E. coli. Whereas the expression of the NBD of LmrC
gave rise to soluble aggregates exclusively (which were not used for
further analysis), purification of the NBD of LmrD yielded (besides
soluble aggregates) monomeric protein that was enzymatically
biotinylated (bLmrD-NBDAviN) (Figure S1F). Binding of these
isolated parts of LmrCD to a-LmrCD#1-5 and the activator
DARPins was then tested in an ELISA (Figure 3B). All DARPins
were found to bind to the LmrD chain, but none of them
recognized the NBD of LmrD or the LmrC chain suggesting that
the epitope(s) are likely to be located at the membrane domain of
LmrD. Alternatively, the isolated NBD of LmrD might adopt a
conformation different to the one found in the full-length
transporter which might not be recognized by the DARPins or
the binding epitope covers a shared surface located on the MD
and the NBD of LmrD.
The binding epitopes were further analyzed in a competition
ELISA, in which bLmrCDAviC was pre-incubated with a tenfold
excess of each DARPin devoid of the Myc-tag and probed for
binding to every DARPinmyc5 immobilized via the Myc-tag
(Figure 6A). Based on the results of this competition ELISA, the
LmrCD-specific DARPins are proposed to bind to at least three
partially overlapping epitopes (Figure 6B). The first epitope
(epitope 1 of binders a-LmrCD#2 and a-LmrCD#4) and the
second epitope (epitope 2 of binders a-LmrCD#3 and a-
LmrCD#5) do not overlap (i.e. no competition for binding
between these two pairs of DARPins to LmrCD was observed). In
binding of the LmrCD-specific DARPins shown in (A) to LmrC (bLmrC-GFP), LmrD (bLmrD-GFP) and the nucleotide binding domain of LmrD (bLmrD-
NBDAviN). Binding to LmrCD (bLmrCDAviC) was confirmed as positive control.
doi:10.1371/journal.pone.0037845.g003
Table 1. Biophysical properties of LmrCD-specific DARPins.
DARPin Oligomeric state a)
Binding
stoichiometry
(DARPin: LmrCD) b) KD (nM)
c) ka (610
5 M21s21) c) kd (610
22 s21) c) KD, eq. (nM)
d)
Binders
a-LmrCD#1 Monomer 1.11: 1 10.0 7.40 0.738 10.7
a-LmrCD#2 Dimer/Trimer 0.96: 1 3.9 5.29 0.205 9.2
a-LmrCD#3 Monomer 0.73: 1 53.4 12.3 6.59 53.5
a-LmrCD#4 Monomer No complex 167 2.00 3.34 173
a-LmrCD#5 Monomer 0.75: 1 43.0 5.10 2.19 45.2
Activators
DARPin_Act1 Soluble aggregates n.d. e) n.d. n.d. n.d. n.d
DARPin_Act2 Hexamer n.d. e) 46.7 0.17 0.079 66.8
DARPin_Act3 Monomer 1.16: 1 50.5 4.36 2.20 54.9
a)Derived from elution volume of main peak on Superdex 200 10/300 GL column (Figure S1).
b)Determined by protein chip analysis (Figure 7B).
c)Values obtained by SRP analysis using a 1:1 binding model (Figure 7C).
d)Value obtained by SPR analysis using binding equilibrium data (Figure 7D).
e)Separation of the DARPin-LmrCD complex from DARPin aggregates was not possible on SEC (Figure S1).
doi:10.1371/journal.pone.0037845.t001
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contrast, binding of a-LmrCD#1 and the DARPin activators
(DARPin_Act2 and DARPin_Act3) to LmrCD is competed by
DARPins recognizing epitopes 1 and 2 as well as by themselves.
Hence the binding epitopes of a-LmrCD#1 and the DARPin
activators are suggested to partially overlap with the first two
epitopes. Nevertheless, conformational communication between
two well-separated sites resulting in apparent competition of
binding cannot be excluded. The presence of two distinct epitopes,
one for a-LmrCD#1 (epitope 3) and the other for activator
DARPins (epitope 4), is supported by the large differences in
sequence between a-LmrCD#1 and the activator DARPins
(Figure 6B, Figure S2). Trapping of LmrCD with vanadate did
not help to generate DARPins different from the ones selected in
the absence of trapping agent as DARPin a-LmrCD#2 (non-
vanadate DARPin) shares the epitope with a-LmrCD#4 (vana-
date DARPin), and a-LmrCD#5 (non-vanadate DARPin) shares
the epitope with a-LmrCD#3 (vanadate DARPin). Clearly,
‘‘vanadate’’ DARPins do not bind to a shared epitope that is
distinct from the epitope of the ‘‘non-vanadate’’ binders.
The stoichiometry of binding between the DARPins and
LmrCD after SEC was determined by protein chip technology
(Agilent Technologies) allowing accurate quantification of protein
amounts (Figure 7A and B, Table 1). DARPin_Act3 as well as a-
LmrCD#1, a-LmrCD#2, a-LmrCD#3 and a-LmrCD#5 form
1:1 complexes with LmrCD (Table 1). DARPin_Act1 and
DARPin_Act2 formed soluble aggregates impeding their separa-
tion from LmrCD on SEC whereas the affinity of a-LmrCD#4
appeared to be too low to allow co-elution with LmrCD from the
gel filtration column. Therefore, the stoichiometry of binding
could not be determined for these DARPins.
Determination of the Dissociation Constants by Surface
Plasmon Resonance (SPR)
The affinities of the isolated DARPins to LmrCD were
determined by SPR measurements using a Biacore instrument.
Detergent purified bLmrCDAviC was immobilized on a streptavi-
din-coated chip and binding of the DARPins was assessed
(Figure 7C and D, Table 1). When using a two-state reaction
model (see Materials and Methods), the observed data fitted very
close to the predicted data. However, to assess whether DARPin
binding to LmrCD is correctly described by a two-state reaction
model, 400 nM of a-LmrCD#3 was injected for 100 s, 200 s and
400 s, and DARPin dissociation phases were compared (Figure
S3). The dissociation curves obtained, superimposed almost
perfectly, suggesting that DARPin dissociation was independent
of the association time. These findings indicate that the use of the
two-state reaction model is inappropriate. Therefore, all data were
fitted using a simple 1:1 binding model (see Materials and
Methods), which allowed for the calculation of the dissociation
constants (KD) from the association and dissociation rate constants
ka and kd (Table 1). To determine equilibrium binding constants
(KD,eq., see Materials and Methods, Figure 7D and Table 1),
injection times were chosen that allowed DARPin binding to reach
equilibrium (Figure 7C). With the exception of a-LmrCD#2 and
DARPin_Act2, the KD and KD,eq. were found to be almost
identical. Since KD,eq. is unaffected by known SPR artifacts such as
mass transport and analyte rebinding [59], we refer to the KD,eq. to
describe the affinities of the DARPins for LmrCD in this study.
The KD,eq. values of the majority of LmrCD-specific DARPins
were between 9 nM and 67 nM with the exception of the KD,eq. of
173 nM for a-LmrCD#4. Confirming the SPR measurements, a-
LmrCD#4 binding to LmrCD was too weak for co-elution of the
protein complex during SEC (Table 1); the ELISA signal was
considerably lower than for the other binders (Figure 3A).
DARPin Binding to Membrane-embedded LmrCD
The binding of DARPins to inside-out membrane vesicles
(ISOVs) containing either overproduced AcrBAviC or LmrCDAviC
was further characterized (Figure 8). Based on an analysis using a
protease-cleavable LmrCD-GFP construct (see Materials and
Methods), ISOV preparations were found to contain up to 10%
of the membrane vesicles in the right-side-out orientation (right-
side-out membrane vesicles, RSOVs). Total binding was deter-
mined as the amount of DARPin bound to ISOVs containing the
Figure 4. Identification of LmrCD-activating DARPins. (A) Overexpression of DARPin_Act1 (N), DARPin_Act2 (#), DARPin_Act3 (.) in wildtype
L. lactis increases the resistance towards daunomycin compared to cells expressing control DARPin E3_5* (not interacting with LmrCD) (D). (B) No
differences were observed when experiments in (A) were performed with cells lacking the chromosomal copy of lmrCD. (C) BCECF-AM transport
measurements in pre-energized wildtype L. lactis cells demonstrate activation of LmrCD-mediated extrusion upon expression of DARPin_Act2 (trace
1) but not of control DARPin E3_5* (trace 2). No activation of LmrCD activity was observed upon expression of DARPin_Act2 (trace 3) or control
DARPin E3_5* (trace 4) in L. lactis DlmrCD cells. Shown are representative data from at least three independent measurements (n$3).
doi:10.1371/journal.pone.0037845.g004
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overexpressed target protein. Background binding refers to
binding of the respective DARPin to ISOVs containing an
overexpressed membrane protein that is not recognized by the
binder. For the AcrB-specific DARPin 110819, the membrane
vesicles used for the determination of background binding thus
contained overexpressed LmrCD and vice versa. Specific binding
was then calculated by subtracting background binding from total
binding. Binding of all six DARPins tested was target-specific,
meaning that total binding was stronger than background binding.
The AcrB-specific DARPin 110819, whose structure has been
solved in complex with AcrB by X-ray crystallography, was used
as control. As expected, DARPin 110819 binds relatively poorly to
ISOVs despite its high reported binding affinity of 28 nM because
the binding epitope on AcrB is located at the periplasmic loops
and is therefore predominantly hidden in the vesicle lumen [18].
The binding signal for DARPin 110819 therefore originates from
the estimated 10% RSOVs present in the ISOV preparation.
Despite the fact that AcrB is expressed better than LmrCD (not
shown), binding of a-LmrCD#2 and DARPin_Act3 to LmrCD-
containing ISOVs resulted in signals that were around three times
Figure 5. DARPin expression does not significantly alter expression of LmrCD proteins. (A, B) A V5-tag was introduced in frame at the 59-
end of genomic lmrD in L. lactis (denoted L. lactis NZ9000 lmrDV5). Plasmid-encoded DARPin activators or the control DARPin E3_5* were expressed in
L. lactis NZ9000 lmrDV5 in the presence and absence of daunomycin (14 mM for DARPin_Act3 and E3_5* and 28 mM for DARPin_Act1 and
DARPin_Act2, respectively). The expression levels of genomic LmrDV5 were then quantified by comparing the Western blot signal obtained using an
anti-V5 antibody (A) with total protein detected by SYPRO ruby staining (B). (C) The relative amounts of LmrDV5 expression were quantified by
densitometry. Each bar represents the average of three independent data points (n = 3) of which one data point is shown in (A) and (B).
doi:10.1371/journal.pone.0037845.g005
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bigger than the ones of DARPin 110819 binding to AcrB-
containing ISOVs (Figure 8A). Since the binding affinities of a-
LmrCD#2 (9 nM) and DARPin_Act3 (55 nM) are in the same
order of magnitude as of DARPin 110819 (28 nM), these LmrCD-
specific DARPins appear to recognize epitopes at the cytoplasmic
portion of LmrD, which are accessible in ISOVs. Specific binding
of a-LmrCD#1 on the other hand is half as high as for DARPin
110819 whereas it is roughly the same for a-LmrCD#3. DARPin
binding to these epitopes is therefore either restricted in
membrane-embedded LmrCD or the epitope is only accessible
from the physiological outside of the membrane. We also
attempted to perform these DARPin binding experiments using
RSOVs generated from E. coli using the EDTA-lysozyme method
[60]. Studies on the accessibility of a C-terminal GFP fusion
partner on LmrD to protease cleavage from the external surface of
membrane vesicles indicated that, despite careful preparations, a
substantial portion (up to 50%) of LmrCD-GFP containing
membrane vesicles were in the inside-out orientation, and that
Figure 6. Epitope mapping of LmrCD-specific DARPins by ELISA. (A) Analysis of the LmrCD-specific DARPins by a competition ELISA. Binding
of bLmrCDAviC to immobilized Myc-tagged DARPins was competed with an excess of DARPins devoid of Myc-tag. (B) Schematic drawing of the four
proposed binding epitopes on LmrCD recognized by the LmrCD-selective DARPins based on the results of the competition ELISA shown in (A). The
number of the epitopes follows the numbering in the main text. (C) The phylogenetic tree of the LmrCD-specific DARPins corresponds well with the
proposed binding epitopes. The branches of the phylogenetic tree are highlighted with the color code used to label the four suggested binding
epitopes in (B).
doi:10.1371/journal.pone.0037845.g006
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therefore, this type of membrane vesicles could not be used to
study the accessibility of the binding epitopes (data not shown).
Background binding to ISOVs varied between the different
DARPins and correlated with the aggregation behavior on SEC
(Figure S1). Low background binding was observed for the
DARPins a-LmrCD#1, a-LmrCD#3 and the AcrB-DARPin
110819, whereas a-LmrCD#2, DARPin_Act2 and DARPi-
n_Act3 interacted with membrane vesicles lacking the target
protein (Figure 8A).
Specific binding of DARPin_Act2 to LmrCD in ISOVs was low
in the initial binding experiment, most likely due to its slow on-rate
of binding (Figure 8A, Table 1). Therefore, binding of DARPi-
n_Act2 and a-LmrCD#3 to membrane-embedded LmrCD in
ISOVs was determined at a prolonged incubation time (200 min
instead of 40 min) and at increasing DARPin concentrations
(0.35 mM as in the initial experiment, 1 mM and 2 mM) (Figure 8B).
Although background binding of DARPin_Act2 remains high,
specific binding was substantially increased, in particular at a
DARPin concentration of 2 mM. For the DARPin a-LmrCD#3
on the other hand, background binding was very low and maximal
specific binding was achieved already at a concentration of 1 mM.
Taken together, these binding assays suggest that specific protein-
protein interactions between the activator DARPins and mem-
brane-embedded LmrCD are likely to provide the basis for the
activation of LmrCD-mediated drug transport, although indirect
mechanisms due to binding of the DARPin activators to the
membrane cannot be excluded. Binding of DARPin_Act2 and
DARPin_Act3 to LmrCD-containing ISOVs indicates that the
DARPin activators can bind to their epitope on LmrD when
expressed in the cytoplasm of L. lactis. If we assume a protein
concentration of 200 mg/ml in the cytoplasm of L. lactis [61] and
estimate the DARPin expression level to amount for 2% of total
protein (not shown), the DARPin concentration inside the cell is
about 4 mg/ml or 200 mM. The DARPin concentration in the cell
exceeds its binding affinities by more than three orders of
magnitude and therefore the binding epitopes are saturated with
bound DARPins.
DARPin Activators Stimulate the Basal ATPase Activity of
LmrCD Reconstituted in Proteoliposomes
To further elucidate the mechanism by which the DARPin
activators stimulate the function of LmrCD, detergent-purified
LmrCD was reconstituted into proteoliposomes made of polar
E. coli lipids and egg-phosphatidylcholine mixed at a ratio of 3:1
[55]. Reconstituted LmrCD exhibits basal ATPase activities that
are three times lower than the activity of purified LmrCD in its
micellar form (not shown). Addition of increasing concentrations
of daunomycin to reconstituted LmrCD (5–200 mM) increased its
ATPase activity in a dose-dependent manner, reaching two-fold
stimulation at 200 mM daunomycin (Figure 9A). The ATPase
activity of reconstituted LmrCD in the presence of the DARPin
activators and the control DARPin E3_5 was then compared to
samples to which no DARPins were added (Figure 9B). The
addition of DARPin E3_5 did not change the ATPase activity of
LmrCD at any concentration of daunomycin. On the other hand,
ATP hydrolysis of LmrCD was significantly stimulated upon
addition of the three DARPin activators up to 1.6 fold in case of
DARPin_Act2. These observations in proteoliposomes were found
to be statistically significant in three independent reconstitution
experiments, one of which is shown in Figure 9B. The DARPin
activators are therefore capable of increasing the ATPase activity
of LmrCD to a similar extent as 50 mM of daunomycin for which a
1.8 fold increase is seen (Figure 9A and B). The increase of
LmrCD’s ATPase activity by the DARPin activators and
daunomycin was found to be additive, suggesting that the
molecular mechanism underlying these stimulatory effects are
distinct. Basal and DARPin_Act2-stimulated ATPase activity of
reconstituted LmrCD was further elucidated over a range of ATP
concentrations (Figure 9C). The data was fitted using the Hill
equation, and the apparent Km for ATP and Vmax of the ATPase
reaction as well as the Hill coefficient were determined. The errors
represent standard errors of the parameters derived from
nonlinear regression analysis. In presence of DARPin_Act2, the
apparent affinity of LmrCD for ATP was not significantly altered
(Km,app of 0.8560.06 mM and 0.7360.09 mM for DARPin_Act2
and E3_5, respectively). Vmax on the other hand was doubled in
the presence of DARPin_Act2 (Vmax of 500622 nmol/min/mg of
protein versus 247619 nmol/min/mg of protein). The Hill
coefficient was found to be unaltered in presence of DARPin_Act2
(2.060.3 and 2.060.5 for DARPin_Act2 and E3_5, respectively).
The sigmoidal nature of the fitted curve suggests positive
cooperativity between the non-canonical and the consensus
composite catalytic site of LmrCD, a finding reminiscent of the
maltose transporter and the isolated NBDs of HlyB [62,63].
Discussion
The in vitro selection of binders against integral membrane
proteins using ribosomal display is very fast (2–3 weeks of lab work
under ideal circumstances) and the biochemical conditions can be
controlled. Nevertheless, only few successful examples of in vitro
selected binders specific for membrane protein have been
reported, most likely due to the many unknowns that exist
regarding enrichment of specific binders against these hydropho-
bic proteins [18,29–36]. In this work we have made important
progress in the screening procedure of DARPins raised against
membrane proteins. We found that successful in vitro selection
depends on two critical factors. Firstly, the quality of the target
protein preparation is crucially important for success. LmrCD has
proven to be a suitable target since it could be purified to near
homogeneity, was catalytically active and could be isolated as
heterodimeric species by SEC (Figure S1A and B). Secondly,
during DARPin identification it is important to introduce a cross-
specificity ELISA using a set of different membrane proteins.
Figure 7. Biophysical characterization of the DARPin-LmrCD complexes. (A, B) Stoichiometry analysis as exemplified by the LmrCD/a-
LmrCD#2 complex. (A) LmrCD and the LmrCD/a-LmrCD#2 complex were separated by SEC (Superdex 200 PC3.2/30, GE Healthcare) with a void
volume V0 = 0.85 ml and a total volume Vt = 2.4 ml. A fraction corresponding to heterodimeric LmrCD in complex with a-LmrCD#2 complex (red bar)
was subjected to protein chip analysis (lane 3, inset). LmrCD and the DARPin a-LmrCD#2 were also analyzed (lanes 1 and 2, inset). The peak at a
retention volume of 1.2 ml corresponds to aggregated LmrCD. (B) The peak area of the protein chip chromatogram corresponding to LmrCD and a-
LmrCD#2 of lane 3 in (A) were calibrated with dilution series of LmrCD and DARPin of known protein concentrations (not shown) and were used to
determine the stoichiometry of the LmrCD-DARPin complexes (Table 1). (C) Affinities of the DARPins to LmrCD were determined by surface plasmon
resonance as shown for a-LmrCD#3. The colored lines correspond to the measured traces at different DARPin concentrations, the fitted curves (1:1
binding model) are shown as black lines. (D) The steady state DARPin binding signals achieved at the end of the association phase shown in (C) were
plotted against the DARPin concentration and fitted using an equilibrium binding equation equivalent to the Michaelis-Menten equation. In this
analysis, equilibrium dissociation constants (KD, eq.) were generated.
doi:10.1371/journal.pone.0037845.g007
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Using optimally prepared LmrCD, we obtained a relatively large
number of DARPins (around 70%) that showed strong cross-
reactivity with MsbA and AcrB. Further analysis showed that
many of these unspecific DARPins formed soluble aggregates.
Both observations might relate to the hydrophobicity of the target
proteins, which can drive selection of hydrophobic binding
surfaces in DARPins that tend to aggregate in an aqueous
environment. Indeed, DARPin aggregation was not observed at all
when DARPins were selected against a soluble test protein (MBP)
using the same selection procedure (data not shown). On the other
hand, the highly specific DARPins were much less aggregation-
prone and about half of them were monomeric as judged from
comparing the SEC profiles of the DARPins under study with the
monomeric control DARPin E3_5 (Figure S1C). Because the
cross-specificity ELISA was performed with DARPin-containing
crude cell extracts, there was no need to purify the DARPins for
the initial specificity analysis, which greatly accelerated the
identification of binders. This screening regime would also be
applicable to more difficult membrane protein targets with a
further decreased binder hit rate.
A handful of the LmrCD-specific DARPin binders were
subsequently characterized by surface plasmon resonance and
size exclusion chromatography. With the exception of the
DARPin a-LmrCD#4, the KD,eq. values for binding were found
to range between 9 and 67 nM. The binding stoichiometry of
these high-affinity binders with heterodimeric LmrCD is 1:1. The
LmrCD-specific DARPins are suggested to recognize at least three
overlapping epitopes on the LmrD chain. The surface of LmrD
might therefore harbor one or several hot spot epitopes that are
preferably recognized by the DARPins. Recently, a hot spot
epitope that is recognized by nine highly diverse DARPins has
been reported for AcrB [19]. The fact that a handful of high
quality DARPins specific for LmrCD could be readily identified,
indicates that the randomized DARPin scaffold is sufficiently
diverse to recognize a multitude of binding sites on the membrane
protein target. Given the high binding affinities achieved and the
various epitopes recognized on LmrCD, these DARPins can be
Figure 8. DARPin binding to membrane-embedded LmrCD. (A) Six DARPins (each at a 350 nM concentration) specific for AcrB or LmrCD were
probed for binding to ISOVs containing either overproduced AcrBAviC or LmrCDAviC. Bound DARPins were detected on Western blot (left panel). The
signals of the DARPin-specific bands were quantified by densitometry (right panel). Total binding denotes the quantified amount of DARPin bound to
membrane vesicles containing overexpressed target protein. Background binding refers to binding to membrane vesicles containing overexpressed
LmrCDAviC in case of the AcrB DARPin 110819, or overexpressed AcrBAviC when LmrCD-specific DARPins were used. Specific binding was calculated by
subtracting background binding from total binding. (B) Binding of DARPin_Act2 and a-LmrCD#3 to ISOVs containing either overproduced AcrBAviC
or LmrCDAviC was further assessed using increasing concentrations of DARPin (0.35 mM, 1 mM and 2 mM) and analyzed by Western blot (left panel).
The data was quantified as in (A) (right panel). The data represent typical results observed in n = 3 experiments.
doi:10.1371/journal.pone.0037845.g008
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used for chaperone-assisted membrane protein crystallography
[64].
Binding experiments using LmrCD-containing ISOVs suggest
that the DARPins a-LmrCD#2 and DARPin_Act3 bind to
epitopes located at the cytoplasmic side of LmrCD. DARPin
activators expressed in the L. lactis cells are therefore expected to
readily reach their binding epitope in vivo. Since these DARPins
recognize full-length LmrD, but not the isolated NBD of LmrD, it
is likely that they bind to the cytoplasmic loops of the membrane
domain of LmrD. The other LmrCD-specific DARPins tested (a-
LmrCD#1 and a-LmrCD#3) were found to bind to membrane-
embedded LmrCD as well. However, the relatively weak binding
signals suggest that access to the binding epitopes is either partially
restricted by the lipid bilayer or that the binding epitope is only
accessible from the physiological outside of the cell, which is
hidden in the vesicle lumen of ISOVs. In the latter case, the
binding signal would originate from the approximate 10% of
RSOVs found in ISOV preparations.
The drug resistance phenotype in L. lactis associated with the
genomic expression of LmrCD was used to screen our pre-selected
DARPins for those that influence the functional properties of this
multidrug transporter. We observed the production of DARPins in
the cytoplasm of L. lactis with a relatively low toxicity compared to
expression in E. coli. Three homologous DARPins (DARPin_Act1,
Act_2, and Act3) were obtained, which enhance the LmrCD-
associated resistance to daunomycin and activate efflux of
BCECF-AM, but which, surprisingly, do not alter the resistance
to Hoechst 33342. This finding is reminiscent to a study on
ABCB1, in which small molecules were found to increase its
transport activity for some drugs whereas the transport of other
drugs was not affected or even decreased [65].
We considered the possibility of an increased LmrCD produc-
tion level in L. lactis in the presence of DARPin activators that
might act as folding chaperones. To test this hypothesis, a V5-tag
was introduced in frame with lmrD on the chromosome of L. lactis,
an approach that, to the best of our knowledge, was carried out for
the first time in this bacterium. With this tool it was demonstrated
that the expression of the activator DARPins in L. lactis does not
lead to changes in LmrCD production levels in the presence as
well as in the absence of daunomycin. As a proof of concept,
LmrCD expression was increased 1.5-fold in the presence of
daunomycin, which agrees well with RT-PCR experiments
detecting a transient two-fold increase of mRNA transcription
from lmrCD upon drug stimulation [66]. From this experiment we
concluded that the increased daunomycin resistance as well as the
enhanced BCECF-AM efflux originates from a direct stimulation
of the activity of LmrCD transporters as a consequence of
DARPin binding.
Figure 9. ATPase activity of reconstituted LmrCD is stimulated
by DARPin activators and daunomycin. Each symbol or bar
represents the average of three data points. (A) The ATPase activity of
reconstituted LmrCD is stimulated in the presence of daunomycin in a
dose-dependent manner. (B) Reconstituted LmrCD (protein:lipid ratio of
1:50, proteoliposomes diluted to obtain an LmrCD concentration of
70 nM) was incubated with DARPin activators and control DARPin
E3_5* (2.5 mM) and the ATPase activity was determined in the absence
and presence of 50 mM daunomycin (triplicates). As a control, buffer
instead of DARPins were added to LmrCD. According to t-test analysis,
the measured ATPase activity differences between DARPin_Act1 to Act3
and the buffer control are statistically significant (p,0.01 in the absence
and p,0.05 in the presence of daunomycin, respectively). (C) The
ATPase activities of LmrCD in the presence of DARPin_Act2 and E3_5
were determined over a range of ATP concentrations. The data points
were fitted to the Hill equation.
doi:10.1371/journal.pone.0037845.g009
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To gain more insight into the potential mechanism underlying
the activation of drug transport, the influence of the DARPin
activators on the ATPase activity of reconstituted LmrCD was
studied. The DARPin activators were found to stimulate the
ATPase activity of reconstituted LmrCD to a similar extent as
daunomycin applied at a concentration of 50 mM. Activation of
the basal ATPase activity of LmrCD upon DARPin expression is a
plausible explanation for the observed daunomycin resistance
increase in L. lactis. However, it cannot explain why the resistance
of lactococcal cells to Hoechst 33342 was not affected by the
expression of the DARPin activators. The exact mechanism
behind the modulation of LmrCD-mediated drug transport by the
DARPin activators is possibly much more complex. Recent studies
on Pdr5, a heterodimeric multidrug transporter of Saccharomyces
cerevisiae revealed a single mutation at one NBD which abolished
drug resistance against rhodamine-like compounds whereas
transport of other drugs was unaffected [67]. Likewise, a screen
identified small molecules dramatically altering the drug transport
profile of ABCB1 based on a molecular mechanism that remains
elusive [65]. These findings cannot yet be comprehensively
explained by current models of ABC transporter mechanism and
illustrate the limitation of our knowledge.
Beyond the activation of the basal ATPase by the DARPin
activators, we speculate that DARPin binding to LmrCD might
stabilize a conformational transition state at a rate-limiting step
during daunomycin and BCECF-AM transport. DARPin binding
could, for example, increase the overall rate of transport by
stabilizing the inward-facing state resulting in increased fractional
occupation during substrate binding, or enhance the dissociation
of the substrate from outward-facing LmrCD. But also the
resetting of LmrCD from the outward-facing to the inward-facing
state after ATP hydrolysis and drug release might be accelerated
by the DARPin activators. Finally, in addition to these possible
effects of DARPin binding on the maximal rate of efflux, DARPin
binding might directly influence the drug binding affinity of
LmrCD by imposing structural changes in drug binding surfaces.
The effect of DARPins on the mechanism of transport in in vitro
models (e.g. proteoliposomes) will be studied in future work.
In conclusion, we obtained three DARPins that activate
multidrug export by LmrCD in intact cells and stimulate the
ATPase activity of the transporter reconstituted into proteolipo-
somes. Our work demonstrates the potential of in vitro selected
artificial binding molecules to manipulate membrane transport
processes in vivo. Unlike chemical modulators, binding proteins
have the potential to stabilize any conformational (transition) state
of a membrane transporter, and offer the possibility to functionally
and structurally study membrane proteins in unprecedented ways.
When targeting membrane transporters associated with human
disease, DARPins could therefore be of great biopharmaceutical
importance.
Materials and Methods
Molecular Cloning and Expression of lmrCD and Other
Transporters
The primers and genetic constructs are listed in Table S1 and
Table S2. The lmrCD genes as well as the genes of msbA and acrB
were cloned with a coding region for an Avi-tag sequence at their
39-end, which allows the site-specific biotinylation of the target
proteins for the purpose of protein immobilization during
ribosome display and ELISA. A DNA fragment encoding the
Avi-tag sequence flanked by the restriction sites NheI and BamHI
was formed by annealing the two oligonucleotides avitag_for and
avitag_rev, and was ligated into the E. coli cloning vector pGEM
using the NcoI and XbaI restriction sites, yielding pGEM_Avi.
The lmrCD genes were amplified from the chromosome of
Lactococcus lactis subsp. cremoris MG1363 using the primers
lmrCD_DecaHisN_AviC_for for introduction of an N-terminal
His10-tag in LmrC and lmrCD_AviC_rev to add a C-terminal
Avi-tag to LmrD. The PCR product was cut with NcoI and XbaI
and cloned into the pGEM_Avi digested with NcoI and NheI
yielding pGEMLmrCDAviC. Two independent clones were
sequenced and were found to carry a nucleotide substitution
compared to the published sequence of Lactococcus lactis subsp.
cremoris MG1363 [68] at the triplet position of C179 in LmrC,
which is an arginine in our clone (TGC R CGC). In addition, a
construct lacking the C-terminal Avi-tag was cloned by amplifying
lmrCD from pGEMLmrCDAviC using the forward primer
lmrCD_NdeI_Presc_that introduces a linker and a prescission
protease cleavage site at the 59-end, and the reverse primer
lmrCD_rev. The PCR product was digested using NdeI/XbaI and
ligated into pGEMLmrCDAviC cut with the same enzymes,
resulting in plasmid pGEMLmrCD. The tagged lmrCD genes
were then sub-cloned via NcoI/XbaI either into the lactococcal
pNZ8048 vector [54] or the Escherichia coli expression vector
pBAD24 [69] yielding the expression vectors pNZLmrCDAviC,
pNZLmrCD, pBADLmrCDAviC and pBADLmrCD, respectively.
The msbA gene was cloned into pGEM_Avi via the restriction sites
NcoI/NheI amplifying the msbA gene with the primers msbA_-
DecaHisN_for and msbA_AviC_rev from the clone pNZMsbA
[44] yielding pGEMMsbAAviC. The gene of acrB from E. coli
devoid of NcoI sites (Murakami and van Veen, unpublished) was
amplified with the primers acrB_HisC_AviC_for and acrB_His-
C_AviC_rev and cloned via NcoI/NheI into pGEM_AviC
yielding pGEMAcrBAviC. The tagged msbA and acrB genes were
sub-cloned into pBAD24 using the restriction sites NcoI and XbaI
resulting in pBADMsbAAviC and pBADAcrBAviC. All sequences
were confirmed by DNA sequencing. The genes coding for lmrC,
lmrD and lmrCD were also cloned in frame with a C-terminal GFP
(that is cleavable by 3C protease) into pBAD24 applying the
recently developed FX-cloning method [70]. Similarly, coding
regions of the NBDs of LmrC and LmrD (which includes residues
G336 to D579 and G424 to E664 of LmrC and LmrD,
respectively) were cloned into a FX-vector adding a His10-tag, a
3C protease cleavage site and an Avi-tag to the 59-end of the
cloned genes (Geertsma and Dutzler, unpublished). The Walker B
glutamate of the consensus ATPase site of LmrCD was mutated to
glutamine using a quick-change standard protocol
(LmrD_E587Q). LmrCD protein containing a C-terminal Avi-
tag (LmrCDAviC) was produced in and purified from L. lactis
NZ9000 DlmrA DlmrCD [55] following published protocols [45,71].
The enzymatic site-specific biotinylation of the Avi-tag was carried
out in vitro using purified BirA yielding biotinylated LmrCDAviC
(bLmrCDAviC) [51], which was then used for DARPin selection
and ELISA. MsbAAviC and AcrBAviC were expressed in E. coli
harboring the corresponding pBAD24 expression vectors and were
purified and biotinylated accordingly.
DARPin Selection
The N3C DARPin library was chosen to select binders against
biotinylated LmrCDAviC (bLmrCDAviC) using the ribosome
display method [12,28,72]. In all selection rounds, 0.03% DDM
was used as detergent instead of the commonly used Tween-20 in
the standard ribosome display buffer WBT-BSA, containing
50 mM Tris-acetate pH 7.5, 150 mM NaCl, 50 mM MgOAc,
and 0.5% BSA. For the DARPin selection against vanadate-
trapped bLmrCDAviC, the protein was incubated with 1 mM ATP
and 1 mM Na3VO4 (freshly boiled as 100 mM stock, pH 9–10)
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prior to (1 h on ice) and during the incubation with the ribosomal
complexes. For the first three rounds, the selection was carried out
using the surface panning method by immobilizing bLmrCDAviC
via neutravidin on a solid support as described in the protocol of
Zahnd et al. [72]. The washing times before mRNA elution, were
set to 5, 2615 and 2630 min in the first, the second and the third
selection round, respectively. The fourth selection round was
carried out with the solution panning method [31]. 60 nM of
bLmrCDAviC was added to the stabilized DARPin in vitro
translation mixture (260 ml) and panned for 90 min. Streptavi-
din-coated magnetic beads (20 ml suspension Dynabeads MyOne
Streptavidin T1, Invitrogen) were used to capture the biotinylated
bLmrCDAviC with bound ribosomal complexes during 15 min.
The beads were rinsed twice with 300 ml WBT-BSA containing
0.03% b-DDM (WBT-BSA-DDM), placed into a fresh tube, and
washed for 30 min. After another tube change and another
30 min of washing, the mRNA was eluted and purified according
to the standard protocol [72].
Crude Cell Extracts and ELISA
The pools of DARPins from the 4th selection round were
expressed from the vector pQE30myc5 [31] in E. coli XL-1 Blue
yielding DARPins carrying an N-terminal RGS-His6 tag (with the
protein sequence MRGSHHHHHH) and a C-terminal Myc5-tag
(with five times the sequence MEQKLISEEDLNE). DARPin-
containing crude cell extracts were used to identify LmrCD-
specific binders by ELISA as described [31]. The DNA sequences
of all identified DARPins have been deposited in GenBank under
the accession numbers JQ425604-JQ425611.
SEC of Isolated DARPins and the LmrCD-DARPin
Complexes
The Myc5-tag fusion with the DARPins leads to the formation
of higher oligomeric species (not shown), and the DARPins were
therefore sub-cloned into the pQE30 vector (Qiagen) devoid of a
Myc-tag for further analysis and purified via Ni2+-NTA chroma-
tography and SEC (Superdex 200 10/300 GL, GE Healthcare)
according to standard procedures [14]. For the quantification of
the stoichiometric compositions of the LmrCD-DARPin complex-
es, Ni2+-NTA purified LmrCD (10 mM) was mixed with a twofold
excess of freshly gel-filtrated DARPin and incubated for 30 min.
The protein mixture was separated by SEC (Superdex 200 PC3.2/
30, GE Healthcare), after which fractions were analyzed by on-
chip protein analysis according to the manufacturer’s protocol
(Protein 80 Kit, Agilent Technologies).
Surface Plasmon Resonance
The affinities of selected DARPins towards detergent purified
bLmrCDAviC were determined by surface plasmon resonance on
a Biacore T100 machine (GE Healthcare). Because initial SRP
measurements in a buffer containing 0.03% DDM were difficult
to interpret, the dissociation constants were determined in the
presence of Tween-20 instead. To test the stability of LmrCD in
Tween-20, DDM was replaced with highly pure Tween-20
(Anapoe-20, 0.05%, Anatrace) in the washing and elution step
during LmrCD purification by Ni2+-NTA chromatography.
LmrCD purified using Tween-20 exhibited an ATPase activity
of 297624 nmol/min/mg of protein and its SEC elution profile
was indistinguishable from the one obtained with DDM (not
shown). For the SRP measurement, the detergent was changed
from DDM to Tween-20 after the immobilization of bLmrCDA-
viC on the Biacore chip, which lead to highly accurate and
undisturbed measurements. The target protein was purified
freshly as described above and 600 response units (RU) were
immobilized in flow cell 2 of a streptavidin-coated SA chip (GE
Healthcare), whereas flow cell 1 was used for referencing.
Affinities were determined in 20 mM Tris/HCl pH 7.5,
150 mM NaCl containing 0.05% (v/v) Tween-20 at 10uC and
a flow rate of 20 ml/min. The DARPin concentration was
determined by OD280 using a NanoDrop1000 Photospectrometer
and calculated based on theoretical extinction coefficients (www.
expasy.ch/tools/protparam.html). For each DARPin, a 3-fold
dilution series of six different concentrations were used for the
kinetic measurements (concentration ranges: 0.1 nM–72.9 nM
for a-LmrCD#1, a-LmrCD#2; 0.3 nM –218.7 nM for a-
LmrCD#3, a-LmrCD#5 and DARPin_Act3; 1 nM –729 nM
for a-LmrCD#4; 3 nM - 2187 nM for DARPin_Act2). Every
DARPin concentration was injected twice starting with the lowest
concentration, increasing to the maximal concentration and then
decreasing back to the lowest concentration. The association and
dissociation phases were set as follows (the first number denotes
association time/the second number denotes dissociation time):
a-LmrCD#1, a-LmrCD#2 and DARPin_Act2 (700 s/2400 s);
a-LmrCD#3 (240 s/1000 s); a-LmrCD#4, a-LmrCD#5 and
DARPin_Act3 (400 s/1200 s). The data were best fitted using a
two-state reaction model. This model assumes that the DARPin
(A) and LmrCD (B) form an initial complex (AB) with an
association rate constant ka1 (in M
21 s21) and a dissociation rate
constant kd1 (in s
21). This initial complex (AB) is then converted
into an alternative complex (AB*) with the association rate
constant ka2 (in s
21) and a dissociation rate constant kd2 (in s
21).
In this model, the dissociation constant KD (M) is calculated using
the following equation:
KD~
kd1
ka2
: kd2
(kd2zka2)
However, a control experiment in which a saturating concen-
tration of a DARPin was injected for varying times revealed, that
the two-state reaction model is inappropriate (see Results and
Figure S3). Therefore, the data were fitted using a simple 1:1
binding model and the dissociation constant KD was calculated
using the following equation in which ka is the association rate
constant and kd the dissociation rate constant:
KD~
kd
ka
In addition, the steady-state response units at the end of each
injection (i.e. when association and dissociation are in equilibrium)
were plotted against the injected DARPin concentration
(Figure 7D). The equilibrium constant KD,eq. was determined by
non-linear regression using an equilibrium binding equation
equivalent to the Michaelis-Menten equation in which R denotes
the SPR response at equilibrium, Rmax denotes the maximal SPR
response and [DARPin] is the DARPin concentration:
R~
Rmax DARPin½ 
KD,eq:z DARPin½ 
LmrCD-Specific in vitro Selected DARPins
PLoS ONE | www.plosone.org 15 June 2012 | Volume 7 | Issue 6 | e37845
Functional Screening in L. lactis
The control DARPin E3_5 [14] was cloned into the lactococcal
vector pNZ8048 from which it was expressed in L. lactis. During
the course of the study, DNA sequencing of the pNZ8048 clone of
the control DARPin E3_5 revealed the replacement of the second
repeat with the duplicated sequence of the third repeat in a
recombination event. This variant of E3_5 (E3_5*) was mono-
meric (not shown) and was used as control DARPin in the
functional experiments in L. lactis. For the functional screening of
the DARPins in L. lactis, the DARPin pools of the 4th selection
round were expressed from pNZ8048 in the presence of nisin A
(10 ng/ml) and daunomycin (10 mM or 18 mM to screen for
inhibitors or activators, respectively). The plasmids encoding for
potential inhibitory or activating DARPins were isolated, se-
quenced and retransformed into wildtype L. lactis NZ9000 and
L. lactis NZ9000 DlmrA DlmrCD. Resistance towards daunomycin
and Hoechst 33342 was determined by growing the cells at various
drug concentrations. A pre-culture devoid of nisin (150 ml) was
inoculated 1:100 with an overnight culture, after which cells were
grown for 210 min. The preculture was then diluted 1:100 into
medium containing 10 ng/ml nisin after which daunomycin was
added to various concentrations, and growth of cells was allowed
for 15 to 18 h. Final OD660 were measured and normalized by
setting the final OD660 reached in the absence of drug to 100.
Normalized values were plotted versus the daunomycin concen-
tration. The curves were fitted with a 4-parameter sigmoidal
equation in which y stands for the normalized final OD660, y0
describes the background OD660, x stands for the daunomycin
concentration, x0 is the inflection point of the curve, and a and b
are fitting parameters (SigmaPlot 10, default settings).
y~y0z
a
1ze
{(
x{x0
b
)
IC50 for daunomycin was defined as the daunomycin concen-
tration at which the OD660 after growth for 15–18 h is half as high
as in the absence of the drug.
Transport Assay with BCECF-AM
L. lactis NZ9000 and L. lactis NZ9000 DlmrA DlmrCD harboring
the expression plasmids for DARPin_Act2 and the unselected
DARPin E3_5* were grown to an OD660 of 0.6 and induced for
2 h with 5 ng/ml nisin A. Cells were harvested and washed twice
with ice-cold fluorescence buffer (50 mM potassium phosphate
pH 7.0, 5 mM MgSO4). For the fluorescence measurements, the
OD660 was adjusted to 0.5 and the cells were pre-energized by the
addition of 0.5% glucose whilst stirring. Nigericin and valinomycin
(1 mM each) were added prior to the addition of the fluorescent
substrate. Non-fluorescent BCECF-AM was added at a final
concentration of 0.2 mM. Subsequently, the formation of the
fluorescent BCECF was monitored at excitation and emission
wavelengths of 502 nm and 525 nm, respectively using slit widths
of 2.5 nm and 4 nm, respectively.
Quantification of LmrCD Production Levels in L. lactis by
the Introduction of a V5-tag
The sequence of the V5 tag (with the protein sequence
GKPIPNPLLGLDST) was introduced in frame with the genomic
lmrD gene at its 39-end in L. lactis using the Campbell-type
recombination method [73]. The DNA sequence of the V5 tag
containing the appropriate sticky overhangs was generated by
annealing the oligonucleotides V5-tag_for and V5-tag_rev and
cloned as double-stranded DNA fragment into pGEM_Avi cut with
BamHI/NheI yielding pGEM_V5 and thereby replacing the Avi-
tag sequence. An 860 bp stretch of chromosomal DNA downstream
to the lmrD gene was amplified with the primers lmrD_V5_for1 and
lmrD_V5_rev1 and introduced into pGEM_V5 using the restriction
sites BamHI/XbaI resulting in pGEMLmrCDV5*. The last 1583 bp
of lmrD were amplified with the primers lmrD_V5_for2 and
lmrD_AviC_rev, cut with NcoI/XbaI and cloned in frame with
the V5 tag sequence into pGEMLmrCDV5* cut with NcoI/NheI
yielding pGEMLmrDV5. The DNA fragment on pGEMLmrDV5
containing the V5 tag sequence flanked by a part of lmrD and a
stretch of DNA downstream of the lmrD gene on the L. lactis
chromosome was sub-cloned into pORI280 via NcoI/XbaI and
transformed into E. coli EC1000 (repA+) resulting in the plasmid
pORI280LmrDV5 [73,74]. Wildtype L. lactis NZ9000 was trans-
formed with pORI280LmrDV5 as described [55] yielding three blue
colonies after 3 days of incubation at RT. PCR analysis of the
chromosomal DNA revealed that two of these clones were the result
of the Campbell-type integration of pORI280LmrDV5. The second
recombination step was performed by growing a positive clone for a
total of 50 cell divisions in the absence of erythromycin and the
subsequent screening for white colonies on M17 agar plates. Two
white colonies were found (out of around 4000 colonies screened)
and confirmed to encode the lmrD gene fused with the V5 tag
sequence by Western blotting. This new strain was named L. lactis
NZ9000 lmrDV5. The plasmids encoding the activator DARPins and
the control DARPin E3_5* were transformed into L. lactis NZ9000
lmrDV5. A 1:100 inoculated preculture of transformed cells was
grown for 210 min in M17, 0.5% maltose, 5 mg/ml chloramphen-
icol and 50 ml thereof were used to inoculate 5 ml of the same
medium containing 10 ng/ml nisin with or without daunomycin
addition (14 mM for DARPin_Act3 and E3_5* and 28 mM for
DARPin_Act1 and DARPin_Act2, respectively). Each sample was
prepared in triplicates. The cultures were grown for 15 h and
harvested by centrifugation. Cells were resuspended in 350 ml of
50 mM Na-HEPES (pH 7), 1 mM MgSO4, 10% (wt/v) glycerol,
1 mM PMSF, 25 mg/ml DNaseI and trace amounts of lysozyme.
After the addition of glass beads (300 mg, 0.1-mm diameter),
samples were disrupted in a FastPrep device (MP Fastprep-24, MB
Biomedicals) twice for 30 s at force 6.5. Cell membranes were
harvested by centrifugation (55000 g) resuspended by SDS-PAGE
loading dye and the proteins were separated on a 10% tricine gel
[75]. Each sample was analyzed on two SDS-PAGE gels, one
dedicated to Western blotting and the other to the analysis of the
protein amounts with SYPRO ruby staining (a total of 6 gels due to
the triplicates). For the Western blotting analysis, the gels were
blotted onto a nitrocellulose membrane (wet blotting) and blocked in
TBST (TBS containing 0.1% Tween-20) supplied with 5% milk
powder overnight. The anti-V5 antibody (Sigma, clone V5-10,
1:3000 diluted in TBST) was panned for 160 min and the
membrane was washed three times for 10 min with TBST. After
incubation with a secondary anti-mouse HRP antibody (Jackson
ImmunoResearch Laboratories, 1:2500 in TBST) and another
three washing steps, the Western blot signal was detected with a
LAS-3000 imaging system (Fujifilm) using ECL reagent (PIERCE).
The second SDS-PAGE gel corresponding to the samples analyzed
by Western blot was stained with SYPRO ruby staining (Invitrogen)
and the fluorescent signal was read with the LAS-3000 imaging
system. The Western blots and the ruby-stained gels were quantified
using the Aida software (Raytest). The data were normalized by
setting the LmrDV5 level determined in cells expressing the control
DARPin in the absence of drugs to 1. The standard deviations of the
triplicates were calculated.
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DARPin Binding to Membrane Inserted Target Protein in
ISOVs
For the production of membrane vesicles, LmrCDAviC and
AcrBAviC were overproduced in E. coli C43 (DE3). Inside-out
membrane vesicles (ISOVs) were obtained after cell disruption at
20000 psi (Constant Systems). ISOVs containing overexpressed
LmrCD-GFP were prepared to determine the membrane vesicle
orientation by cleaving off the GFP at the external side using 3C
protease, followed by SDS-PAGE and quantification of the
cleavage reaction using in-gel fluorescence of remaining LmrCD-
GFP and cleaved GFP. Based on these experiments, ISOV
preparations contained 10% or less membrane vesicles of the
opposite (right-side-out) orientation. The membrane vesicles were
diluted at a protein concentration of 0.2 mg/ml in 1 ml of TBS,
pH 7.4. In a first set of experiments (Figure 8A) DARPins
(350 nM) were allowed to bind for 40 min to the ISOVs. In a
second set of experiments (Figure 8B), the DARPin_Act2 and a-
LmrCD#3 used at concentrations of 0.35 mM, 1 mM and 2 mM
were allowed to bind for 200 min. The membranes were
harvested by centrifugation for 20 min at 55000 g. The pellets
were resuspended with 800 ml of TBS to wash off unbound
DARPins, spun again, after which the pellets were resuspended
with SDS-PAGE loading dye (40 ml). Total membrane proteins
in membrane vesicles, and bound DARPins, were separated by
SDS-PAGE using tricine gels [75] and blotted onto nitrocellulose
membranes. The protein mixture was separated by SDS-PAGE
[75] and the bound DARPins were quantified by Western
blotting using RGS-His antibody (Qiagen) and detection by ECL
(PIERCE).
Reconstitution of LmrCD and ATPase Activity Assay
Ni2+-NTA-purified LmrCD expressed in L. lactis was reconsti-
tuted at a protein:lipid ratio of 1:50 (w/w) into acetone-washed
and ether-extracted total E. coli lipids mixed with egg phospha-
tidylcholine (Avanti) in a ratio 3:1 (w/w) in 50 mM K-HEPES
pH 7.0 following published protocols [41,76]. Where indicated,
SEC-purified DARPins (2.5 mM) were added to the proteolipo-
somes and incubated in 50 mM K-HEPES pH 7 for 12 h.
Daunomycin (where indicated) and MgSO4 (10 mM) were added
shortly prior to the assay start. The ATPase assay was performed
in 96-well PCR plates on the heating block of a PCR machine.
40 ml of reconstituted LmrCD (70 nM, including DARPins and
daunomycin where appropriate) was added to 10 ml of 5-fold stock
of highly pure ATP solution (SigmaUltra, 1 mM final concentra-
tion if not stated otherwise, dissolved in ddH2O adjusted to pH 7
using KOH) whilst the temperature was set to 4uC. The ATP
hydrolysis reaction was initiated by changing the temperature to
30uC for 20 min and stopped by denaturing the samples at 80uC
for 30 s. LmrCD mutated at the Walker B glutamate of the
consensus composite ATPase site (LmrD_E587Q) was reconsti-
tuted and used for background subtractions. This mutation was
shown previously and confirmed by us to be incapable of
hydrolyzing ATP [47]. The amount of generated Pi was quantified
colorimetrically using the malachite green/molybdate method
[55]. The datapoints of the ATPase activities measured at
increasing ATP concentrations (Figure 9C) were fitted with the 3
parameter Hill equation (Sigmaplot 10, default settings), in which y
denotes the ATPase activity, x stands for the concentration of
ATP, a corresponds to Vmax, b denotes the Hill coefficient, and c
corresponds to Km,app.
y~
axb
cbzxb
Data Analysis
Statistical analyses were performed with the Student’s t-test with
a 95% confidence interval for the sample mean. If not stated
otherwise, error bars represent the standard deviation (SD).
Supporting Information
Figure S1 Preparation of biotinylated target proteins
for the DARPin selections and ELISAs, and character-
ization of selected DARPins by SEC. (A) SDS-PAGE analysis
of purified LmrCDAviC. The protein bands corresponding to
overproduced LmrCDAviC are apparent in the total detergent-
solubilized membrane fraction (lane 1). Pure protein is eluted from
the Ni2+-NTA column (lane 2). (B) Ni2+-NTA purified LmrCDAviC
shown in (A) was in vitro biotinylated and separated by SEC to
remove aggregated protein and excess biotin. Fractions of the peak
at 12.50 ml corresponding to heterodimeric bLmrCDAviC were
used for the DARPin selections and ELISA (red bar). The strong
peak at the void volume of the column (9 ml) besides aggregated
LmrCD also contained genomic DNA that escaped from DNaseI
treatment (as evidenced by the strong A254 signal relative to the
A280 signal). (C, D), Gel filtration profiles of studied DARPins on
Superdex 200 column. The maxima of the main peaks were as
follows: (C) a-LmrCD#1:16.84 ml; a-LmrCD#2:15.11 ml; a-
LmrCD#3:16.37 ml; LmrCD#4:16.80 ml; a-
LmrCD#5:17.01 ml; E3_5:16.89 ml (D) DARPin_Act1:10.32 ml;
DARPin_Act2:13.25 ml; DARPin_Act3:16.38 ml. (E, F), SEC
profiles of LmrC-GFP and LmrD-GFP (E) as well as of LmrD-
NBDAviN (F). The fractions indicated by the red bar were used for
the ELISA shown in Figure 3B.
(TIF)
Figure S2 Sequence alignment of the LmrCD-specific
DARPins identified in this study. The sequence of the
consensus designed DARPin framework is given in the top line,
where ‘‘x’’ stands for all amino acids except proline, glycine and
cysteine and ‘‘y’’ stands for histidine, glutamine or tyrosine.
(TIF)
Figure S3 SPR control experiment disfavors a two-state
reaction model of DARPin binding to LmrCD. The fits of
the SPR sensograms were found to match better using a two-state
reaction model instead of a 1:1 binding model (see Materials and
Methods). To test whether the two-state reaction model was
appropriate for fitting, a saturating concentration of a-LmrCD#3
(400 nM) was injected onto a SPR SA-chip containing 600 RU of
immobilized bLmrCDAviC for 100 s, 200 s and 400 s (each
injection was performed twice). The traces were superimposed at
the starting point of the dissociation curve. DARPin dissociation is
virtually identical irrespective of the duration of association time,
indicating that the two-state reaction model is not appropriate.
Therefore, all SPR data were fitted using a 1:1 binding model
(Figure 7C and Table 1).
(TIF)
Table S1 Primers used in this study.
(DOC)
Table S2 Genetic constructs used in this study.
(DOC)
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APPENDIX 
 
A1. CHAPTER F 
Expression, purification and DARPin selection against 
the bacterial ABC exporters LmrA & YDDA  
F.1 Introduction 
Multidrug resistance (MDR) is observed in medical treatment, where cells become resistant 
to the structurally distinct and relatively lipophilic drugs. MDR is frequently a manifestation 
of overexpression of active transporters which vectorially pump a variety of drug molecules 
across the lipid membrane. P-glycoprotein is one of the best studied ABC transporters and is 
associated with increased efflux of drugs in cancer cells1,2. P-glycoprotein and its bacterial 
homologs MsbA (from Gram-negative E.coli) and LmrA (from Gram-positive Lactococcus 
lactis)3 were shown to be polyspecific drug pumps4. There is a plethora of biochemical 
information available for ABC exporters but detailed structural information is limited, 
despite the reported crystal structures of Sav1866 (PDB ID 2HYD), 3 closely homologues of 
MsbA (PDB ID 3B60, 3B5W and 3B5X), P-glycoprotein (PDB ID 3G5U), and TM287/288 (PDB 
ID 3QF4). In order to describe a detailed transport mechanism, a transport protein needs to 
be crystallized in multiple conformations. No single homolog of any ABC exporter has yet 
been crystallized in multiple conformations which would describe the distinct states of the 
transport cycle. This demonstrates the difficulty to crystallize membrane transporters in 
different conformations. 
In addition, factors such as poor over-expression, conformational heterogeneity and 
the amphipathic nature hamper membrane protein crystallography. In the past, 
crystallization chaperones have been used to overcome the conformational heterogeneity 
and to extend the hydrophilic surface area5-7. This can facilitate the crystallization of proteins 
difficult to crystallize. Crystallization chaperones such as DARPin have also been successfully 
used to crystallize proteins in novel conformations. This has been demonstrated for the 
multidrug transporter AcrB, which  was co-crystallized with a DARPin in an asymmetric 
conformation (PDB ID 2J8S)8.  
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In this chapter the use of DARPins for the co-crystallization of ABC transporter as an 
alternative to antibody fragments was explored. LmrA, the first bacterial ABC multidrug 
transporter from Lactococcus lactis9 was chosen as candidate to select DARPins against and 
to use these DARPins as chaperones to crystallize LmrA. LmrA is a homodimer ABC exporter9. 
One monomer consists of 590 amino-acids forming a hydrophobic domain with 6 
transmembrane helices and a hydrophilic ATP-binding cassette domain. Since, LmrA is a 
prokaryotic homolog of MDR proteins such as P-glycoprotein, structure determination of 
these proteins facilitated by a specific DARPin would be a significant contribution towards 
understanding the function of clinically relevant transporters. 
The second homodimeric ABC transporter chosen was YDDA consisting of two 
polypeptide chains of 64985 Da molecular weight each. The yddA gene is identified as a 
putative gene for an ABC transporter in the E.coli genome10,11. It is classified as a putative 
homodimeric exporter (http://www.uniprot.org/uniprot/P31826) of unknown function. 
F.2 Results 
F.2.1 Biochemical characterization of LmrA (ATPase activity) 
Detergent solubilized (C12E8) LmrA was purified by IMAC. The homogeneity and the purity of 
the purified protein were analyzed by size-exclusion chromatography (SEC) and SDS-PAGE. 
LmrA eluted as homogeneous dimer in SEC (Figure_F1). The ATPase activity of detergent 
purified LmrA was performed using the method described in experimental procedure (F.4.2). 
Detergent purified LmrA is functional, as it exhibited basal ATPase activity (Figure_F1C). 
F.2.2 Characterization of DARPins specific for LmrA 
Selection and screening of DARPins against LmrA was performed by Dr. Markus Seeger. The 
N2C DARPin library was used for DARPins selection by ribosome display.  LmrA and LmrA-
specific binders were expressed and purified by IMAC. Purified LmrA and selected DARPins 
were mixed at a ratio of 1:3 and were incubated for 15 minutes at 4°C. The LmrA-DARPin 
complexes were separated from the excess DARPin by SEC. The fractions containing the 
LmrA-DARPin complex were analyzed by SDS-PAGE (Figure_F2B). All DARPins were found to 
form a complex with LmrA. The SDS-PAGE analysis suggested that DARPins H2, F3 and G6 
seem to be forming a sub-stoichiometric complex with LmrA, because the bands of the 
DARPins appeared relatively weak on coomassie-stained gel (Figure_F2B). A quantitative  
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analysis to analyze the stoichiometry for different LmrA-DARPin complexes was not 
performed. 
 
F.2.3 Crystallization of LmrA alone and the LmrA-DARPin 
complexes 
IMAC purified LmrA was purified by SEC and LmrA-DARPin complex was formed as described 
above. LmrA and the LmrA-DARPin complex were concentrated to 10-18 mg/ml and used for 
crystallization in 1:1, 1:2 and 1:3 ratios of protein and mother liquor respectively.  
Mackinnon screens (GS020-GS025) from the NCCR structural Biology platform were used to 
set up crystallization plates. We used different nucleotides (ATP and ADP) and their non-
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hydrolyzing analogs (AMP-PNP, ADP-VO4
-3) as ligand, which might have increased the 
homogeneity of the purified protein. Crystallization efforts for LmrA alone and in complex 
with DARPins did not yield any suitable condition for crystal growth. 
 
F.2.4 Biochemical characterization of YDDA (ATPase assay) 
Detergent (β-DDM) solubilized YDDA was purified by IMAC. The homogeneity and purity of 
purified protein was analyzed by SEC and SDS-PAGE, respectively. YDDA eluted as 
homodimeric and homogenous protein in SEC. Detergent purified YDDA showed no basal 
ATPase activity (Figure_F1C).  
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F.2.5 Screening of YDDA specific DARPins  
DARPin selection against YDDA was performed by Christian Spoerri using a N3C DARPin 
library. The enriched pool of DARPins after the third round of RD was subcloned into the 
expression vector pQE30. About 200 DARPin clones were analyzed for binding to bYDDAAviC 
by crude extract ELISA. Maltose binding protein was used as a negative control in crude 
extract ELISA. 9 specific binders for YDDA were found (Figure_F4). 
F.2.6 Analysis of the YDDA-DARPin complex formation 
Sequencing of the 9 YDDA-specific DARPins revealed that they were unique and therefore 
were used for further experiments (Figure_F5). 6 binders were overexpressed and purified 
by Ni+2-NTA chromatography. IMAC purified DARPin and YDDA were mixed at a 3:1 ratio, and 
incubated for 15 minutes at 4°C. The YDDA-DARPin complex was separated from the excess 
DARPin by SEC. SDS-PAGE analysis indicated complex formation for all selected DARPins with 
YDDA (Figure_F6).  
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Further, IMAC purified DARPins were analyzed by SEC for homogeneity. All 
preparations contained higher oligomeric forms of DARPin besides the monomeric form. In 
order to rule out the possibility that DARPins co-elute with YDDA due to the occurrence of 
higher oligomeric states, YDDA and DARPins were gel-filtrated individually before complex 
formation. To this end, equal volume (500 µl) of homogenous fractions of DARPin 
(monomeric) and YDDA (Dimeric) were mixed. An additional concentration step was omitted 
to avoid the formation of DARPin oligomers. The mixture (1 ml) was separated by SEC and 
the fractions corresponding to the YDDA-DARPin complex were analyzed by SDS-PAGE 
(Figure_F7). In contrast to the initial analysis, it was later found that monomeric DARPins 
purified by SEC do not elute in complex with YDDA. This suggested that: i) soluble aggregates 
of DARPins interact unspecifically with YDDA and therefore elute as a pseudo-complex, 
and/or ii) soluble aggregates of DARPin co-elute with YDDA in SEC.  
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It has to be noted here that these experiments were performed prior to the work on 
MsbA described in the Chapter B and C. based on our experience with YDDA, an additional 
step of gel-filtration of IMAC purified DARPin was routinely included to remove soluble 
aggregates of DARPin, prior to complex formation with the target protein.  
F.3 Discussion 
This chapter describes the first attempts of DARPin assisted crystallography of membrane 
proteins in this thesis.  The lessons learned here are discussed below and helped to improve 
the selection and screening procedures of binders against MsbA and LmrCD (Chapters B, C 
and E).  
Two ABC transporter proteins namely LmrA and YDDA were successfully expressed 
and purified. LmrA is the first multidrug transporter protein found in Gram positive bacteria, 
while YDDA is from Gram-negative bacteria and its function is unknown. LmrA and YDDA 
could be purified as dimeric and homogenous proteins in detergents C12E8 and β-DDM, 
respectively. Detergent purified LmrA exhibited basal ATPase activity, while YDDA did not 
show basal ATPase activity. Addition of a substrate might be required to stimulate the 
ATPase activity of YDDA. Subsequently, we selected specific DARPin binders against the two 
detergent solubilized ABC transporters LmrA and YDDA. LmrA-specific DARPins were used 
for co-crystallization experiments (Figure_F2A). Despite serious efforts, all crystallization 
attempts were unsuccessful. No suitable condition was found from where LmrA alone or the 
LmrA-DARPin complex would crystallize. 
N2C DARPin binders were initially used to co-crystallize LmrA. Therefore, N3C rather 
than N2C DARPins for binder selections against YDDA were chosen because it was reasoned 
that their bigger size could better facilitate crystal contacts6,8. Complex formation between 
purified YDDA and DARPin was analyzed by gel-filtration. In an initial set of experiments, 
ELISA-positive binders were used directly after IMAC for complex formation with YDDA. In 
these experiments, it was found that all DARPin eluted in complex with YDDA as analyzed by 
size-exclusion chromatography. However, a careful examination of the oligomeric state of 
DARPin binders raised the concern, that most of them were forming soluble aggregates 
(Figure_F7A), and thus the elution fractions of these oligomers coincide with the elution of 
YDDA. To test this hypothesis, we mixed YDDA with freshly gel- filtrated monomeric DARPin 
and avoided any further concentration of the YDDA-DARPin mixture.  
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SDS-PAGE analysis of the complex eluted by SEC showed that the DARPins did not 
elute in complex with YDDA (Figure_F7B). This analysis suggested that the higher oligomers 
of DARPin were responsible for the presumed protein-complex obtained earlier. Only a 
stoichiometry analysis of the target protein-DARPin complex can reveal either a sub-
stoichiometric complex (suggesting low affinity between the target protein and the binder) 
or a higher-stoichiometry (implying that the binder might be forming soluble aggregates). 
For YDDA, a number of rather weak binders have been obtained that give an ELISA signal but 
do not co-elute in complex with YDDA in SEC. The reason for the accumulation of unspecific 
DARPin could be due to: (i) surface panning in ribosome display, where a target protein is 
immobilized on a solid surface. Besides certain advantages of surface panning (requires 
smaller amounts of target protein), it has several disadvantages: a part of the protein surface 
is always masked during immobilization and unspecific DARPin binding to the microtiter 
plate surface has also been observed12.  An alternative method is to use solution panning, 
where a biotinylated target protein is first mixed with binder library in solution and protein 
complexes are captured using streptavidin coated magnetic beads. Solution panning was 
successfully used for DARPin selection against MsbA, described in Chapter C.2.2, and (ii) 
ELISA format used in screening of YDDA specific binders. The ELISA format used involves 
target protein immobilization on a solid surface via Neutravidin-biotin interaction, upon 
which the three dimensional structures might be compromised during the 8-10 hours long 
ELISA experiment which involves washing steps and room temperature incubation. An ELISA 
format where a target protein is added to ELISA experiment at a very late stage is therefore 
better suited for delicate membrane proteins. Huber et al. have reported an ELISA protocol 
for successful binder screening for CitS12, in which the DARPin is immobilized first via myc-
tag and biotinylated target protein is added towards the end of the protocol. For the 
screening of MsbA-specific DARPins, we have used the ELISA set up based on myc-tagged 
DARPins. 
F.4 Experimental procedure 
F.4.1 Cloning, expression and purification 
F.4.1.1 LmrA 
Lactococcus lactis cells transformed with pNZ8048_lmrA13 were a kind gift of Hendrik van 
Veen at Cambridge University, Cambridge. Lactococcus lactis carrying pNZ8048_lmrA were 
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grown in M17 media (OXOID CM 0817) at 30°C to an OD600 of 0.8. Protein expression was 
induced with Nisin (40 pg/ml final concentration) for 3–4 h at 30 °C. Harvested cell pellet was 
resuspended  in 20 mM Tris-Cl (pH 7.4), 150 mM NaCl, 25 μg/ml DNaseI and protease 
inhibitor cocktail (Sigma) and cells were incubated with lysozyme (2mg/ml) for 30 minutes at 
30°C. Cells were lysed using EmulsiFlex-C3 (Avestin) cell disrupter. Unbroken cells and cell 
debris were removed by centrifugation at 8000 rpm (HiCen XL, A8.20 rotor) for 10 min at 4°C 
and membrane vesicles were then harvested by centrifugation at 45,000 rpm (Ti70, Sorvall 
ultracentrifuge) for 60 min at 4°C. LmrA was solubilized using 1% C12E8 and 0.1% β-DDM in 
1X-TBS from membrane vesicles at 4°C for 90 minutes. The insolubilized membrane fraction 
was removed by centrifugation at 45,000 rpm for 60 min at 4°C and the cleared lysate was 
loaded onto a Ni2+-NTA gravity flow column containing 1.5 ml resin (Qiagen). The resin was 
washed with 30 mM imidazole pH 7.5, 1X-TBS and 0.03 % C12E8 (50 ml), and the protein was 
eluted in the 1X-TBS, 250 mM imidazole pH 7.5, 10% glycerol and 0.03 % C12E8 (7 ml). All gel-
filtration experiments were performed using a Superose 6, 10/300, column (GE Healthcare). 
F.4.1.2 YDDA 
The yddA gene with and without C-terminal Avi tag was cloned in the E.coli expression 
vector pET28-CH by Dr. Daniel Frey in our laboratory14. Plasmids harboring the ydda gene 
were transformed into E.coli BL-21(DE3) cells and cells were grown in 2YT media at 37°C. 
Protein production was induced at OD600 of 0.7 – 0.8 with 0.2 mM IPTG for 12-14 hours at 
18°C. Harvested cell pellets were resuspended in 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 25 
μg/ml DNaseI and protease inhibitor cocktail (Sigma) and cells were lysed using EmulsiFlexC3 
(Avestin) cell disrupter. Unbroken cells and cell debris were removed by centrifugation at 
8000 rpm (SS34 rotor) for 10 min at 4°C and membrane vesicles were then harvested by 
centrifugation at 45,000 rpm (Ti70 rotor) for 60 min at 4°C. YDDA was solubilized from 
membrane vesicles using 1% β-DDM in 50 mM Tris/HCl (pH 7.4), 150 mM NaCl (TBS) at 4°C 
for 90 minutes. The insolubilized membrane fraction was removed by centrifugation at 
45,000 rpm (Ti70 rotor) for 60 min at 4°C and cleared lysate was loaded onto a protino Ni-
IDA resin (Macherey-Nagel) gravity flow column containing 1.5 ml resin. The resin was 
washed with 2.5 mM imidazole pH 7.5, TBS and 0.03 % β-DDM (50 ml) and YDDA was eluted 
from the column using 150 mM imidazole pH 7.5 (7 ml) in the same buffer. The protein was 
concentrated in a 100 kDa cutoff concentrator and aggregated material was separated by 
SEC in 20 mM Tris/HCl (pH 7.5), 150 mM NaCl and 0.03% β-DDM. YDDAAviC was expressed 
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and purified similarly as described above and purified YDDA was supplemented with 10% 
glycerol and was snap-frozen in liquid nitrogen and stored at -80°C. All gel-filtration 
experiments were performed using a Superdex 200, 10/300, column (GE Healthcare 
column). 
F.4.1.3 Designed Ankyrin Repeat Proteins (DARPins) 
RD selection using the N2C DARPin library and screening by ELISA against LmrA was done by 
Dr. Markus Seeger, while the N3C DARPin library was used for selection against YDDA by 
Christian Spörri.   
For YDDA, the DARPins pool from the 3rd selection round was amplified with the 
primers EWT5 and MTS46. The PCR amplified product was digested using BamHI/HindIII 
restriction enzyme and ligated into pQE30 (Qiagen) containing an N-terminal RGS-6his tag. 
Expression and purification of DARPins are described in Chapter C (C.4.2.2).  
F.4.2 ATPase assay 
The coupled enzyme ATPase assay is based on the conversion of phophoenolpyruvate (PEP) 
to pyruvate by pyruvate kinase coupled to the conversion of pyruvate to lactate by lactate 
dehydrogenase (LDH). The latter step requires NADH which is oxidized to NAD+. NADH, but 
not NAD+, absorbs strongly at 340 nm, enabling to calculate the NADH concentration by 
monitoring the absorbance at 340 nm. The assay was done in buffer 20 mM Tris-Cl (pH 7.4), 
150 mM NaCl and 0.03% of β-DDM or 0.05% of C12E8. The final concentration of the reagents 
used in the assay were NADH (0.3 mM), PEP (4 mM), pyruvate kinase (55 µg/ml), LDH (12 
µg/ml), MgCl2 (3.3 mM) and ATP (3.3 mM). 
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A.2 Abbreviations 
3D   three-dimensional 
aa   amino acid 
ABC   ATP-binidng cassette 
AcrB   Acriflavine resistance protein B 
AMP-PNP       Adenylyl-imidodiphosphate 
ADP/ATP  Adenosine diphosphate/ Adenosine triphosphate 
AP   Alkaline phosphatase 
bMsbAAviC   Biotinylated-MsbAAviC 
BCECF-AM  2’, 7’-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester 
BirA   Biotin ligase enzyme 
BSA   Bovine serum albumin 
C12E8   Dodecyl octaethylene glycerol ether 
CitS   Citrate transporter 
DARPin  Designed ankyrin repeat protein 
DDM   n-dodecyl-β-D-maltoside   
DNA   Deoxyribonucleic acid 
DNBD   DARPin for the nucleotide binding domains 
DTT   Dithiothreitol 
EC    Enzyme commission 
E.coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
EPR/ESR  Electron paramagnetic resonance/Electron spin resonance 
GPCR   G-protein coupled receptor 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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IgG   Immunoglobulin G 
IC50   Half maximal inhibitory concentration 
IMAC   immobilized metal-ion affinity chromatography 
ISOVs   Inside-out membrane vesicles 
KD   Equilibrium dissociation constant 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
LPS   Lipopolysaccharide 
M5M        1,5-pentanediyl bismethanethiosulfonate 
M11M   3,6,9-trioxaundecane-1,11-diyl bismethanethiosulfonate 
MBP   Maltose binding protein 
MDR   Multidrug resistance 
mRNA   Messenger ribonucleic acid 
MTS   Methanethiosulfonate 
NAD+   Nicotinamide adenine dinucleotide 
NBD   Nucleotide binding domain 
OD   Optical density 
PCR   Polymerase chain reaction 
P-gp   P-glycoprotein 
PDB   Protein data bank 
RD   Ribosome display 
RSOVs   Right-side-out membrane vesicles 
RT   Room temperature 
SDS-PAGE  Sodium dodecylsulfate polyacrylamide gel electrophoresis 
SPR   Surface plasmon resonance 
TBS150   20 mM Tris/HCl (pH 7.4), 150 mM NaCl 
TMD   Transmembrane domain 
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UDM   n-undecyl-β-d-maltopyranoside 
A.3 Oligonucleotides  
● Oligonucleotide for the construction of expression vectors for MsbA_E.coli constructs 
Name of the primer  Sequence of the primer 
E-Q_For   5'-CTG ATT CTG GAC CAA GCT ACC TCG GC-3' 
E-Q_REV   5'-GCC GAG GTA GCT TGG TCC AGA ATC AG-3' 
MsbA_D-G_ for 5’-CCT CGG CTC TGG GAA CCG AAT CC-3’ 
MsbA_D-G_ Rev  5‘-GGA TTC GGT TCC CAG AGC CGA GG-3’ 
MsbA_PstI_For  5’-AAA ACT GCA GAT GCA TAA CGA CAA AGA TCT CTC TAC-3’ 
forward_MsbA  5'-ATA TCC ATG GGC CAT CAC CAT CAC CAT CAT CAT CAT CAT CAC AGC-3' 
Reverse_MsbA  5' ATA TTC TAG ATT ATT ATT GGC CAA ACT GC-3' 
 
● Oligonucleotide for the construction of expression vectors for NBD of MsbA_E.coli constructs 
NBD_MsbA_KpnI  5’-AAA GGT ACC TTG GCC AAA CTG CAT TTT GTG AAG-3’ 
NBD_MsbA_PstI  5’-AAA CTG CAG ATG CGT GCG ACT GGC GAC GTG GA-3’ 
NBD_MsbA_XbaI  5’-AAA TCT AGA TTA TTA TTG GCC AAA CTG CAT TTT GTG AAG-3’ 
NBD 537H_A_F  5’-CTC TGG TGA TTG CCG CCC GCT TGT CTA CCA T-3’ 
NBD 537H_A_R  5’-ATG GTA GAC AAG CGG GCG GCA ATC ACC AGA G-3’  
  
 
● Oligonucleotide for the construction of expression vectors for TMD of MsbA_E.coli constructs 
MsbAEC_TM_S_KpnI  5’-AAA AGG TAC CCT CCT GCT CAC TGT CCA GAA TG-3’ 
MsbAEC_TM_L_KpnI  5’-AAA AGG TAC CAT TGC GGA ATT CCA CGT CGC CAG-3’ 
 
● Oligonucleotide for the construction of expression vectors for MsbA_E.coli constructs used in 
cross-linking and EPR study 
MsbA25A-C_F   5’-GTG GCC AAC CAT TTG CCC TTT CAA AGC GG-3’  
MsbA25A-C_R   5’-CCG CTT TGA AAG GGC AAA TGG TTG GCC AC-3’  
MsbA65_F2   5’-GCT CCG TGC TGT GCT GGA TGC CGC T-3’  
MsbA65_R2   5’-AGC GGC ATC CAG CAC AGC ACG GAG C-3’  
MsbA_71_F  5’-CCG CTG GTG TGC ATC GGG CTG ATG-3’   
MsbA_71_R   5’-CAT CAG CCC GAT GCA CAC CAG CGG-3’ 
 
MsbA_C88-S_F  5’-GTC TCC AGC TAC AGC ATC TCC TGG GTA-3’ 
MsbA_C88-S_R  5’-TAC CCA GGA GAT GCT GTA GCT GGA GAC-3’ 
MsbA R103_C_F2  5’-ACC ATG CGT CGC TGC CTG TTT GGT CAC-3’  
MsbA R103_C_R2  5’-GTG ACC AAA CAG GCA GCG ACG CAT GGT-3’  
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MsbA_173_F  5’-G ATC ATT TTG ATT TGC CTG GCA CCG ATT -3’   
MsbA_173_R  5’- C AAT CGG TGC CAG GCA AAT GAT C-3’                    
MsbA191N-C_F  5’-CGA AGC GTT TTC GCT GCA TCA GTA AAA ACA TG-3’  
MsbA191N-C_R  5’-CAT GTT TTT ACT GAT GCA GCG AAA ACG CTT CG-3’  
MsbA_261_F  5’-ATC GCC TCT TTG TGC CTG GCG TTT GTT-3’ 
MsbA_261_R                  5’-AAC AAA CGC CAG GCA CAA AGA GGC GAT-3’ 
MsbA206S-C_F  5’-CAG GTG ACC ACC TGC GCA GAA CAA ATG-3’  
MsbA206S-C_R  5’-CAT TTG TTC TGC GCA GGT GGT CAC CTG-3’  
  
MsbA246S-C_F  5’-GGA TGA AAA TGG TTT GCG CCT CTT CCA TCT C-3’  
MsbA246S-C_R  5’-GAG ATG GAA GAG GCG CAA ACC ATT TTC ATC C-3’  
MSBA_ C315-S_F  5’-GGT ATG GCG GCT AGC CAG ACG CTG TTT-3’ 
MSBA_ C315-S_R  5’-AAA CAG CGT CTG GCT AGC CGC CAT ACC-3’ 
MsbA_482_F  5’- GCG TGC TGC TCT GCG GCG GTC AGC G-3’  
MsbA_482_R  5’- CGC TGA CCG CCG CAG AGC AGC ACG C-3’  
MsbA_A518C_F 5’-C GAA TCC GAA CGT TGC ATT CAG GCG GCA C-3’  
MsbA_A518C_R  5’-G TGC CGC CTG AAT GCA ACG TTC GGA TTC G-3’ 
MsbA L539_C_f2  5’-GAT TGC CCA CCG CTG CTC TAC CAT TGA AA-3’  
MsbA L539_C_R2  5’-TTT CAA TGG TAG AGC AGC GGT GGG CAA TC-3’  
● Oligonucleotide for the construction of expression vectors for MsbA_ST or MsbA_VC constructs 
MsbA_ST_PstI_F  5’-AAA ACT GCA GAT GCA TAA CGA TAA AGA TCT CTC TAC G-3’ 
MsbA_ST_KpnI_R  5’-AAA AGG TAC CTT ATC ATT GGC CAA ATT GCA TCT TAT GTA G-3’ 
MsbA_ST_XbaI_R  5’-AAA ATC TAG ATT ATC ATT GGC CAA ATT GCA TCT TAT GTA G-3’ 
MsbA_VC_R_XbaI  5’-AAA TCT AGA TTA TCA TTC ACC AAA CTG GAT GCG ATG-3’ 
MsbA_VC_F_PstI  5’-AAA CTG CAG ATG TCA TTG CAC TCT GAC GAA TCT A-3’ 
MsbA_VC_R_KpnI  5’-AAA GGT ACC TTC ACC AAA CTG GAT GCG ATG-3’ 
● Oligonucleotide for the construction of expression vectors for DARPin_55 used in cross-linking 
and EPR study 
DARPin55_C12_F  5’-CCA TCA CGG ATG CGA CCT GGG TAA GG-3’ 
DARPin55_C12_R  5’-CCT TAC CCA GGT CGC ATC CGT GAT GG-3’ 
DARPin55_C29_F  5’-GAT CAG GAC GAC TGC GTT CGT ATC CTG-3’ 
DARPin55_C29_R  5’-CAG GAT ACG AAC GCA GTC GTC CTG ATC-3’ 
DARPin55_C151_F  5’- GTA AGA CCG CTT TCT GCA TCT CCA TCG ACA ACG G-3’ 
DARPin55_C151_R  5’- CCG TTG TCG ATG GAG ATG CAG AAA GCG GTC TTA C-3’  
DARPin55 C160_F  5‘-CGG TAA CGA GTG CTG GCT GAA ATC-3’ 
DARPin55 C160_R 5’-GAT TTC AGC CAG GCA CTC GTT ACC G-3‘ 
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A.4 Plasmids 
A.4.1 E.coli expression vector 
Plasmid name                         Comment/relevant details   Reference 
 
1). MsbA_lyzlnk_EC   10his-tag followed by 3C protease site at N-terminus, E.coli MsbA gene,   This thesis 
Amp
r 
, Arabinose induction 
 
2). MsbA_lyzlnk_EC_(E-Q)    10his-tag followed by 3C protease site at N-terminus, E.coli MsbA(E506Q)   This thesis 
  mutant gene, Amp
r 
, Arabinose induction                   
 
3). MsbA_lyzlnk_ST                      10his-tag at N-terminus, S.typhimurium MsbA gene, Amp
r 
, Arabinose   This thesis 
induction             
  
4). MsbA_lyzlnk_VC                     10his-tag at N-terminus, V.cholerae MsbA gene, Amp
r 
, Arabinose   This thesis 
 
5). MsbA_AviC  10his-tag at N-terminus and Avi-tag at C-terminus, E.coli MsbA gene, Amp
r 
,   This thesis 
 Arabinose induction                    
 
6). MsbA_VC_AviC  10his-tag at N-terminus and Avi-tag at C-terminus, V.cholerae MsbA gene,   This thesis  
Amp
r 
, Arabinose induction                    
 
7). MsbA_ST_AviC  10his-tag at N-terminus and Avi-tag at C-terminus, S.typhimurium MsbA gene,  This thesis  
Amp
r 
, Arabinose induction   
8). MsbA cys less  10his-tag followed by 3C protease site at N-terminus, E.coli MsbA cysteine less  This thesis  
gene, Amp
r 
, Arabinose induction    
9). MsbA_lyzlnk_25  10his-tag followed by 3C protease site at N-terminus, E.coli single cysteine MsbA  This thesis 
 gene, Amp
r 
, Arabinose induction      
 
10). MsbA_lyzlnk_65, MsbA_lyzlnk_78, MsbA_lyzlnk_88, MsbA_lyzlnk_103, MsbA_lyzlnk_173, MsbA_lyzlnk_191,  
MsbA_lyzlnk_206, MsbA_lyzlnk_246, MsbA_lyzlnnk_315, MsbA_lyzlnk_482, MsbA_lyzlnk_518, MsbA_lyzlnk_539,  
   10his-tag followed by 3C protease site at N-terminus, E.coli single cysteine MsbA mutants, Amp
r 
, Arabinose induction  
(the mutated residue number is denoted in each construct).       This thesis 
 
11). NBD_lyzlnk_EC 10his-tag followed by 3C protease site at N-terminus, NBD of E.coli MsbA, Amp
r 
,  This thesis  
Arabinose induction 
12). NBD_lyzlnk_Ec_E-Q 10his-tag followed by 3C protease site at N-terminus, NBD (E506Q) of E.coli MsbA,  This thesis 
 Amp
r 
, Arabinose induction  
13). NBD_EC_AviC  10his-tag at N-terminus and Avi-tag at C-terminus, NBD of E.coli MsbA, Amp
r 
,  This thesis 
Arabinose induction 
14). TM_EC_AviC  10his-tag at N-terminus and Avi-tag at C-terminus, TMD of E.coli MsbA, Amp
r 
,  This thesis 
 Arabinose induction 
15). pQE_MTS55  6his-tag at N-terminus,  MsbA specific DARPin named as DARPin_55, Amp
r 
, IPTG  This thesis 
 induction 
16). pQE_MTS55_N Cys, pQE_MTS55_C Cys, pQE_MTS55_12 Cys, pQE_MTS55_29 Cys, pQE_MTS55_151 Cys,  
pQE_MTS55_160 Cys  6his-tag at N-terminus, single cysteine mutants of MsbA specific DARPin_55, Amp
r 
,  
IPTG induction        This thesis 
17). pQE_DARPin55 myc5  6his-tag at N-terminus, 5X(myc tag) at C-terminus, DARPin_55, Amp
r 
, IPTG induction  This thesis 
18). pQE_DNBD14  6his-tag at N-terminus, E.coli MsbA_NBD specific DARPin, Amp
r 
, IPTG induction  This thesis 
19). pET28-CH_ydda  6his-tag at C-terminus, E.coli YDDA, Kan
r
, IPTG induction   Daniel Frey 
A.4.2 L. lactis expression vector 
20). pNZ8048lmrA  6his-tag at N-terminus, L.lactis expression, Cm
r
, Nisin induction   Markus Seeger 
 
Amp
r
- Ampicillin resistance 
Cm
r
- Chloramphenicol resistance 
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